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Abstract
Mouse embryonic stem cells (mESCs) and mouse epiblast stem cells (mEpiSCs)
represent opposite ends of a pluripotency continuum, respectively referred to as naïve and
primed pluripotent states. A third, recently discovered intermediate state has been
described as the ‘formative state’. Metabolism has been traditionally regarded as a byproduct of cell fate; however, recent evidence now supports metabolism as promoting
stem cell fate. Pyruvate kinase muscle isoforms 1 and 2 (PKM1 and PKM2) catalyze the
final, rate limiting step of glycolysis generating adenosine triphosphate (ATP) and
pyruvate; however, the precise role(s) of these isozymes in naïve, formative, and primed
pluripotency is unclear. Steric-blocking morpholino oligonucleotides were employed to
modulate the levels of PKM1/2; this thesis characterized the cellular expression,
localization patterns, and contributions of PKM1 and PKM2 in mESCs, chemically
transitioned mouse epiblast-like cells (mEpiLCs) representing formative pluripotency,
and mEpiSCs using immunoblotting, flow cytometry, and confocal microscopy. My
results indicate that PKM1 and PKM2 are not only localized to the cytoplasm, but also
accumulate in distinct subnuclear regions of mESCs, mEpiLCs, and mEpiSCs as
determined by a comprehensive and quantitative, confocal microscopy colocalization
methodology.
In Chapters 2 and 3, I employed orthogonal projections, and airyscan processing to
investigate the localization patterns of PKM1/2. I determined that the subnuclear
localization of PKM1/2 shifts during the pluripotent development across mESCs,
mEpiLCs, and mEpiSCs. The appropriateness and power of the Pearson’s Correlation
Coefficient and Manders’ Overlap Coefficient for assessing nuclear and cytoplasmic
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protein colocalization in pluripotent stem cells (PSCs) by immunofluorescence confocal
microscopy was validated and expanded upon. In Chapter 4, I describe a key research
tool of this thesis using flow cytometry, this improved technique allows for the
identification of formative pluripotency cells from naïve and primed populations using
the cell surface markers SSEA1 and CD24. Additionally, I utilized this advanced
methodology in Chapter 5 to assess the influence of PKM1/2 modulation on pluripotency
state. Altering PKM1/2 levels affected the ability of naïve state cells to transition to the
formative state, it also influenced the transition of formative cells to a primed-like state.
In conclusion, the results suggest that nuclear PKM1/2 assists with distinct pluripotency
state maintenance and lineage priming by non-canonical mechanisms. These results
advance our understanding of the overall mechanisms controlling naïve, formative, and
primed pluripotency.
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Lay Summary
Prior to implantation, an embryo is referred to as a blastocyst. The blastocyst contains a
small pocket of cells called the inner cell mass. These cells can become all cell types of
an individual, a characteristic coined ‘pluripotency’. Isolated inner cell mass cells can be
grown in the lab to study how the embryo develops and how pluripotent stem cells
function. Stem cells require sources of energy to maintain themselves and growth with
the process of metabolism. Pluripotent stem cells progressively specialize over the
timeline of the pluripotent continuum. The first stage of the continuum is called the naïve
state, where a cell is pluripotent, but is not fully ready to turn into a new cell. First, a
naïve cell must develop into a formative state cell, this state is an intermediate point
needed to gain the ability to turn into any cell of the fetus, and the only state that a cell
can turn into a germ cell. Before making the decision to leave pluripotency, the cell
enters the final stage, the primed state, where it is ‘primed’ for cell lineage choices. This
thesis examined two main proteins that are known to aid in cellular digestion of the
building blocks needed to grow and generate energy, pyruvate kinase muscle isoforms 1
and 2 (PKM1/2). PKM1/2 affect the ability of pluripotent stem cells to stay as naïve cells
or develop into becoming formative, or primed stem cells. This thesis utilized several
improved methods to examine the effects of altering the levels and localization of
PKM1/2 on pluripotent and metabolic state of the naïve, formative, and primed stages.
This knowledge helps us to understand how embryonic stem cells stay pluripotent and
specialize into other types of cells.
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Epigraph
“We can judge our progress by the courage of our questions and the depth of our
answers, our willingness to embrace what is true rather than what feels good.”
Dr. Carl Sagan

Since starting this project in 2015, I have struggled with the concept of progression and
finding contentment with the answers I was generating. Failure was a big part of the first
3 years of my PhD, few experiments worked, even fewer produced results worthy of
further investigation. During my first year in the lab, I witnessed PKM1 appearing to
reside in the nucleus of my stem cells under a basic fluorescent microscope, something
that had never been reported in any cell type at the time. Naturally, I doubted this initial
finding, but I thought it was interesting enough to present to my lab resulting in
discussion. This small qualitative finding was the seed to give me the courage to not only
investigate whether it was in fact in the nucleus, but also create my own, more
comprehensive, and improved methodology for nuclear cytoplasmic colocalization. I
embraced my ideas and forged a path to success. By finding courage in my questions and
working to improve the field, I was able to begin answering my query. Showing nuclear
PKM1 felt like real progress, but it required asking deeper questions and answering those
question in new and better ways. Science is not static; science is highly dynamic and
craves both improvement and change; this project resulted in enhancements to current
methodologies that will benefit projects well outside of the scope of my study. Overall,
this project required a willingness to embrace the scientific method, and despite setbacks
and troubleshooting, I was able to turn kernels of proof into more substantial evidence of
something novel.
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Chapter 1
1.0.0.

Preface.

1.0.1. Mammalian blastocyst inner cell mass development.

Following fertilization by the union of a sperm and egg, the first mammalian cell
differentiation event yields two distinct cell lineages, the trophectoderm (TE) and the
inner cell mass (ICM) (Marikawa and Alarcón 2009). The TE and ICM are cellular
precursors of the placenta and embryonic germ cell layers respectively. The eutherian
placenta provides a necessary means for maternal nourishment of the developing embryo
and this unique feature is conserved in the eutherian evolution of the TE. The cells of the
ICM will go onto specialize into the cells of the adult organism, including the germ cells.
These ICM cells are classified as pluripotent, they have the capability to self-renew
indefinitely or specialize into any cell derivative of the three germ cell layers.

1.0.2. The first cell lineage determination.

Approximately 16-20 hours post-fertilization, the first cleavage of the zygote occurs
resulting in the formation of two blastomeres. The subsequent cleavage events that
follow, occur in 12- to 24-hour intervals. Between the third and fourth cleavage events,
individual blastomeres undergo a morphogenetic change called ‘compaction’, resulting in
a dramatic increase in cell-to-cell contact. This is fueled by the formation and action of
E-Cadherin (Cadhern1; Cdh1) mediated adherens junction formation that transitions the
eight-cell stage preimplantation embryo from a grape-like cluster into a fully mulberrylike compacted cell mass called the morula. Aside from providing cell-to-cell adhesion,
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E-Cadherin also plays a critical and indirect role in generating the contractile forces
needed for tissue compaction by removing acto-myosin from ectopic cell-to-cell surfaces
(Stephenson, Yamanaka, and Rossant 2010; Klompstra et al. 2015; S. Yamada and
Nelson 2007). This allows acto-myosin to accumulate and form a shell-like surface
around the embryo, and generates the contraction necessary for compaction to occur
(Maître et al. 2015). The formation of the ICM begins following the fifth cleavage event,
where secreted vacuoles from outer TE blastomeres begin to form, grow, and combine
within the embryo to form the fluid-filled blastocyst cavity (Aziz and Alexandre 1991). It
is here that the TE and ICM combine to make up what is now referred to as the
‘blastocyst’. The TE epithelializes from the outer blastomeres with the ICM forming on
the basal surface from aggregated cells on the opposite side of the blastocyst cavity, this
orientation is referred to as the ‘embryonic and abembryonic poles’ respectively and
forms the embryonic-abembryonic axis.

1.1.0. The pluripotent continuum.

Within the developing murine embryo, naïve embryonic stem cells (mESCs) are derived
from the inner cell mass (ICM) of an embryo at the pre-implantation blastocyst-stage,
whereas primed epiblast stem cells (mEpiSCs) are more developmentally differentiated
and can be derived from the late post-implantation epiblast (Nichols and Smith 2009).
These two pluripotent states exist as the beginning and end of the pluripotent continuum.
Both states have several distinguishing features aside from their developmental timeline.
Morphologically, naïve cells are domed with a glistening appearance in culture, and their
colonies are tolerant to single cell dissociation, whereas primed cells are characteristically
flattened and respond poorly to enzymatic passaging (Tesar et al. 2007). In females, naïve
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cells contain two activated X chromosomes, the paternally inherited X chromosome is
inactivated in extraembryonic lineages following cleavage and is correspondingly
inactivated in primed cells (Heard 2004). In terms of signalling, mESCs maintain the
ability to indefinitely self-renew through activation of the transcription factor ‘signal
transducer and activator of transcription 3’ (Stat3) by leukemia inhibitory factor (LIF)
supplementation (Williams et al. 1988; A. G. Smith et al. 1988; H Niwa et al. 1998).
When cultured with serum and LIF, mESCs can be maintained in vitro, however, they
exist in a heterogenous composition that includes both naïve and cells exiting naïve state.
In contrast, homogenous mESC cell culture is maintained through LIF supplementation
with a small molecule blockage strategy referred to as 2i, a small molecular cocktail
containing inhibitors of mitogen-activated protein kinase and glycogen synthase kinase 3
(Wray et al. 2011; Burdon et al. 1999). The combination of LIF/2i supplementation in the
absence of sera promotes naïve cell homogeneity by suppressing differentiation without
hindering cell division, the resulting state is referred to as the ‘ground-state’.
Alternatively, mEpiSCs do not require LIF or 2i, instead they require activin and
fibroblast growth factor (FGF, together FA supplemented media) addition to their
medium to achieve a stable, proliferative primed state (Brons et al. 2007; Tesar et al.
2007). Either end of the pluripotent continuum is hallmarked with unique metabolic
preferences, with naïve cells are metabolically bivalent, utilizing both glycolytic and
oxidative phosphorylation (OXPHOS), whereas primed cells are preferentially glycolytic
even in oxygen rich environments (Figure 1.1.) (Zhou et al. 2012).
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Figure 1.1. Pluripotent stem cells of the pre- and post- implantation murine
blastocyst and corresponding metabolic preferences.
Phase contrast microscopy imaging of mESCs, mEpiLCs and mEpiSCs. Explanting cells
of the inner cell mass of between Embryonic day (E) 3.5 and E4.5, supplemented with
LIF and 2i media promotes domed colonies of cells with glistening borders representing
the naïve pluripotent state. The formative state can be modelled by exchanging LIF/2i
supplementation with FA media over 48 hours, these mEpiLCs are like the cells of the
E5.5 to E6.0 post-implantation epiblast. Explanting cells of the post-implantation epiblast
between E6.0 and E7.5 cultured in FA results in flattened colonies of cells representing
the primed pluripotent state. The naïve and primed pluripotent states differ in metabolic
preferences as naïve cells are bivalent utilizing glycolysis and OXPHOS and primed cells
preferentially utilizing aerobic glycolysis. Scale bars represent 200 m.
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Between either end of the pluripotent continuum exists an interval of pluripotency
hallmarked by the primordial germ cell and lineage differentiation competency. This
executive, intermediate phase is referred to as formative pluripotency, and corresponds
with E5.5-6.0 in the mouse embryo (A. Smith 2017). While naïve and primed pluripotent
states are well characterized, the intermediate formative state and how stem cells exit
pluripotency during differentiation is an area with much to still understand. One area that
has been particularly neglected is an investigation of formative state’s metabolic
preferences. In this thesis, mESCs were exposed to FA for 48, 72, and 96 hours to
produce and model the formative state and exit of the naïve and formative states towards
a primed-like state. After 48 hours of FA treatment, mEpiLCs become reminiscent of
E5.75 mouse ICM cells (Hayashi et al. 2011). At 72 hours following FA media
supplementation, mEpiLCs exhibit a apoptosis event, cementing them towards a primedlike pluripotent fate path (Hayashi et al. 2011). Through additional passages and
continued FA media treatment, primed-like pluripotent state cells are achieved. These
conditions and timelines were employed to simulate a primed-like pluripotent state by
exposing mESCs to FA over 96 hours with a single passage at 48 hours (Morgani,
Nichols, and Hadjantonakis 2017).

Recently, stable formative pluripotent lines have been derived from humans and mice
(Kinoshita et al. 2020). Stable formative lines can be generated though the addition of
traditional FA media and supplementation of a tankyrase inhibitor, which works to inhibit
Wnt/-Catenin signalling (Menon et al. 2019). This is a ground-breaking finding as the
formative pluripotent state works to promotes the phased progression model of
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pluripotent development, which dictates that during development and achievement of
competency for cell lineage specification, cells of the naïve pluripotent state will progress
through formative into the primed pluripotent state before differentiating into a somatic
cell (A. Smith 2017). Additionally, formative state cells are the only stem cell capable of
efficient differentiation into primordial germ-like cells (PGCLCs). This demonstrates a
competency for germ cell generation that is not inherent to naïve pluripotency (Hayashi et
al. 2011). If correct, the phased progression model of pluripotent development would
benefit from an effective method in studying phased progression transitioning efficiency.
The cell surface markers Stage specific embryonic antigen 1 (SSEA1) and CD24 have
been used to distinguish between the naïve and primed pluripotent states via flow
cytometry (Shakiba et al. 2015). SSEA1 has elevated expression in naïve cells, whereas
CD24 is elevated in primed pluripotency (Shakiba et al. 2015). For these reasons I was
inspired to pursue the investigation of cell surface marker expression in transitioning
formative state pluripotency cells, relative to both naïve and primed state cells. Currently,
there are few effective methods for discriminating the formative state from naïve or
primed pluripotency, and with the advent of a stable formative cell line (Kinoshita et al.
2020), the study of exiting the naïve state and traversing through the phased progression
model of cell specification is better enabled. Delineation of naïve, formative, and primed
states is important to the field of pluripotency as recent advances allow researchers to
stably culture formative stem cells for the study of specification and development. Until
recently, primed pluripotency was the only stable culture of human PSCs, as the naïve
state is a transient stage outside of mouse and rat models (Ying and Smith 2017).

7
1.1.1. Non-canonical roles of metabolism.
Increasing evidence promotes metabolism as having a critical role in the establishment,
maintenance, and differentiation of pluripotent stem cells. Elevated reactive oxygen
species (ROS) associated with OXPHOS has been implicated not only with apoptosis, but
also in cell differentiation acting as second messengers and influencing the epigenetic
landscape (Sarsour et al. 2009; Maryanovich and Gross 2013). When there is a demand
for cells to proliferate, the proliferative state has a metabolic precursor response, whereby
pyruvate shunting to the mitochondria is decreased. In addition, there is an elevated
glycolytic response resulting in an upregulation of anabolic gene expression and
biosynthetic pathways. This trend is profiled by a simultaneous increase in aerobic
glycolysis, and decrease in OXPHOS; such phenotype is evident in both tumor and
embryonic development (Vander Heiden, Cantley, and Thompson 2009). When
reprogramming from the primed-to-naïve pluripotent state through overactivation of LIF,
the reverse metabolic shift is witnessed, a transition from aerobic glycolysis to increased
OXPHOS and metabolic bivalency (Carbognin et al. 2016). As OXPHOS is dependent
on mitochondrial respiration, this shift also demonstrates mitochondrial reprogramming.
Overactivation of LIF promotes the gene Stat3, which is critical in self-renewal, can bind
to the mitochondrial genome and promotes the naïve phenotype and reversion of primed
pluripotency (Carbognin et al. 2016). Elevated Stat3 also promotes naïve associated
genes, increases stem cell proliferation, and both OXPHOS and mitochondrial gene
transcription (Carbognin et al. 2016). My investigation sheds light on the role of
metabolism and pyruvate shuttling during early development and enhances knowledge of
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cell conversion, this may advance the ability to effectively model disease, and eventually
apply cell replacement therapies through enhanced cell differentiation.

Traditionally, human induced pluripotent stem cells (hiPSCs) reflect metabolic trends of
primed PSCs, exhibiting increased glycolytic flux and decreased OXPHOS. Relative to
their somatic cell origins, iPSCs are proliferative, requiring a greater amount of energy,
yet have a substantial decrease in OXPHOS activity. Indeed, hiPSCs exhibit aerobic
glycolytic metabolism like primed cells, showing distinct similarities to cancer cell
metabolism and structural differences within the mitochondria (Jasanoff 1992; Ishida et
al. 2020). Epigenetic changes are partially responsible for these metabolic trends. One
alternate route for this glycolytic flux is contribution towards the pentose phosphate
pathway (PPP), which is implicated in having an a key role in energy flux in iPSCs
(Prigione et al. 2015). HIF-1𝛼 and HIF-2𝛽 are required during the initial stages of
reprogramming and counter intuitively, HIF-2𝛽, if stabilized, can hinder reprogramming
efficiency. During early reprogramming of iPSCs from somatic cells, there is a sudden
and unexpected burst of OXPHOS, this event is referred to as OXPHOS burst. This
sudden burst is required for reprogramming, despite the end iPSC metabolic fate being
preferentially glycolytic. Induction of the OXPHOS burst event upregulates estrogenrelated nuclear receptors and PGC-1/ (co-factors). Recent evidence suggests that the
OXPHOS burst is necessary to cause HIF-1𝛼 activation by increasing the activity of
NRF2 promoting a switch in metabolism from being OXPHOS to glycolytic (Hawkins et
al. 2016).
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1.1.2. Pyruvate kinase muscle isoforms.

Mammals express four tissue specific pyruvate kinase (PK) isozymes: M1, M2, L, and R,
each with unique properties and tissue expression to meet specific metabolic demands (K.
Yamada and Noguchi 1999). PK-Liver and Red Blood (LR) gene expresses L and R in a
tissue-promotor specific manner. L is present in the kidneys and liver tissue, whereas R
in red blood cells (W. Yang and Lu 2015). PKM1/2 is the enzyme responsible for
catalyzing the final and rate limiting step of glycolysis, the enzyme plays a role in
directing the fate of pyruvate towards lactate or acetyl CoA for glycolysis and OXPHOS
(W. Yang and Lu 2015). This step involves the catalysis of phosphate from
phosphoenolpyruvate (PEP) to ADP producing the second ATP of glycolysis and
pyruvate.

PKM1/2 are alternatively spliced isoforms from the PKM gene (Figure 1.2) (Wong, De
Melo, and Tang 2013). Heterogeneous nuclear ribonucleoproteins A1/A2 and
polypyrimidine-tract binding protein work to splice PKM1 through the exclusion of exon
9 and inclusion of exon 10, whereas PKM2 is spliced to include exon 10 and exclude
exon 9 (K. Yamada and Noguchi 1999). PKM1 is expressed in most somatic tissues that
have a high energy requirement. The overexpression or replacement of PKM2 in place of
PKM1 restricts tumorigenesis and cancer progression (Anastasiou et al. 2012; Chaneton
and Gottlieb 2012). However, PKM2 is the predominant pyruvate kinase isoform in
cancer cells, but is also expressed in most somatic cells apart from liver, brain, and
paradoxically muscle in adult tissues (W. Yang and Lu 2015; Christofk et al. 2008).
PKM1/2 activity is regulated based on expression level, and both homotropic and
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heterotropic allosteric interactions with fructose 1,6-bisphosphate (FBP) and PEP
respectively, allosteric interactions are not evident with M1 isozyme, which maintains an
active homotetrameric conformation (Boles et al. 1997; Imamura and Tanaka 1982).
When FBP levels decrease, PKM2 homotetramers dissociate into homodimers, these
conformations are interconvertible (Wong, De Melo, and Tang 2013). The PKM2 dimer
is associated with aerobic glycolysis and anabolism, this isoform is also formed in the
presence of Tyr phosphorylated peptides regardless of FBP levels. In turn, this causes
phosphorylation on Y105 which prevents FBP binding, a key trait of Warburg
metabolism (the Warburg Effect), where even in the presence of oxygen, cells are
preferentially glycolytic (Gupta and Bamezai 2010). The Warburg Effect is the metabolic
preference for glycolysis, and it is typical of most cancers (O. Warburg. 1924). Despite
appearing to be a poor method of generating maximal ATP levels, most cancer cells do
not reply on mitochondrial respiration, but rather employ aerobic glycolysis, despite
apparent oxygen availability. This metabolic preference was first characterized in 1924,
yet we are only now starting to understand the mechanisms and rationale behind this
counterintuitive process. Mouse and human primed pluripotent cells are similar to
specific cancer cells regarding their metabolic preferences as both are preferentially
glycolytic despite oxygen being available (Zhou et al. 2012). Given this similarity, the
results of this thesis document PKM2 residing within the nucleus of these highly
proliferative stem cells, this is a key trait of the Warburg Effect. PKM2 is a target for
many cancer treatments, and the results of my study demonstrate that PKM1 and PKM2
isoforms have novel expression patterns between pluripotent states. As human ESCs
(hESCs) and most cancer cell lines exhibit the Warburg Effect, studying the unknown
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mechanisms of PKM2 interactions within PSCs is a critical area of focus (X. Liu et al.
2019; Shyh-Chang, Daley, and Cantley 2013).
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Figure 1.2. Alternative splicing schematic of pyruvate kinase muscle isoforms 1/2.
Pyruvate kinase muscle isoforms 1 and 2 (PKM1/2) is alternatively spliced from the PKM
gene. Mature PKM1 mRNA excludes exon 10, and conversely, mature PKM2 mRNA
excludes exon 9. Image was created by Joshua Dierolf and Martin Krzywinski.
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PKM2 interacts with: OCT4, a marker of pluripotency in ESCs, HIF-1𝛼 master regulator
of metabolism, STAT3, and 𝛽-CATENIN (W. Yang and Lu 2015). Interestingly, the
interaction of OCT4 increases during a transition from the dimeric and phosphorylated
conformation associated with the Warburg Effect (Morfouace et al. 2014). It is currently
assumed that the interaction of PKM2 and OCT4 has a role in mitosis and tumor
nourishment, however, this mechanism has yet to be delineated (Hitoshi Niwa, Miyazaki,
and Smith 2000). Dimeric PKM2 also associates with HIF-1𝛼, this interaction promotes
transcriptional coactivation of HIF-1𝛼 through positive feedback regulation, additionally,
this promotes the Warburg Effect in at least two ways. Firstly, when PKM2 is
hydroxylated by and bound to prolyl hydroxylase 3, there is an interaction with HIF-1 𝛼
that results in transactivation of the glycolytic enzymes lactate dehydrogenase A (LDHA)
and pyruvate dehydrogenase kinase 1 (PDK1), transactivation of vascular endothelial
growth factor can also occur. PKM2 also transactivates HIF1𝛼 target genes such as
GLUT1, LDHA and PDK1 (which inhibits OXPHOS via pyruvate shunting) by altering
interactions at hypoxia response elements (HRE), and these alterations include improved
recruitment of p300 and enhanced binding of HIF-1𝛼 (Luo et al. 2011). HIF-1 works to
regulate PKM expression for both isozymes (M1/M2), with only dimeric PKM2
interacting directly with HIF-1𝛼 by enhancing HIF1𝛼 binding and enlisting p300 at
HREs, this in turn transactivates key glycolytic enzymes required for the Warburg Effect.
Additionally, HIF-1𝛼 transcriptionally regulates OCT4, further implicating PKM2 as an
important gene in proliferation and aerobic glycolysis (Prigione et al. 2015). Within the
nucleus, dimeric PKM2 can operate as a protein kinase through phosphorylation of
STAT3 (Tyr705), thus enhancing the transcriptional activity of STAT3, and subsequently
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activating MEK5 and histone H3 (Thr11) (Gao et al. 2012). PKM2 can translocate to the
nucleus through epidermal growth factor induction by transactivation of 𝛽-CATENIN
through the phosphorylation of tyrosine Y333 (Figure 1.3). This interaction contributes
to c-MYC and cyclin D transcription. However, an interaction with Wnt and PKM2 is
not evident (Weiwei Yang et al. 2011). Interactions with c-MYC require more research,
but interestingly a depletion of c-MYC in naïve cells will force mESC into a ‘diapause’
like state of quiescence (Scognamiglio et al. 2016). PKM2 can also be methylated, for
example, methylation by coactivator-associated arginine methyltransferase 1 (CARM1).
Protein-protein interaction of PKM2 and CARM1 along with methylation of PKM2’s Cdomain also promotes the Warburg effect and activates a transition from oxidative
phosphorylation to aerobic glycolysis (F. Liu et al. 2017). Downregulating intragenic
DNA methylation can influence pre-splicing of alternative splice events for PKM1/2.
Importantly, CARM1 does not methylate PKM1, however, CARM1 and PKM1 proteins
do interact, and CARM1 primarily methylates dimeric PKM2 over the tetrameric
conformation. Currently, epigenetic regulation of PKM2 in PSCs has not been
thoroughly investigated (Singh et al. 2017). Pyruvate destined for an OXPHOS is
irreversibly decarboxylated into acetyl CoA within the mitochondria by pyruvate
dehydrogenase complex (PDC) for processing within the tricarboxylic acid cycle. PKM2,
PDC-(E2 subunit), and histone acetyltransferase p300 form a complex with the CYP1A1
enhancer of arylhydrocarbon receptor. Through this complexing, nuclear PKM2
promotes cell proliferation through enhanced detoxification of detrimental endogenous
metabolites and aids in acetyl CoA production (Matsuda et al. 2016). The mechanism of
how transcriptional activation fully regulates these enzymes, and their function is still
largely unknown. Relative to PKM2, the alternative isozyme PKM1 has been vastly
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understudied, however, recent publications have determined PKM1 is involved in
chemoresistance, and may have additional non-canonical roles (Fushida et al. 2018; Wei
et al. 2017). Indeed, PKM1 has been recently documented binding with Hepatocyte
Nuclear Factor 4∝ (HNF4∝), before translocating to the nucleus of hepatoma cells(Wei et
al. 2017). This may suggest a potential non-canonical role for the traditional cytoplasmic
metabolic enzyme. PKM1 has been found present in chemo-resistant cancerous cells and
following knockdown increased cellular chemotherapy sensitivity (Taniguchi et al. 2016).
There is a clinical need to study PKM1/2 modulation in metabolically active cells as
PKM1/2 are heavily implicated in the transition of healthy cells to utilizing Warburg
Effect over OXPHOS. As such PKM2, and now PKM1 is the target of several cancer
related approaches (Wei et al. 2017; W. Yang and Lu 2015). As this transition is similar
to the bivalent-to-glycolytic switch from naïve to primed pluripotency, there is a
developmental importance in studying the influence of PKM1/2 modulation. Current
strategies have included knocking in alleles of PKM1/2 (Konno, Ishii, et al. 2015), using
siRNA (Goldberg and Sharp 2012) and shRNA (Qin et al. 2017) strategies, lentiviral
overexpression (Qin et al. 2017), pharmacological approaches (Giannoni et al. 2015;
Hasenoehrl et al. 2017; Wei et al. 2017) and miRNAs (Konno, Koseki, et al. 2015;
Taniguchi et al. 2015).
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Figure 1.3. A proposed model of PKM1/2 isoforms in naïve and primed pluripotent
stem cells.
Intracellular PKM1/2 exist as active tetramers, the PKM2 tetrameric conformation is
destabilized following phosphorylation promoting a dimeric conformation. Dimeric
PKM2 is translocated to nuclei and promotes the Warburg Effect. As primed cells have
been described as preferentially aerobic glycolytic in metabolic preference, nuclear
PKM2 by dimeric PKM2 translocation is proposed. As naïve cells are metabolically
bivalent, a mix of OXPHOS and glycolytic promoting conformations is presumed. Image
created by Joshua Dierolf and Martin Krzywinski in Illustrator.
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My thesis is focused on providing an increased understanding of the mechanisms
controlling early cell differentiation and enhanced cell reprogramming through
modulation of metabolic processes. This is an area of interest in stem cell biology as
other groups have successfully and are continually attempting to achieve increased
reprogramming efficiencies in iPSCs by promoting the characterized iPSC metabolism of
elevated glycolysis and decreased OXPHOS. A well-established example is the
upregulation of HIF activity to promote glycolysis, which interestingly also increases
PKM2 activity. Likewise, pyruvate dehydrogenase kinase (PDHK) activity inhibits
pyruvate dehydrogenase (PDH), stunting for OXPHOS to occur and even the addition of
FBP treatment promotes a metabolic switch to glycolysis and increased reprogramming
efficiency (Folmes et al. 2011; Zhu et al. 2010). By promoting OXPHOS instead, cellular
reprogramming efficiency of somatic cells can alternatively be decreased. While cancer
cells and primed pluripotent stem cells share a preference for aerobic glycolysis, there is
still an apparent role for OXPHOS in PSCs, this is an area in need of greater research and
PKM1/2 may have a vital role in this capacity. Recent studies have no longer alluded to
metabolism as influencing pluripotency, but have claimed that metabolism actively
promotes pluripotency (Ryall et al. 2015). When considering the metabolic preferences
of naïve and primed pluripotent states, and the switch from aerobic to anaerobic
metabolism, it is important to consider their in vivo counterparts, the cells of the pre- and
post- implantation embryo. These metabolic preferences are thought to be intrinsically
programmed into these states due to the limited oxygen availability of their in vivo origins
within the reproductive tract (Carbognin et al. 2016). Further study into the metabolic
preferences of the formative state, and the formative interval of embryo development is
needed. If the phased progression model of pluripotent development is correct, and the

18
notion of intrinsic programming based on in vivo origins holds true, then it would be
expected that the shift towards aerobic glycolysis is established during the formative
interval and in the formative state.

1.2.0. Rationale.
PKM1/2 have been independently implicated in naïve and primed cells, yet their role in
the developmental transition between pluripotent states has yet to be fully elucidated
(Konno, Ishii, et al. 2015; Qin et al. 2017). Knocking in an allele of either the Pkm1 or
Pkm2 gene indicates that Pkm2, but not Pkm1 has a role in maintaining the naïve state
following a differentiation stimuli as determined by a transcriptional assay in mESCs
(Konno, Ishii, et al. 2015). Overexpression of either PKM1 or PKM2 increases
pluripotent transcript abundance in naïve mESCs. Additionally, it has been demonstrated
that PKM2 can translocate to the nuclei of primed hESCs, when silenced, cells do not
exhibit altered glucose metabolism suggesting a non-canonical role for PKM2
(Christensen, Calder, and Houghton 2015). PKM2, and recently PKM1 have been
implicated to have other potential non-canonical roles, outside of metabolic enzymatic
activities, such as promoting aerobic glycolytic activity and proliferation typical of
cancerous cells (Hamabe et al. 2014; Wei et al. 2018; Palsson-McDermott et al. 2015;
Stone et al. 2018; Weiwei Yang and Lu 2013; Growth 2018; Wei et al. 2017; Fushida et
al. 2018). With the advent of new flow cytometric approaches and improved
characterization of the formative state, this thesis seeks to delineate expression,
localization, and influence of PKM1/2 on the naïve, formative, and primed pluripotent
states of murine embryonic stem cells.
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1.3.0. Governing Hypothesis.
Pyruvate kinase muscle isoform 1 and 2 expression are differentially expressed in naïve,
formative, and primed pluripotent states; and enhance the progression of pluripotent state
development in murine embryonic stem cells.

1.4.0. Thesis Objectives.
This research investigates the role of PKM1/2 in the maintenance and differentiation of
naïve, formative, primed-like, and primed pluripotent states through the following
objectives:
1. Optimize quantitative confocal colocalization of fluorescently tagged antisera
against PKM1 and PKM2 to subcellular regions of naïve, formative, and primed
mESCs
2. Characterize protein and transcript abundance along with subcellular localization
of PKM1/2 isoforms in naïve, formative, and primed mPSCs.
3. Optimise the application of flow cytometry using SSEA and CD24 cell surface
markers to delineate naïve, formative and primed pluripotent states.
4. Determine the influence of modulating PKM1/2 in naïve mESCs and primed
mEpiSCs and transitioning towards formative mEpiLCs and primed-like
mEpiLCs.
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2.0.2. Summary:
This chapter details 3D morphological topography of mouse pluripotent stem cell colony
architecture optimization and nuclear protein localization by co-immunofluorescence
confocal microscopy analysis. Colocalization assessment of nuclear and cytoplasmic cell
regions is detailed to demonstrate nuclear localization in mouse epiblast stem cells
(mEpiSCs) by confocal microscopy and orthogonal colocalization assessment. Protein
colocalization within mouse embryonic stem cells (mESCs), mouse epiblast-like cells
(mEpiLCs), and mEpiSCs, or any pluripotent stem cell with a high nuclear-tocytoplasmic ratio, can be efficiently completed using these optimized protocols.

2.1.0. Introduction:
Immunofluorescence microscopy allows for the visualization of fluorescence light energy
emitted from a fluorophore representing the cellular localization of a specific protein of
interest. Activation of a fluorophore can be direct or indirect, depending on whether it is
conjugated to a primary or secondary antibody respectively (Joshi and Yu 2017).
Observable differences in immunofluorescence localization is readily distinguished
within a cell using this technique, however, quantification of target protein levels is
challenging. Colocalization is an effective quantitative method of comparison between
two images within a specific region of interest (ROI), and their level of correlated spatial
overlap in pixels used to determine quantity (Adler and Parmryd 2012). The following
methods have been developed to quantitatively compare the levels of nuclear and
cytoplasmic colocalization for a gene of interest within a specific ROI using
immunofluorescence imaging by confocal microscopy.
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Pluripotency markers such as octamer-binding transcription factor 4 (OCT4), sex
determining region Y – box 2 (SOX2), and NANOG are nuclear localized transcription
factors that are expressed within pluripotent stem cells (PSCs). They represent ideal
candidate nuclear markers that can be contrasted with overall nuclear DNA staining using
Hoechst DNA or an equivalent binding dye as a nuclear reference. Since PSCs, such as
mouse epiblast stem cells (mEpiSCs), are typically grown on a feeder cell layer of mouse
embryonic fibroblasts (MEFs) for support, OCT4, SOX2, and NANOG become useful
stem cell colocalization proteins, as they are not expressed in the MEFs. Choosing the
optimal control protein is key, as PSCs have high nuclear to cytoplasmic size ratios,
increasing the difficulty in distinguishing between nuclear and cytoplasmic protein
localizations (Oh et al. 2005; Pagliara et al. 2014).

The protein of interest in this protocol is pyruvate kinase muscle isoform 2 (PKM2), a
metabolic protein that can translocate from the cytoplasm to the nucleus in cancer cells
(Yang and Lu 2013). The metrics described compare spatial overlap and correlation
between two fluorescent channels include the algorithms for calculating Manders’s
Overlap Coefficient (MOC) and Pearson Correlation Coefficient (PCC), these metrics are
published for induced PSCs and neuronal differentiation (Seibler et al. 2011). The MOC
is a measure of the spatial overlap of pixels between two images within a ROI (Manders,
Verbeek, and Aten 1993). However, the MOC is quite sensitive to photobleaching,
therefore ensuring proper confocal imaging with appropriate laser intensities is paramount
(Dunn, Kamocka, and McDonald 2011),(Zinchuk, Zinchuk, and Okada 2007). By
applying the removal of non-relevant pixels, non-oversaturated images can eliminate
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problems associated with the signal-to-noise sensitivity affected by photobleaching.
Therefore, the MOC is a valuable tool in determining if the pixels associated with the two
validated proteins exist in the same spatially-relevant ROI (Aaron, Taylor, and Chew
2019). Conversely, the PCC is a measure of covariance between pixels. It is more
accommodating in terms of what images can be compared, and represents the other main
measurable parameter of colocalization, correlation of pixel distribution between images
(Dunn, Kamocka, and McDonald 2011). The PCC of pluripotent stem cell colonies may
be decreased compared to individual cells as the PCC measures pixel correlation,
therefore, examining the subcellular structures of individual cells will be emphasized
more than areas representing extra, non-relevant pixels found in generalized regions of
cell colonies (Dunn, Kamocka, and McDonald 2011). Due to the large nuclearcytoplasmic size ratio of pluripotent stem cells, this limitation of PCC, should not be an
issue, and in my experience, there is little to no change between individual cells and total
colony PCC or MOC. Proper optimization and consistency in cell fixation and processing
is critical for consistency and successful colocalization in all studies of this type. It is
essential that all samples, specimens, treatments, and replicates are consistently exposed
to well thought out, empirically determined protocols that are consistently applied
throughout the entire process and across all experimental replicates. Additionally, the
following protocol is also effective for quantifying protein colocalization within naïve
mouse embryonic stem cells (mESCs) and formative mouse epiblast-like cells
(mEpiLCs), but should work well for any colocalization study, especially for pluripotent
stem cells or cell with a high nuclear-to-cytoplasmic ratio.
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The mechanisms controlling PKM1 and PKM2 nuclear translocation are largely
unknown, however, PKM1 may complex with hepatocyte nuclear factor 4∝ (HNF4∝),
and this can be enhanced with the addition of the drug Oroxylin A (OA) and the oncogene
JMJD5 is implicated in the nuclear translocation of PKM2 (Wei et al. 2017; Wang et al.
2014). Nuclear translocation of PKM2 as a characteristic of the Warburg effect is well
supported by fluorescent imaging and nuclear-to-cytoplasmic fractionation (Yang et al.
2011, 2012; Yang and Lu 2013; Prakasam et al. 2017; Giannoni et al. 2015). Typical
confocal image analysis employing visual interpretation of overlaid fluorescent images is
a purely qualitative means of spatial localization, however, accurate quantitative
measurement of spatial localization can effectively occur within the context of a wellcontrolled comparison of two fluorophores to determine the degree of colocalization (Wu
et al. 2012). Quantitative colocalization analysis (QCA) is most commonly divided into
two metrics representing the relationship between two fluorophores, these measures are
the degree of, i) overlap and ii) correlation (Dunn, Kamocka, and McDonald 2011). The
degree of spatial location by overlapping images was first quantified by Otsu in 1979,
where pixels of two images were overlapped after applying a threshold (Otsu 1979).
Manders’s Overlap Coefficient (MOC) better distinguishes pixels ignored from the
threshold from higher intensity pixels but at the cost of being influenced by
autofluorescence and an insensitively to differences between the signal-to-noise ratios of
the two fluorophores (Manders, Verbeek, and Aten 1993; Aaron, Taylor, and Chew
2019). While the MOC is a measure of co-occurrence of two fluorophores, within the
spatially shared regions of a cell, two markers may interact or share a similar trend in
intensity localization and may be functionally related or interact. Thus, the colocalization
metric of correlation can indicate that two fluorophores share an associative relationship
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(Aaron, Taylor, and Chew 2019). The Pearson Correlation Coefficient (PCC) compares
the variation of signal intensity between the intersection of two images, taking into
account the total population of pixels (Aaron, Taylor, and Chew 2019). As such, this
calculation can determine the direction of linear association between the fluorophores
(Aaron, Taylor, and Chew 2019; Pearson and Henrici 1896). The MOC and the PCC are
commonly used calculations to quantify fluorescent protein spatial overlap and
correlation (Adler and Parmryd 2012). Despite the accuracy and power of QCA, this
technique has been not been utilized to its full extent, especially so, in its application to
measuring protein colocalization in pluripotent stem cells (Dunn, Kamocka, and
McDonald 2011). This may be due to an on-going debate within the field of QCA over
the correct use and interpretation of overlap and correlation metrics (Adler and Parmryd
2010; Aaron, Taylor, and Chew 2019). Thus, a second primary objective of my study
was to contrast both PCC versus MOC in the analysis of PKM1/2 colocalization with
nuclear and cytoplasmic protein markers during naïve, formative, and primed
pluripotency cell cultures (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).

The measurement of colocalization is a complicated and hotly debated area of biology
(Adler and Parmryd 2010; Aaron, Taylor, and Chew 2019). The term colocalization is
largely used to measure two main components with different applications, namely
correlation or co-occurrence of two fluorophores to each other based on pixel distribution
(Aaron, Taylor, and Chew 2019). Co-occurrence in immunofluorescence is the
presentation of fluorescent pixels existing in the same spatial distribution, it is an
indicator of overlap between markers, whereas correlation is a measurement of the
relationship between the pixel intensities and may indicate a biochemical interaction

32
(Manders, Verbeek, and Aten 1993). There are several coefficients used to quantify
colocalization such as M1, M2, k1, k2 (Manders’s coefficients), MOC, PCC, Spearman’s
rank correlation, and the intensity correlation quotient (Manders, Verbeek, and Aten
1993; Agnati et al. 2005; Adler and Parmryd 2012). The controversy lies specifically in
the usefulness and relevance of the MOC, and the alleged superiority of the PCC. In
2010, Alder and Parmryd first published work that diminished the usefulness of MOC in
colocalization studies, outlining the metric as a hybrid measurement of correlations and
co-occurrences, and arguing that the MOC was not a suitable metric for either
colocalization by correlation or co-occurrence (Adler and Parmryd 2010). This was
determined by an additive offset of pixels which did not affect the PCC but increased the
MOC to a higher level of co-occurrence. As such, the MOC has been criticized as not
being the best metric of co-occurrence due to the influence of correlation (Adler and
Parmryd 2010). However, this view has since been contested using biological samples
demonstrating that both the MOC and PCC are valid measures of colocalization that add
different qualities to determining interactions between two fluorochromes and their target
proteins (Aaron, Taylor, and Chew 2019). Immunofluorescence is commonly considered
as primarily a qualitative technique and the literature into colocalization often uses
generalized descriptors, such as ‘moderate’ or ‘strong’ association within PCC ranges.
To bring greater consistency to the field, and offer greater validity to the quantitative
nature of colocalization, a method of colocalization range descriptors has been developed
by Zinchuk et al. (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013), and it is this
approach that was implemented in this thesis to assign a quantitative designate to the
colocalization of PKM1 and PKM2 within mESCs. Zinchuk et al. labelled PCC values
within set ranges to a classification, that included: Correlation: very weak: -1 – -0.27,
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weak: -0.26 - 0.09, moderate: 0.1 – 0.48, strong: 0.49 – 0.84, and very strong: 0.85 – 1.0
(Zinchuk, Wu, and Grossenbacher-Zinchuk 2013). MOC values fall into set ranges of:
Overlap: very weak: 0 – 0.49, weak: 0.50 – 0.70, moderate: 0.71 – 0.88, strong: 0.89 –
0.97, and very strong: 0.98 – 1.0 (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013). My
results support claims that the MOC is a valuable metric of colocalization. By comparing
MOC and PCC values relative to a positive and negative biological reference, a stronger
baseline set than that produced by using only the improved descriptors. Nuclear (OCT4)
and cytoplasmic (GAPDH) proteins were uniquely employed as control markers to
correlate their nuclear localization with a well characterized DNA intercalating nuclear
stain- Hoechst, which established a robust positive and negative reference to nuclear
colocalization, allowing for the direct comparison of MOC and PCC values to one
another. Comparing these well-defined positive references to the qualifying range
standards set by Zinchuk et al. has produced data that supports comparing colocalization
by correlation as being superior to spatial overlap in my system (Zinchuk, Wu, and
Grossenbacher-Zinchuk 2013). However, there is still valuable knowledge to gain from
the MOC, but the PCC data shows a greater distinction between internal reference
controls.

2.2.0. Materials:
1. Washing Solution: Dulbecco’s Phosphate Buffered Saline (no magnesium, no
calcium) (DPBS(-/-))(GibcoTM 14190144).
2. Permeabilization solution: 0.1 % Triton X-100 (Sigma-Aldrich TX1568-1) diluted
in DPBS(-/-).
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3. Sterilizing Ethanol: 70 % lab-grade ethanol diluted in MilliQ water.
4. Antibody Dilution Solution: 10 % serum from host-species of secondary antibody
diluted in DPBS(-/-)-T (0.1 % Tween-20).
Primary Antibodies:
•

OCT4: Oct-3/4 Antibody (C-10) (Santa Cruz sc-5279) – 1:50 dilution.

•

GAPDH: GAPDH (6C5) (Santa Cruz sc-32233) – 1:50 dilution.

•

PKM2: PKM2-specific Polyclonal antibody (ProteinTech 15822-1-AP) – 1:50
dilution.
Secondary Antibodies:

•

Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa
Fluor Plus 555 (Invitrogen A32732) – 10 g/mL dilution.

•

Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor
488 (Invitrogen A11001) – 1 g/mL dilution.

5. mESC and mEpiLC substratum: 0.1 % porcine gelatin (Sigma-Aldrich G2500) in
MilliQ water and autoclave sterilized.
6. mEpiSC substratum: 10 g/mL/cm2 sterile fibronectin (Roche 11051407001)
MilliQ water.
7. 1.25mm glass coverslips.
8. Kimberly-Clark Professional™ Kimtech Science™ Kimwipes™ Delicate Task
Wipers, 1-Ply (Kimberly-Clark Professional™ 34155).
9. Parafilm™ M Wrapping Film (Fisher Scientific S37441).
10. Humidified container (i.e., Pyrex dish filled with a small amount of water and
covered in plastic wrap).
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11. Light-tight box.
12. 6-Well cell culture plates (Thermo Scientific NuncTM Cell-Culture treated
Multidishes 140675).
13. Tweezers (the finer tipped, the better).
14. Nuclear stain such as NucBlue™ Live Ready Probes™ Reagent (Invitrogen
R37605).
15. Mounting medium such as ProLong™ Gold Antifade Mountant (ThermoFisher
Scientific P10144).

2.3.0. Methods:
The quantification of immunofluorescence colocalization protocol requires detailed
planning of the experimental design prior to starting. The theory behind the set-up of this
methodology is similar to a multi-stain flow cytometry experiment, where controls of
each cell type including unstained, single florescent stains, and multi-fluorescent stains
(including both antibody stains and live/dead viability stains) are required in biological
triplicate. To complete an accurate colocalization experiment or perform an optimal
immunofluorescence study, it is advised that an antibody titration (concentration dilution
series) be completed for each new cell type or antiserum used. A control sample of each
cell type with a single Hoechst stain or another DNA binding equivalent should be
included. If an isotype control for each marker is not available, minimally include a
secondary only control. A dual fluorescent stain of Hoechst to the nuclear or
pluripotency marker of choice will provide a valuable nuclear reference as well. It is
recommended that each biological replicate be run in technical triplicate to ensure that
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colonies within each passage and imaging set are representative of the true post-imaging
calculations. All biological replications within a statistical set should be run within a
single sitting of an experimental run by confocal microscopy, including the identical laser
settings and general threshold parameters. Deviating from these will result in inconsistent
measures. A benefit to completing this modality that cannot be accomplished with flow
cytometry is that you can revisit the imaging process of coverslips at any point in time
using confocal microscopy if controls are re-analyzed and new thresholds are set.

2.3.1. Coverslip Preparation.
Wash 1.25 mm thick coverslips with 70 % ethanol diluted in MilliQ water. Dry the
coverslip with a Kimwipe and UV within a covered 6-well culture dish in a biosafety
cabinet for 1 hour to sterilize and dry (see Note 1). Coat coverslips with 200 L of sterile
0.1 % gelatin or substratum of choice. Incubate overnight in an incubator (37 C at 5 %
CO2). Alternatively, for mEpiSCs weaned off MEFs, coat coverslips with 200 L of 10
g/mL/cm2 fibronectin for 45 minutes at room temperature (see Note 2). Aspirate
residual substratum. Plate cells on the outline of the substratum. Eject cell suspension in
place of the substratum (see Note 2). Allow for cells to attach for 1 hour before gently
filling the well with the corresponding cell media for overnight incubation (see Note 3).

2.3.2. Staining Preparation.
Wash cells once with Dulbecco’s Phosphate-Buffered Saline without calcium/magnesium
(DPBS(-/-)) (see Note 4). Incubate coverslips in chilled 4 % paraformaldehyde (Sigma Aldrich) diluted in DPBS(-/-) for 10 minutes. Wash once with chilled DPBS(-/-) for 10
minutes (see Note 5). Permeabilize adhered cells with 0.1% TritonX-100 for 10 minutes
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(see Note 6). Wash once for 10 minutes with chilled DPBS(-/-). Block the samples by
incubating the colony adhered coverslips in 10 % serum (from host-species of secondary
antibody) diluted in chilled DPBS(-/-)-T (0.1 % Tween-20) for 30 minutes. No additional
washing step is required.

2.3.3. Simultaneous Primary Antibody Staining.
Dilute primary antibodies in 10 % serum (from host-species of secondary antibody)
diluted in chilled DPBS(-/-)-T. On a piece of parafilm, pipette 100 L per coverslip
spaced out 5 cm apart (see Note 7). Using a pair of sterile tweezers, lift each coverslip
from the corner and gently dry the coverslip by touching the edge of the glass with a
folded Kimwipe (see Note 8). Once dry, place the coverslip cell-side-down on the diluted
antibody. The solution should fully cover the surface of the glass in contact with the
parafilm if done correctly. Incubate coverslips with primary antibodies in blocking serum
overnight at 4℃. To avoid dehydration of the coverslip, allow the incubation to take
place in a humidified container. All samples should incubate for the same length of time
to be comparable by colocalization. Remove the coverslip from the humified container
by lifting the upside-down coverslip from the parafilm slowly. Place the coverslip in a 6well plate cell side-up submerged in chilled DPBS(-/-). Wash coverslip(s) once for 10
minutes each in chilled DPBS(-/-). Dilute secondary antibodies in 10% serum (from hostspecies of secondary antibody) diluted in chilled DPBS(-/-)-T. On a piece of parafilm,
pipette 100 L per coverslip spaced out 5 cm apart. The surface tension will hold the
diluted antibody in place. Incubate coverslips with secondary antibodies in blocking
serum for 1 hour at room temperature. Humidified incubation is not necessary for this
duration of time. All samples incubating with a secondary antibody are now light
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sensitive, it is recommended that handling and future steps are completed under dimlighting. Wash coverslip(s) with chilled DPBS(-/-), add 4 drops/mL of NucBlue™ Live
Ready Probes™ Reagent (Hoechst 33342) for 5 minutes. Not all samples will get a
Hoechst staining step, always pay attention to your experimental design. Wash once with
chilled DPBS(-/-) for 10 minutes.

2.3.4. Mounting and Slide Preparation.

Mount onto 70 % ethanol cleaned, dry, and labelled microscope slides using a
commercially available mounting media such as ProLong™ Gold Antifade Mountant.
Place the coverslip cell side-down on an edge held up by the cover using tweezers and
gently drop the lifted edge over the mounting media to avoid bubbles. Seal with nail
polish unless using an adhesive resin-based mounting media (see Note 9). Store in a
light-tight box until you are ready to image on a fluorescent microscope.

2.3.5. Immunofluorescence Colocalization Optimization and Analysis.

To accurately image, quantify, and compare mESCs, mEpiLCs and mEpiSCs, one must
establish and apply a single, consistent set of laser parameters for each marker. My
analysis was completed on a ZEISS LSM800 confocal microscope with an Airyscan
detector and ZEISS Zen system imaging software. Zen Lite, while a free option, does not
have the ability to do colocalization analysis in suite. The basic steps of this protocol
should be effective for all confocal immunofluorescence microscopic systems, however,
if ZEISS Zen system software is unavailable, ImageJ/FIJI are free softwares that offer
similar colocalization capabilities and other valuable plugins such as particle analysis and
noise reduction that will work with the described protocol.
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Figure 2.1. Nuclear and cytoplasmic colocalization optimization of mEpiSCs.
a) 3D representation of a mEpiSC colony generated from a Z-stack before being
processed into an orthogonal projection. X, Y and Z dimensions can be measured, as
mEpiSC colonies have a flattened morphology, this approach is useful when comparing
the morphologically domed/glistening, naïve mESCs. b) Nuclear, cytoplasmic and
protein of interest thresholds of the markers OCT4, GAPDH, and PKM2 respectively in
mEpiSCs. Channel thresholds are set to just above the solid green phase of the
scatterplots in single stained controls with both lasers running at their optimized
intensities. c) Dual stained mEpiLC for GAPDH (green) and PKM2 (orange).
Scatterplot of the dual stained specimens detailing nuclear to protein of interest areas of
colocalization. Pixel correlation and overlap are measured above the thresholds. Scale
bars represent 20 µm.
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Identify the appropriate stage settings and focus onto colonies at 40x and 63x objectives
using a Hoechst or equivalent single stained samples (see Notes 10 and 11). Optimize
the corresponding laser to each protein marker of interest to the brightest specimen. All
the select laser parameters should not result in autofluorescence of any cell type in that
laser configuration. If your microscope does not contain a Z-stack module (see Note 12).
Complete a Z-stack series at 40x magnification set to just beyond the top and bottom of a
centered colony. For mESCs, mEpiSCs and mEpiSC, 40x should allow for an entire
medium size colony to be in view. These images can be used to examine and visually
compare the 3D topography of each pluripotent state colony (Figure 2.1.a) (see Note 13).
Process z-stacks into orthogonal projections (see Note 14). Select the brightest samples
of each single stained marker to set the base threshold. Select the colocalization or
scatterplot option, in Zeiss software this is a tab labelled ‘Colocalization’. This should
appear as a quadrant with a crosshair containing two, adjustable thresholds (Figure 2.1.b).
Set the x-axes to one of the channels examined and the y-axes to the other channel.
Threshold should be adjusted to keep the signal below the solid green fluorescence
(Figure 2.1.b) (see Note 15). Once the threshold is set, use these settings on each of the
dual stained images (Figure 2.1.c), the quadrant labelled ‘3’ represents pixels beyond both
control thresholds. A corresponding table with completed calculations is available on the
Zeiss Zen system under the table option. Depending on your software, you may need to
calculate the MOC and PCC.
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Use the following formulae and compare biological replicates as mean ±SEM (Dunn,
Kamocka, and McDonald 2011):

𝑀𝑂𝐶 =

∑𝑖(𝑅𝑖 × 𝐺𝑖 )
√∑𝑖 𝑅𝑖2 × ∑𝑖 𝐺𝑖2

𝑃𝐶𝐶 =

∑𝑖 (𝑅𝑖 − 𝑅̅ ) × (𝐺𝑖 − 𝐺̅ )
√∑𝑖 (𝑅𝑖 − 𝑅̅ )2 × ∑𝑖(𝐺𝑖 − 𝐺̅ )2

Where ‘R’ and ‘G’ represent the fluorophore intensities of the first and second laser
channels respectively. As a check compare Hoechst-stained controls (nuclear reference)
to nuclear protein markers such as OCT4, SOX2, or NANOG to verify the accuracy of
overlap and correlation to nuclear staining.

2.3.5. Qualifying Descriptors:

PCC and MOC ranges can be qualified into useful and publishable descriptors (Zinchuk,
Wu, and Grossenbacher-Zinchuk 2013).
PCC: [very weak: -1 – -0.27], [weak: -0.26 - 0.09], [moderate: 0.1 – 0.48], [strong: 0.49
– 0.84], [very strong: 0.85 – 1.0]
MOC: [very weak: 0 – 0.49], [weak: 0.50 – 0.70], [moderate: 0.71 – 0.88], [strong: 0.89
– 0.97], [very strong: 0.98 – 1.0]

2.4.0. Notes:
Note 1: To avoid coverslips from sticking to the dish, prop coverslips onto a wall of the dish.
Note 2: Allow for surface tension to hold the selected substratum in place on the coverslip.
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Note 3. If seeding MEFs prior to mEpiSCs, repeat this step 24-hours post-MEF seeding with
mEpiSCs.
Note 4. Typical protocols state to wash cells up to 3 times, however, mEpiSCs do not stick to
their substratum very well, especially when coated onto feeders. The generation of mEpiLCs
results in a mass-apoptosis event 48 hours into generation, it is highly recommended that they be
treated with the utmost care during washing steps. All washing steps need to be completed
gently and all liquid ejection needs to be directed off the adhered cells. Avoid agitation of the
plate during washing steps to improve adherence.
Note 5. Take care that the DPBS(-/-) is in liquid form without slush that may increase
mechanical stress upon ejection.
Note 6. This concentration and duration allow for small, medium, and large colonies
maintaining either the domed or flattened morphologies of mESCs or mEpiSCs to be
permeabilization throughout the structure and underlying MEF layer. Exceeding this
concentration or duration will lead to decreased adherence and morphological integrity leading
to poor 3D topographical imaging.
Note 7. The surface tension will hold the diluted antibody in place.
Note 8. Residual liquid will be pulled off of the coverslip without physically contacting the
adhered cells or subjecting them to unnecessary aspiration. Lifting the coverslips is performed
easier in liquid, reducing the surface tension effect of the glass on the plate.
Note 9. Clear, viscous nail polish works best if no resin-based mounting media is available.
Note 10. If your microscope has the option to save stage settings, save this parameter for each
cell type examined for future reference.
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Note 11. If you are unsure of which protein marker will fluoresce, the brightest out of the cell
types or treatments you are examining, briefly image each and select the brightest and least
bright of each protein marker.
Note 12. If your microscope does not contain a Z-stack module. Single slice images can still be
compared using this protocol, proceed to Step.6. Individual cells can be outlined in both modes,
this is especially important for examining only mEpiSCs if grown on feeders (Figure 2.1. B)) or if
comparing individual cells to the total colony.
Note 13. If time and memory space is not an issue, use the smallest slice size possible at
the greatest resolution for optimal imaging.
Note 14. These images retain data from the individual slices and are easier to compute
for post-image analysis.
Note 15. Some microscopes have a Costes algorithm included, if this option is opted for,
double check that the crosshair is accurately placed.

2.5.0. Discussion:
Traditionally, colocalization is employed to investigate close interaction between two
proteins of interest through fluorescent imaging. However, this view is myopic and
understates the power that a well-controlled and optimized colocalization study can
demonstrate. Colocalization is not simply a method to propose interaction, but rather a
form of quantitative analysis that demonstrates correlation between proteins indicative of
biomolecular interaction and localization overlap within a defined cellular region.
Colocalization is actually a physics-based approach to determining trends in pixel
orientation between two sets of data (Comeau, Costantino, and Wiseman 2006). From
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this approach, when a greater quantity pixel of one set of data occupies the same space,
they will overlap to a higher degree than another set that is offset. Additionally, when
compared based on a scatterplot of pixel orientation, trends in pixel distribution can
determine if there is a correlation to their placement (Dunn, Kamocka, and McDonald
2011). Taken together, two fluorophores that occupy the same cellular space can be
measured in terms of overlap and two fluorophores that show similar pixel distribution
may also correlate in pixel intensity. These two metrics can be measured by the
Manders’s overlap coefficient (MOC) and Pearson’s correlation coefficient (PCC)
respectively and represent the two components of colocalization (Dunn, Kamocka, and
McDonald 2011).

These methods will accurately and comprehensively determine differences in nuclear and
cytoplasmic expression and changes by fluorescence imaging. Due to the high nuclearto-cytoplasmic size ratio, traditional methods of nuclear translocation validation, such as
nuclear extraction and subsequent immunoblotting, present a challenge in separating the
cytoplasmic and nuclear fractions within stem cells (Oh et al. 2005). Nuclear-tocytoplasmic ratios are valuable for validating pluripotency state, due to the defined
nuclear localization of OCT4, SOX2, and NANOG, imaging studies are of particular
relevance to establishing mPSC pluripotency (Perestrelo et al. 2017).

The accuracy of this methodology relies on the addition of the nuclear reference, namely
Hoechst relative to OCT4. Comparing two nuclear references ensures that the
localization differences between the proteins of interest (in example; PKM2) and the
nuclear comparison marker (OCT4) are valid. Other studies using colocalization have not
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utilized this methodology however my unpublished works show that this is an invaluable
tool of validation (Dierolf, Watson, and Betts 2020). Additionally, I apply an entire
additional dimension relative to a typical colocalization by analysing orthogonal
projections of three-dimensional stacks of colonies as opposed to a two-dimensional
comparison, this is beneficial as cells are not 2-dimensional and their expressed proteins
do not simply conform to a single layer of expression and localization (Dunn, Kamocka,
and McDonald 2011). The main challenge of applying this methodology is the difficulty
associated with transitioning and plating pluripotent states. When transitioning from
naïve-to-primed-like states your samples will also shift from expressing E- to Ncadherins and undergo a period of mass apoptosis 48 hours into transitioning (Theunissen
et al. 2016; Hayashi et al. 2011). Taken together, cell adhesion and viability are
extraordinarily difficult to optimize and control for during this pivotal stage of the
protocol (Hayashi et al. 2011). This is one of the few, if not only colocalization methods
designed specifically for cells grown in colonies and with cells having high nuclear-tocytoplasmic size ratios, as such, other colocalization methodologies likely will not
provide for accurate colocalization of proteins in these cell types. Additionally, I further
improved this methodology by implementing qualified descriptor sets for MOC and PCC
ranges to serve as accurate descriptors and metrics of spatial overlap and correlation
(Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).

The field of colocalization microscopy is mired in controversy, and perhaps rightly so, as
the variety and reproducibility of techniques leaves much to be desired and the lack of
proper guidelines is evident (Adler and Parmryd 2010; Aaron, Taylor, and Chew 2019;
Wu et al. 2012). Currently, several groups are contemplating the validity of the MOC as
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a way to measure spatial overlap or as a metric of colocalization at all (Aaron, Taylor, and
Chew 2019; Adler and Parmryd 2010). These varying points of view stem from
differences in opinion on biologic relevance and physics-based approaches on validation
(Adler and Parmryd 2010, 2012; Zinchuk, Zinchuk, and Okada 2007). This doubt in the
MOC is valid in a poorly optimized study as the MOC is sensitive to the intensity of
undesired signals of interest due to high saturation or poor imaging techniques (Aaron,
Taylor, and Chew 2019). When poorly imaged or oversaturated MOC is elevated,
however, I circumvent such an artefact in three ways; 1) by setting a threshold on a
titrated sample in the cell type of the highest expression for each parameter, 2) by
outlining areas/regions of interest to avoid any potential non-specific binding sites, and
finally 3) using a the nuclear reference to the nuclear comparison marker allows for any
potential elevated MOC value to be precisely localized. In a poorly executed study, an
elevated MOC would show little difference between controls and the additional nuclear
reference. These results promote the MOC is a valuable metric of spatial overlap for stem
cell related colocalization studies. In the context of the traditional misconception of
colocalization, the MOC is will not demonstrate any level of molecular interaction
between two proteins of interest.

The ways in which the degree of interaction between two or more molecules is
determined by the metric of correlation or the degree of colocalization. With regards to
correlation, the algorithm recommended in this study and that which is used in most
publications is PCC. PCC is not as controversial as MOC, however, it can be improved
upon by calculating the Spearman coefficient, a metric of correlation that identifies nonlinear relationships between pixel distribution that are otherwise masked by the PCC

48
which is only sensitive to direct, linear relationships (Aaron, Taylor, and Chew 2019).
The Spearman coefficient measures intensity in ranks instead of raw intensity like the
PCC, allowing for an averaging of intensities that will reveal correlated, non-linear
relationships to be portrayed and analyzed as linear scatterplots. Unlike the MOC, the
PCC is sensitive to a high signal to noise ratio, similar to the recommendations for a
quality MOC measurement, a well-controlled and calibrated study needs to take place for
an accurate PCC value, otherwise, increases the signal-to-noise ratio will decrease any
measured correlation (Dunn, Kamocka, and McDonald 2011). To accurately compare
PCC values amongst groups it is important that colony size and cell culture parameters
are as similar as possible to allow for the highest signal-to-noise ratio possible. Together
the metrics of MOC and PCC are the basic, core components of colocalization and work
together to inform the relationship of two fluorophores co-occurrence and correlation
with each other. This metholodology comprehensively assesses all these parameters and
has applied both PCC and MOC to functions to measure differences accurately and
precisely in nuclear and cytoplasmic protein localization patterns in pluripotent stem
cells.

2.6.0. Acknowledgements:
mESC and mEpiSC pluripotent stem cell lines were graciously gifted from Dr. Janet
Rossant. This research was funded by a Canadian Institutes of Health Research operating
grant to A.J.W. and D.H.B. and Natural Sciences and Engineering Research Council of
Canada grant to D.H.B. The funding sources played no role in design, data collection,
analysis, decision to publish, or preparation of this study and manuscript.

49
2.7.0. References:
Aaron, Jesse S, Aaron B Taylor, and Teng-Leong Chew. 2019. “The Pearson’s
Correlation Coefficient Is Not a Universally Superior Colocalization Metric.
Response to ‘Quantifying Colocalization: The MOC Is a Hybrid Coefficient – an
Uninformative Mix of Co-Occurrence and Correlation.’” Journal of Cell Science
132 (1): jcs227074. https://doi.org/10.1242/jcs.227074.
Adler, Jeremy, and Ingela Parmryd. 2010. “Quantifying Colocalization by Correlation:
The Pearson Correlation Coefficient Is Superior to the Mander’s Overlap
Coefficient.” Cytometry Part A 77A (8): 733–42.
https://doi.org/10.1002/cyto.a.20896.
———. 2012. “Colocalization Analysis in Fluorescence Microscopy.” Methods in
Molecular Biology 931: 97–109. https://doi.org/10.1007/978-1-62703-56-4_5.
Agnati, Luigi F, Kjell Fuxe, Maria Torvinen, Susanna Genedani, Rafael Franco, Stan
Watson, Gastone G Nussdorfer, Giuseppina Leo, and Diego Guidolin. 2005. “New
Methods to Evaluate Colocalization of Fluorophores in Immunocytochemical
Preparations as Exemplified by a Study on A2A and D2 Receptors in Chinese
Hamster Ovary Cells.” Journal of Histochemistry & Cytochemistry 53 (8): 941–53.
https://doi.org/10.1369/jhc.4A6355.2005.
Comeau, Jonathan W D, Santiago Costantino, and Paul W Wiseman. 2006. “A Guide to
Accurate Fluorescence Microscopy Colocalization Measurements.” Biophysical
Journal 91 (12): 4611–22. https://doi.org/10.1529/biophysj.106.089441.
Dierolf, Joshua G, Andrew J Watson, and Dean H Betts. 2020. “Differential Localization
Patterns of Pyruvate Kinase Isoforms in Murine Naïve, Formative and Primed
Pluripotent States.” BioRxiv, January, 2020.04.12.036251.
https://doi.org/10.1101/2020.04.12.036251.
Dunn, Kenneth W., Malgorzata M. Kamocka, and John H. McDonald. 2011. “A Practical
Guide to Evaluating Colocalization in Biological Microscopy.” American Journal of
Physiology-Cell Physiology 300 (4): C723–42.
https://doi.org/10.1152/ajpcell.00462.2010.
Giannoni, Elisa, Maria Letizia Taddei, Andrea Morandi, Giuseppina Comito, Maura
Calvani, Francesca Bianchini, Barbara Richichi, et al. 2015. “Targeting StromalInduced Pyruvate Kinase M2 Nuclear Translocation Impairs Oxphos and Prostate
Cancer Metastatic Spread.” Oncotarget 6 (27): 24061–74.
https://doi.org/10.18632/oncotarget.4448.
Hayashi, Katsuhiko, Hiroshi Ohta, Kazuki Kurimoto, Shinya Aramaki, and Mitinori
Saitou. 2011. “Reconstitution of the Mouse Germ Cell Specification Pathway in
Culture by Pluripotent Stem Cells.” Cell 146 (4): 519–32.
https://doi.org/10.1016/j.cell.2011.06.052.
Joshi, Sonali, and Dihua Yu. 2017. “Chapter 8 - Immunofluorescence.” In , edited by
Morteza Jalali, Francesca Y L Saldanha, and Mehdi B T - Basic Science Methods for
Clinical Researchers Jalali, 135–50. Boston: Academic Press.
https://doi.org/https://doi.org/10.1016/B978-0-12-803077-6.00008-4.
Manders, EMM, FJ Verbeek, and JA Aten. 1993. “Measurement of Co-Localization of
Objects in Dual-Colour Confocal Images.” Journal of Microscopy 169 (3): 375–82.
https://doi.org/10.1111/j.1365-2818.1993.tb03313.x.
Oh, Sun Kyung, Hee Sun Kim, Hee Jin Ahn, Hye Won Seol, Yoon Young Kim, Yong

50
Bin Park, Chul Jong Yoon, Dong-Wook Kim, Seok Hyun Kim, and Shin Yong
Moon. 2005. “Derivation and Characterization of New Human Embryonic Stem Cell
Lines: SNUhES1, SNUhES2, and SNUhES3.” STEM CELLS 23 (2): 211–19.
https://doi.org/https://doi.org/10.1634/stemcells.2004-0122.
Otsu, Nobuyuki. 1979. “A Threshold Selection Method from Gray-Level Histograms.”
IEEE Transactions on Systems, Man and Cybernetics 20 (1): 62–66.
https://doi.org/0018-9472/79/0100-0062$00.75.
Pagliara, Stefano, Kristian Franze, Crystal R McClain, George W Wylde, Cynthia L
Fisher, Robin J M Franklin, Alexandre J Kabla, Ulrich F Keyser, and Kevin J
Chalut. 2014. “Auxetic Nuclei in Embryonic Stem Cells Exiting Pluripotency.”
Nature Materials 13 (6): 638–44. https://doi.org/10.1038/nmat3943.
Pearson, Karl, and Olaus Magnus Friedrich Erdmann Henrici. 1896. “VII. Mathematical
Contributions to the Theory of Evolution.—III. Regression, Heredity, and
Panmixia.” Philosophical Transactions of the Royal Society of London. Series A,
Containing Papers of a Mathematical or Physical Character 187 (January): 253–
318. https://doi.org/10.1098/rsta.1896.0007.
Perestrelo, Tânia, Weitong Chen, Marcelo Correia, Christopher Le, Sandro Pereira, Ana S
Rodrigues, Maria I Sousa, João Ramalho-Santos, and Denis Wirtz. 2017. “Pluri-IQ:
Quantification of Embryonic Stem Cell Pluripotency through An&#xa0;ImageBased Analysis Software.” Stem Cell Reports 9 (2): 697–709.
https://doi.org/10.1016/j.stemcr.2017.06.006.
Prakasam, Gopinath, Rajnish Kumar Singh, Mohammad Askandar Iqbal, Sunil Kumar
Saini, Ashu Bhan Tiku, and Rameshwar N K Bamezai. 2017. “Pyruvate Kinase M
Knockdown–Induced Signaling via AMP-Activated Protein Kinase Promotes
Mitochondrial Biogenesis, Autophagy, and Cancer Cell Survival.” Journal of
Biological Chemistry 292 (37): 15561–76.
https://doi.org/10.1074/jbc.M117.791343.
Seibler, Philip, John Graziotto, Hyun Jeong, Filip Simunovic, Christine Klein, and
Dimitri Krainc. 2011. “Mitochondrial Parkin Recruitment Is Impaired in Neurons
Derived from Mutant PINK1 Induced Pluripotent Stem Cells.” The Journal of
Neuroscience 31 (16): 5970 LP – 5976. https://doi.org/10.1523/JNEUROSCI.444110.2011.
Theunissen, Thorold W, Marc Friedli, Yupeng He, Evarist Planet, Ryan C O’Neil,
Styliani Markoulaki, Julien Pontis, et al. 2016. “Molecular Criteria for Defining the
Naive Human Pluripotent State.” Cell Stem Cell 19 (4): 502–15.
https://doi.org/10.1016/j.stem.2016.06.011.
Wang, H.-J., Y.-J. Hsieh, W.-C. Cheng, C.-P. Lin, Y.-S. Lin, S.-F. Yang, C.-C. Chen, et
al. 2014. “JMJD5 Regulates PKM2 Nuclear Translocation and Reprograms HIF-1 Mediated Glucose Metabolism.” Proceedings of the National Academy of Sciences
111 (1): 279–84. https://doi.org/10.1073/pnas.1311249111.
Wei, Libin, Yuanyuan Dai, Yuxin Zhou, Zihao He, Jingyue Yao, Li Zhao, Qinglong Guo,
and Lin Yang. 2017. “Oroxylin A Activates PKM1/HNF4 Alpha to Induce
Hepatoma Differentiation and Block Cancer Progression.” Cell Death & Disease 8
(7): e2944. https://doi.org/10.1038/cddis.2017.335.
Wu, Yong, Vadim Zinchuk, Olga Grossenbacher-Zinchuk, and Enrico Stefani. 2012.
“Critical Evaluation of Quantitative Colocalization Analysis in Confocal
Fluorescence Microscopy.” Interdisciplinary Sciences: Computational Life Sciences

51
4 (1): 27–37. https://doi.org/10.1007/s12539-012-0117-x.
Yang, Weiwei, and Zhimin Lu. 2013. “Nuclear PKM2 Regulates the Warburg Effect.”
Cell Cycle 12 (19): 3154–58. https://doi.org/10.4161/cc.26182.
Yang, Weiwei, Yan Xia, Haitao Ji, Yanhua Zheng, Ji Liang, Wenhua Huang, Xiang Gao,
Kenneth Aldape, and Zhimin Lu. 2011. “Nuclear PKM2 Regulates β-Catenin
Transactivation upon EGFR Activation.” Nature 480 (7375): 118–22.
https://doi.org/10.1038/nature10598.
Yang, Weiwei, Yanhua Zheng, Yan Xia, Haitao Ji, Xiaomin Chen, Fang Guo, Costas A.
Lyssiotis, Kenneth Aldape, Lewis C. Cantley, and Zhimin Lu. 2012. “ERK1/2Dependent Phosphorylation and Nuclear Translocation of PKM2 Promotes the
Warburg Effect.” Nature Cell Biology 14 (12): 1295–1304.
https://doi.org/10.1038/ncb2629.
Zinchuk, Vadim, Yong Wu, and Olga Grossenbacher-Zinchuk. 2013. “Bridging the Gap
between Qualitative and Quantitative Colocalization Results in Fluorescence
Microscopy Studies.” Scientific Reports 3 (1): 1365.
https://doi.org/10.1038/srep01365.
Zinchuk, Vadim, Olga Zinchuk, and Teruhiko Okada. 2007. “Quantitative Colocalization
Analysis of Multicolor Confocal Immunofluorescence Microscopy Images: Pushing
Pixels to Explore Biological Phenomena.” ACTA HISTOCHEMICA ET
CYTOCHEMICA 40 (4): 101–11. https://doi.org/10.1267/ahc.07002.

52
Chapter 3
A version of this Chapter has been accepted for publication in Experimental Cell
Research.

3.0.0. Chapter Title: Differential localization patterns of pyruvate kinase isoforms
in murine naïve, formative, and primed pluripotent states

3.0.1. CRediT Author Statement:

Joshua Dierolf: Conceptualization, Methodology, Validation, Formal Analysis,
Investigation, Writing – Original Draft, Writing – Review & Editing, Visualization
Dean Betts: Resources, Writing – Review & Editing, Funding Acquisition, Supervision
Andrew Watson: Resources, Writing – Review & Editing, Funding Acquisition,
Supervision

53
3.1.0. Abstract:
Mouse embryonic stem cells (mESCs) and mouse epiblast stem cells (mEpiSCs)
represent opposite ends of a pluripotency continuum, referred to as naïve and primed
pluripotent states, respectively. These divergent pluripotent states differ in several ways
including growth factor requirements, transcription factor expression, DNA methylation
patterns, and metabolic profiles. Naïve cells employ both glycolysis and oxidative
phosphorylation (OXPHOS), whereas primed cells preferentially utilize aerobic
glycolysis, a trait shared with cancer cells referred to as the ‘Warburg Effect’. Until
recently, metabolism has been regarded as a by-product of cell fate, however, evidence
now supports metabolism as being a promoter of stem cell state and fate decisions.
Pyruvate kinase muscle isoforms (PKM1 and PKM2) are important for generating and
maintaining pluripotent stem cells (PSCs) and mediating the Warburg Effect. Both
isoforms catalyze the last step of glycolysis generating adenosine triphosphate and
pyruvate, however, the precise role(s) of PKM1/2 in naïve and primed pluripotency is not
well understood. The primary objective of this study was to characterize the cellular
expression and localization patterns of PKM1 and PKM2 in mESCs, chemically
transitioned epiblast-like cells (mEpiLCs) representing formative pluripotency, and
mEpiSCs using immunoblotting and confocal microscopy. The results indicate that
PKM1 and PKM2 are not only localized to the cytoplasm, but also accumulate in
differential subnuclear regions of mESC, mEpiLCs, and mEpiSCs as determined by a
quantitative, confocal microscopy colocalization employing orthogonal projections, and
airyscan processing. Importantly, the results demonstrate subnuclear localization of
PKM1/2 shifts during the transition from mESCs, mEpiLCs, and mEpiSCs. Finally, the
methodology used comprehensively validates the appropriateness and power of the
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Pearson’s correlation coefficient and Manders’s overlap coefficient for assessing nuclear
and cytoplasmic protein colocalization in PSCs by immunofluorescence confocal
microscopy. I propose that nuclear PKM1/2 may assist with distinct pluripotency state
maintenance and lineage priming by non-canonical mechanisms. These results advance
the understanding of the overall mechanisms controlling naïve, formative, and primed
pluripotency.

3.2.0. Introduction:
Pluripotent stem cells (PSCs) have the capacity for indefinite self-renewal and the
potential to differentiate into the cell types of all three germ layers including the germ line
(Nichols and Smith 2009). The potency of PSCs, such as embryonic stem cells (ESCs),
exists within a continuum with opposite ends described as naïve and primed states
(Nichols and Smith 2009). In mice, naïve mESCs are derived from the inner cell mass
(ICM) of an early, embryonic day (E)3.5 to E4.5, blastocyst-stage embryo, whereas
primed mouse epiblast stem cells (mEpiSCs) are derived later from the epiblast of E5.08.0 post-implantation embryos (Morgani, Nichols, and Hadjantonakis 2017; Evans and
Kaufman 1981; Brons et al. 2007; Tesar et al. 2007; Martin 1981). However, when
cultured in vitro, mEpiSCs more closely resemble the epiblast of E7.25-E8.0 embryos
(Joo et al. 2014; Tesar et al. 2007; Morgani, Nichols, and Hadjantonakis 2017; Kojima et
al. 2014). Human ESCs (hESCs) have traditionally been stabilized at the primed
pluripotent state, however, a naïve hESC line has been recently derived (Ge Guo et al.
2016). Between both ends of the pluripotent continuum exists a recently described
intermediate state called the ‘formative pluripotent state’ (Kalkan and Smith 2014; Smith
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2017). Formative pluripotency is an executive phase and may represent the gene
expression patterns and attributes of mouse epiblast cells within E5.5-6.25 embryo
(Morgani, Nichols, and Hadjantonakis 2017). Like naïve and primed PSCs, formative
PSCs also express NANOG, OCT4, and SOX2 (Chambers et al. 2003; Kalkan and Smith
2014; Hayashi et al. 2011). However, unlike naïve and primed PSCs, the formative
mouse epiblast-like cells (mEpiLCs) can efficiently differentiate into primordial germ
cell-like cells when presented with the appropriate growth factors such as bone
morphogenic protein 4 (Morgani, Nichols, and Hadjantonakis 2017; Ohinata et al. 2009).
Each pluripotent state has several distinguishing features such as unique morphology,
growth factor dependencies, gene expression profiles, epigenetic status, and metabolic
preferences (Morgani, Nichols, and Hadjantonakis 2017; Nichols and Smith 2009).
Morphologically, naïve PSCs are more rounded in appearance and grow as colonies with
glistening edges compared to flattened primed PSC colonies (Nichols and Smith 2009).
This hemispherical morphology of naïve cells is largely due to greater Cdh1 expression,
which can be replicated in mEpiSCs following overexpression of Cdh1 (Ohtsuka,
Nishikawa-Torikai, and Niwa 2012). Culture of mESCs requires leukemia inhibitor
factor (LIF) which promotes ‘ground state’ naïve pluripotency and resists differentiation
through activation of the transcription factor STAT3 (Ohtsuka, Nakai-Futatsugi, and
Niwa 2015). Stabilizing naïve pluripotency requires LIF and the addition of two small
molecule inhibitors (LIF/2i) of MEK1/2 (PD00032) and glycogen synthase kinase-3
(CHIR99021) (Ying et al. 2008; Silva and Smith 2008). Formative cells can be
chemically transitioned from mESCs-to-mouse epiblast-like cells (mEpiLCs) over 48
hours as a transient and heterogenous population (Kinoshita and Smith 2018; Hayashi et
al. 2011). To maintain primed pluripotency and exit the naïve state, mEpiSCs and
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chemically transitioned mEpiLCs are cultured with ACTIVIN-A and FGF-2. While naïve
and primed cells express the core pluripotency associated genes Oct4, Sox2, Nanog, both
states differ in transcriptional programs with Rex1, Esrrb, Dppa3, Klf2/4/5, Tcfcp2l1, and
Pecam delineating the naïve state, and Zic2, T (Brachyury), and Cer1, to list a few,
distinguishing the primed pluripotent state (Morgani, Nichols, and Hadjantonakis 2017).
The formative pluripotent state is reported to highly express Lef1, Pou1fc, and Dnmt3
(Kalkan et al. 2019). Naïve and primed pluripotent states also differ in terms of their
epigenetic landscape, including X-activation and chromatin methylation status
(Takahashi, Kobayashi, and Hiratani 2018). Female primed PSCs display random X
chromosome inactivation, whereas naïve PSCs display activation of both X chromosomes
(Heard 2004). Relative to primed cells, naïve PSCs contain larger regions of active
chromatin as indicated by higher levels of H2k4me3 and histone acetylation (G. Guo et
al. 2009; Gafni et al. 2013). Importantly, naïve and primed PSCs also differ in terms of
their metabolic preferences (W. Zhou et al. 2012). Naïve cells are characterised as being
metabolically bivalent, utilizing both glycolytic and oxidative phosphorylation
(OXPHOS) processes, whereas primed cells are preferentially glycolytic (W. Zhou et al.
2012). Even when cultured in oxygen rich conditions, primed PSCs utilize aerobic
glycolysis and display low OXPHOS gene expression, which, is characteristic of the
Warburg Effect that is active in many cancer cells (Prigione et al. 2010).

Despite the original observations of Dr. Otto Warburg that cells exhibiting the Warburg
Effect consume elevated glucose and direct increased levels of pyruvate towards lactate
formation, most cancers do not gain ATP by glycolysis primarily (Weinhouse et al.
1956). In actuality, glycolysis in the majority of cancer cells is not increased to generate
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ATP, but rather increase precursors necessary for enhancing anabolic processes
(DeBerardinis and Chandel 2016). Indeed, glucose oxidation by OXPHOS still produces
the bulk of ATP in most cancer cells with anaplerotic flux of metabolic intermediates
produced by glutaminolysis and lactic acid fermentation into the TCA cycle including αketoglutarate and even lactate respectively (Feron 2009). The sourcing of metabolites for
ATP production appears to be dependent on the surrounding microenvironments and
cancer subtype (Hensley et al. 2016). For example, non-small cell lung cancer (NSCLC)
cells illustrate metabolic heterogeneity and preferential aerobic and non-aerobic
metabolism processes (Hensley et al. 2016). Within cells exhibiting the Warburg Effect,
an increase in lactate production would be expected within NSCLC cells, elevated lactate
is used a carbon source in the TCA cycle and other increased expression of pyruvate
carboxylase promote higher levels of anaplerotic processes feeding into the TCA cycle
compared to normal lung tissue (Hensley et al. 2016). Misconceptions in distinguishing
the concepts of anabolic processes for cellular proliferation and energy generation
relating to the Warburg Effect need to be tackled not only in cancer research, but also in
stem cell research going forward (DeBerardinis and Chandel 2016).

The Warburg Effect is orchestrated by an upregulation of key transcription factors
including: Oct4, c-Myc, Hif-1∝, and Nf𝜅b along with the glycolytic genes: Hk2, Pgm,
Pdk, and pyruvate kinase muscle isoform 2 (Pkm2) (Levine and Puzio-Kuter 2010).
When upregulated, these aerobic glycolytic associated genes promote anabolism and ATP
generation to boost glycolytic flux (Feron 2009; Guppy, Greiner, and Brand 1993). It is
hypothesized that the high glycolytic flux of mESC maintains their high proliferative
capacity and as such, cellular metabolic state should be considered as a mediator of
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pluripotency and as a regulator of gene expression controlling cell proliferation and
differentiation (Kondoh et al. 2007; Zhang et al. 2018). While metabolism has
traditionally been viewed as a by-product of cell fate decisions, the manipulation of
metabolic genes and their products in stem cells can promote or resist cellular
differentiation and reprogramming (Hawkins et al. 2016; Rodrigues et al. 2015; W. Zhou
et al. 2012). Thus, the developmental progression of naïve-to-primed transitioning occurs
in synchrony with metabolic programming to influence cell fate and pluripotent state as
both a driver and a passenger (Dahan et al. 2019).

Recently, pyruvate kinase muscle isoforms 1 and 2 (PKM1/2) have been implicated in
regulating pluripotency, proliferation, and in the generation of pluripotent stem cells
during reprogramming (Qin et al. 2017). PKM1 and PKM2 are the metabolic enzymes
responsible for catalyzing the final, rate limiting step of glycolysis by directing pyruvate
towards either a lactate or acetyl-CoA fate (Noguchi et al. 1987; Christofk et al. 2008).
Mammals express four tissue specific pyruvate kinase isozymes; M1, M2, L, and R, each
with unique properties and tissue expression patterns to meet specific metabolic demands
(Yamada and Noguchi 1999). PKM1/2 are alternatively spliced isoforms from the PKM
gene and both PKL and PKR are encoded by the PKLR gene (Noguchi et al. 1987). The
M1 and M2 isoforms are spliced by three different heterogenous nuclear
ribonucleoproteins; hnRNPI/hnRNP1/hnRNP2 that involve the inclusion of exon 9 or 10,
respectively (David et al. 2010). PKM1/2 activity is regulated by homotropic and
heterotropic allosteric interactions with fructose 1,6-bisphosphate (FBP) and
phosphoenolpyruvate respectively (Boles et al. 1997; Imamura and Tanaka 1982). PKM1
is expressed primarily in somatic cells, whereas fetal tissues along with essentially all
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cancer cell types exhibit elevated PKM2 with certain types of tumours such as
glioblastomas displaying a complete isoform switch from PKM1 to PKM2 (Desai et al.
2013). The elevated PKM2 found in cancer cells is predominantly the inactive PKM2
homodimer form, which is due to pulsatile phosphofructokinase (Shi, You, and Luo
2019). The active homotetramer is typically bound to its cofactor FBP, however, when
the PKM2 homodimer is phosphorylated (Y105) by the oncogenic linked fibroblast
growth factor receptor type 1, the homotetrameric configuration is disrupted (Hitosugi et
al. 2009; Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M. & Cantley 2008).
This interrupts glucose oxidation and increases glycolysis and lactate production in
aerobic glycolytic preferential cancer cells, even in the presence of abundant oxygen
levels. In contrast, PKM1 operates as a constitutively active homotetramer without a
described allosteric binding site (Jurica et al. 1998).

PKM2 has additional non-canonical roles including its function as a protein kinase,
cytosolic receptor, transcriptional co-activator, and is also implicated in cytokinesis and
chromosome segregation (W. Yang and Lu 2015; Jiang, Wang, et al. 2014; Jiang, Li, et
al. 2014). PKM2 can form a complex with OCT4 resulting in decreased OCT4
transcriptional activity and stemness with increased apoptosis and differentiation (Lee et
al. 2008; Morfouace et al. 2014). Studies also indicate that the interaction of PKM2 and
OCT4 affects mitosis and tumor energy production (Niwa, Miyazaki, and Smith 2000).
PKM2 is implicated in pluripotency through its interaction and transcriptional regulation
of OCT4 in hESCs (Christensen, Calder, and Houghton 2015). Knockdown of PKM2 in
hESCs exhibited no change in lactate production or glucose uptake, however, OCT4
expression decreased substantially (Christensen, Calder, and Houghton 2015). PKM2 is
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observed in the nuclei of the hESCs cultured under both normoxic (20%), and hypoxic
(5%) oxygen conditions, but a significant reduction in PKM2 expression was observed
under normoxia (Christensen, Calder, and Houghton 2015). Overexpression of either
PKM1 or PKM2 results in increased transcript abundance of the pluripotency associated
genes; Eras, Rex1, and Nanog in mESCs (Qin et al. 2017). Upon knockdown of total
PKM, pluripotency associated gene transcript abundance also decreases, but self-renewal
and morphology appear unperturbed (Qin et al. 2017). During reprogramming of somatic
cells into iPSCs, both PKM1 and PKM2 are upregulated within the first 8 days (Qin et al.
2017). Additionally, the knockdown of total PKM during this period hinders
reprogramming and overexpression of PKM2 significantly increases the generation of
iPSC colonies (Qin et al. 2017). PKM1 was originally thought to only be expressed in the
cells of non-proliferative tumors, however, PKM1 has recently been localized in the
nuclei of hepatoma (HepG2 and SMMC-7721 cell lines) cells following Oroxylin A (OA)
treatment and this localization was concluded to promote cellular differentiation to
hepatocytes-like cells (Wei et al. 2017; Israelsen et al. 2013).

Quantitative colocalization analysis (QCA) is most commonly divided into two metrics,
these measures are the degree of overlap and correlation (Dunn, Kamocka, and McDonald
2011). Both MOC and the PCC are commonly used to quantify fluorescent protein
spatial overlap and correlation (Adler and Parmryd 2012). Despite the accuracy and
power of QCA, this technique has been not been utilized to its full extent, especially so,
in its application to measuring protein colocalization in pluripotent stem cells (Dunn,
Kamocka, and McDonald 2011). This study contrasted both PCC versus MOC in our
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analysis of PKM1/2 colocalization with nuclear and cytoplasmic protein markers during
naïve, formative, and primed pluripotency within mouse ES cell cultures

This study, for the first time, comprehensively characterized the subcellular localization
and expression patterns of PKM1 and PKM2 isoforms during transition from naïve,
through the formative and onto the primed murine embryonic pluripotent states. I
accomplished this by optimizing a confocal microscopy colocalization approach
comparing correlation and co-occurrence of PKM1 and PKM2 localization to nuclear
localized OCT4 and cytoplasmic localized GAPDH. Degrees of colocalization were then
applied to our measured values of overlap and correlation using qualified ranges
indicating a spectrum of ‘very weak’ to ‘very strong’ variables of colocalization
(Zinchuk, Wu, and Grossenbacher-Zinchuk 2013). Using these approaches, the data
suggests an elevated nuclear presence of PKM1 and PKM2 in naïve mESCs, formative
state mEpiLCs and primed mEpiSCs as assessed by spatial overlap of PKM1 and PKM2
localization to OCT4 localization. The results also demonstrate a moderate association of
PKM1 and PKM2 to OCT4 localization in naïve mESCs and a strong association between
PKM1 and OCT4 in formative mEpiLCs. Together, the findings suggest a novel, noncanonical role for PKM1 in pluripotent stem cells.

3.3.0. Materials and methods:
3.3.1. Antibody specificity:

Rabbit polyclonal antibodies specific for PKM1 and PKM2 (Proteintech 15821-1-AP,
15822-1-AP) were used to distinguish between PKM1 and PKM2 protein localization and
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abundance in this study. These PKM1 and PKM2 antibodies recognize the corresponding
immunogens of LVRASSHSTDLMEAMAMGSV and LRRLAPITSDPTEATAVGAV,
respectively, and have been knockdown-verified confirming their isoform specificity
(Nakatsu et al. 2015; Horiuchi et al. 2017; Christofk et al. 2008; Ma et al. 2019; Jianan
Chen et al. 2018).

3.3.2. Feeder cell derivation and culture conditions:

Mouse embryonic fibroblasts (MEFs) (CF1 cell line, ThermoFisher) derived from E12.5
mouse embryos were plated and expanded on 0.1% porcine gelatin (Sigma G2500) coated
dishes and irradiated (8000 rads). Irradiated MEFs were cultured in media containing the
following: DMEM (ThermoFisher11960044), 8.9% Qualified FBS (ThermoFisher
12483020, lot# 1936657), 1.1% MEM NEAA (100x) (ThermoFisher 11140050), 1.1%
GlutaMAX (ThermoFisher 35050061). Irradiated MEFs were plated on 0.1% gelatin
dishes and cultured for a minimum of 1 hour prior to mEpiSC plating for
immunofluorescence and 24 hours for all other molecular analyses.

3.3.3. Stem cell culture conditions:
Feeder-free, naïve, mouse embryonic stem cells (mESCs, R1 strain – 129X1 x 129S1;
provided courtesy of Dr. Janet Rossant, Hospital for Sick Children, Toronto, Canada),
feeder-free, primed-like mouse epiblast-like cells (mEpiLCs, chemically converted R1
mESCs) and primed mouse epiblast stem cells (mEpiSCs, strain – 129S2; also provided
by Dr. Janet Rossant) were cultured in the following base media; a 1:1 mixture of
KnockOut DMEM/F12 (ThermoFisher 12660012) and Neurobasal Media (ThermoFisher
21103049) with 0.1% 2-Mercaptoethanol (Gibco 21985-029), 0.25% GlutaMAX
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(ThermoFisher 35050061), 1.0% N2 Supplement (100x) (ThermoFisher 17502048), 2.0%
B27 Supplement (50x) (ThermoFisher 17504044). Base media for the culture of mESCs
were supplemented with 1000 units/mL ESGRO Recombinant mouse LIF protein (EMD
Millipore ESG1107), and 2i small molecule inhibitors: 1 µM PD0325901 (Reagents
Direct 39-C68) and 3 µM CHIR99021 (Reagents Direct 27-H76). Base media for the
culture of mEpiLCs and mEpiSCs were supplemented with 20ng/mL Activin A from
mouse (Sigma-Aldrich SRP6057) and 12ng/mL Fgf-2 from mouse (Sigma-Aldrich
SRP3038). mESCs were passaged using Accutase (STEMCELL Technologies 07920)
and centrifuged at 244 x g for 5 minutes. Primed mouse epiblast stem cells were cultured
in the base medium and supplements as mEpiLCs were along with a substratum of
irradiated mouse embryonic fibroblasts (MEFs). One hour prior to passaging, growth
medium was replaced. Passaging was completed using Gentle Cell Dissociation Buffer
(Gibco 13151-014) for 5 minutes at room temperature. Lifted cells were then centrifuged
at 244 x g for 3 minutes and plated at a density of 1:12 onto fibronectin coated dishes
with MEFs. RNA and protein abundance studies were completed by excluding MEFS for
feeder-free conditions and passaging mEpiSCs with StemProTM AccutaseTM (Thermo
Fisher A1110501) to ensure only MEF free lysates were used. Additionally, during the
preliminary work for this study it was clear that the MEF feeder cells supporting the
mEpiSCs, express the PKM isoforms in abundance. mEpiSCs were weaned off irradiated
MEFs by gentle enzymatic passaging onto fibronectin over two passages, this resulted in
a clean and healthy population of feeder-free mEpiSCs ready for protein abundance
studies.
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3.3.4. Real-Time Quantitative qRT-PCR:

RNA isolation was completed using a RNeasy RNA isolation kit (Qiagen 74104) and
Trizol (Ambion 15596018) hybrid protocol followed by DNAse treatment (Invitrogen
AM1906). cDNA synthesis was completed in accordance with iScript (BioRad 1708891) protocols. Total RNA was extracted from adherent cells using TRIzol Reagent
(Invitrogen) and a RNeasy mini kit (Qiagen). DNAses were then removed using DNAse
Free Kit (AM1906). cDNA synthesis using iScript. Primers were tested in temperature
gradients before cDNA dilution series to determine primer efficiencies. Relative
transcript abundance was compared using mean±SEM with a two-way ANOVA with
Tukey’s multiple comparison test with three biological replicates. Relative transcript
abundance was calculated using the Pfaffl method of quantification, normalized to
mESCs and relative to TATA-binding protein (Tbp) transcript abundance. Forward and
reverse primer designs and annealing temperatures are available in Table 3.1.

Table 3.1 PCR Primers:
Gene

Potency/

Efficiency

Annealing

Sequence

Name

Role

(%)

Temperature

(F = Forward, R = Reverse; 5’ – 3’)

(℃)
Tbp

Reference
gene

Pecam
Dppa3
Rex1
Esrrb

Naïve
Naïve
Naïve
Naïve

99.42434

57.0 - 63.0

F- TACTGAAGAAAGGGAGAATCATGG
R- GAGACTGTTGGTGTTCTGAATAGG

89.999919

63.0

90.327424

63.0

96.622863

63.0

103.71074

63.0

F- CAAGGCCAAACAGAAACCCG
R- GCCTTCCGTTCTCTTGGTGA
F- AAAGTCGACCCAATGAAGGA
R- CGGGGTTTAGGGTTAGCTTT
F- AGAAGAAAGCAGGATCGCCT
R- TATGACTCACTTCCAGGGGG
F- CAGGCAAGGATGACAGACG
R- GAGACAGCACGAAGGACTGC
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Klf2
Klf4
Klf5

Naïve
Naïve
Naïve

Tcfcp2l1 Naïve
Lef1

Dnmt3
Pou1fc
Zic2
Cer1
T(Bra)

Formative

Formative
Formative
Primed
Primed
Primed

106.23229

63.0

102.51493

63.0

102.58943

63.0

99.564838

60.0

108.05468

F- TCGAGGCTAGATGCCTTGTGA
R- AAACGAAGCAGGCGGCAGA
F- TGGTGCTTGGTGAGTTGTGG
R- GCTCCCCCGTTTGGTACCTT
F- TACGGGCGAGAAGCCCTACA
R- GGCACACCATGCACTGGAAC
F- CCGCCCCTACAGTATGTGTT
R- AGTCCCCTAGCTTCCGATTC

57.0

F- AGAAGAAGAAGAGGAAGAGAGAGAAGC
R- AGATGTAGGCAGCTGTCATTCTGG

99.041999

63.0

98.95197

59.4

89.96254

63.0

99.767999

60.0

104.08831

60.0

F- GGCAAGGACGACGTTTTGTG
R- GTTGGACACGTCCGTGTAGTGAG
F- TTTCTCAAGTGTCCCAAGCC
R- ACCACCTCCTTCTCCAGTTG
F- GGTGACCCACGTCTCTGTG
R- CGGATGTGGTTGACCAGTTT
F- ACCTATGTGTGGATGGCTGC
R- AGATCCGGCTTGTCTTCTGC
F- CGGTGGCGAGAGAAGTGAAG
R- CTTCCCTGCGCTCTCTGTG

3.3.5. Western blotting:

Mouse ESCs and mEpiLCs were washed with cold DPBS (calcium chloride/magnesium
chloride/) (PBS(+/+)) (Gibco 14040-133) and all cell types were lysed with PierceTM
RIPA Buffer (ThermoScientific 89900) supplemented with 1X Phosphatase Inhibitor
Cocktail Set 2 (Calbiochem 5246251) and 1X Protease Inhibitor Cocktail Set 1
(Calbiochem 539131). mEpiSCs passaged off MEF-coated plates onto fibronectin
(Roche 11051407001) coated plates for a single passage using StemProTM AccutaseTM to
avoid MEF contamination. mEpiSCs were centrifuged at 244 x g and lysed. Lysates were
sonicated for five, 30 joule pulses over 30 seconds and were rotated at 4 °C for 30
minutes followed by centrifugation of 12000 rcf at 4 °C for 20 minutes with the
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supernatant removed into a fresh, chilled tube. Protein quantification was completed
using a PierceTM BCA Protein Assay kit (Thermo Fisher Scientific 23225). Protein
loading mixes were prepared at 10-25 µg samples in MilliQ H2O, LDS, and Reducing
Agent at 70°C for 10 minutes. Loading mixes were loaded in NuPAGETM 4-12% Bis-Tris
Gels (Invitrogen NuPAGE NP0336), the electroporation solution consisting of 1x MOPS
(BOLT Invitrogen B000102) and 500 µL of sample reducing agent containing
dithiothreitol (Thermofisher NP0009) added. Electrophoresis was completed at 200 V for
50 minutes. Proteins were transferred to a PVDF membrane at 100V for 2 hours in icecold conditions. The protein transferred PVDF membrane (EMD Immobilon
IPVH00010) was blocked in 5% bovine serum albumin (BSA) (ALB001) for
phosphorylated antibodies or 5% skimmed milk (Carnation) in 1x TBST for 1 hour at
room temperature with end-to-end agitation. Primary antibodies were introduced to the
membrane overnight at 4 °C with rotation. Membranes were washed 3 times for 10
minutes in TBST and HRP conjugated secondary antibodies were introduced for 1 hour at
room temperature with rotation. Membranes were then washed three times for 10
minutes each and imaged with Luminata Classico Western HRP Substrate (EMD
WBLUC0500) or Immobilon Forte Western HRP Substrate (EMD WBLUF0500) on a
ChemiDoc. Membranes were stripped using antibody stripping buffer (FroggaBio
ST010) until previous antibody binding was no longer evident. Bands of interest were
compared to 𝛽-ACTIN and/or Ponceaus S for total lane protein densitometry. Western
blotting densitometry results were compared using mean ± SEM, One-way ANOVA,
Tukey’s multiple comparison test with three biological replicates. Primary and secondary
antibodies and their concentrations are listed in Table 3.2.
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Table 3.2 Western blot antibody/marker list:
Primary

Concentration

Antibody/Marker
𝛽-ACTIN

Secondary

Concentration

Antibody
1:50000

A3854

N/A: HRP-

N/A: HRP-

linked

linked

PKM1

1:5000,

Anti-rabbit IgG,

1:2000-10,000,

15821-1-AP

5% TBST

HRP-linked

5% Milk in

Antibody #7074

TBST

Cell Signaling
Technology
pPKM2

1:5000,

Anti-rabbit IgG,

1:2000-10,000,

(Tyr105)

5% BSA in

HRP-linked

5% BSA in

3827S

TBST

Antibody #7074

TBST

Cell Signaling
Technology

PKM2

1:5000,

Anti-rabbit IgG,

1:2000

15822-1-AP

5% Skim milk

HRP-linked

5%Milk in

in TBST

Antibody #7074

TBST

Cell Signaling
Technology

OCT4

1:5000

Donkey anti-

1:10,000,

sc-5279

5% Skim milk

mouse IgG-

5% Skim milk

in TBST

HRP

in TBST

sc-2314
Santa Cruz

68
GAPDH

1:10000

Donkey anti-

1:10,000,

sc-32233

5% Skim milk

mouse IgG-

5% Skim milk

in TBST

HRP

in TBST

sc-2314
Santa Cruz
LAMIN A

1:10000

Anti-rabbit IgG,

1:2000

Ab26300

5% Skim milk

HRP-linked

5% Skim milk

in TBST

Antibody #7074

in TBST

Cell Signaling
Technology
∝-TUBULIN

1ug/mL

Anti-rabbit IgG,

1:2000

5% Skim milk

HRP-linked

5% Skim milk

in TBST

Antibody #7074

in TBST

Cell Signaling
Technology
Ponceau Stain

0.1% (w/v), 5%

N/A

N/A

acetic acid

3.3.6. Immunofluorescence and confocal microscopy:

Cells were plated onto 1.25mm thick coverslips coated with gelatin. When ready, cells
were fixed with 2% paraformaldehyde (PFA) (EMS 15714) in PBS(+/+) for 10 minutes
and washed for 5 minutes with chilled PBS(+/+). Following fixation, cells were
permeabilized with 0.1% Triton X-100 (TX1568-1) in PBS(+/+) for 10 minutes and
washed for 5 minutes with room temperature PBS(+/+). Cells were then blocked in 10%
animal serum of the host-species of the secondary antibody, diluted in 0.1% PBS(+/+)Tween 20 (PBST) for 30 minutes. Primary antibody was diluted in 10% animal serum of
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the host-species of secondary antibody, diluted with 0.1% PBST overnight. Following
primary incubation, cells were washed once for 5 minutes in PSB(+/+) before incubation
in secondary antibody, diluted in 10% animal serum of the host-species of secondary
antibody in 0.1% PBST for 1 hour. See supplementary Table 3.3. for primary and
secondary antibody dilutions. Hoechst staining was completed where necessary
(secondary only controls in the case of colocalization) for 5 minutes in PBS(+/+)
followed two washes in PBS(+/+) for 5 minutes per wash. Cells were then mounted onto
coverslips with Prolong Gold (P36934). Each experiment and their individual cell types
included a secondary only control that was analysed with the same laser intensities as the
treatment samples. Individual treatments were completed in three biological replicates.
Primary and secondary antibodies and their concentrations are listed in Table 3.3.

Table 3.3 Immunofluorescence antibody and stain list:

Primary Antibody Concentration Secondary

Concentration

Antibody
PKM1

1:50

15821-1-AP
PKM2

1:50

1:50

AF2729

10ug/ml

488-G∝M

1ug/ml

A11001
1:50

sc-32233
mNANOG

555-G∝R
A32732

sc-5279
GAPDH

10ug/mL

A32732

15822-1-AP
OCT4

555-G∝R

488-G∝M

1ug/ml

A11001
10ug/ml

488-D∝ G
A11055

10ug/ml

70
SOX2

1:50

sc-365823
HNF-4α

1ug/ml

A11001
1:500

K9218

Phalloidin (647)

488-G∝M

488-G∝M

1ug/ml

A11001

4ug/mL

N/A

N/A

3 drops/mL

N/A

N/A

A22287
Hoechst (NucBlue)

3.3.7. Colocalization: co-occurrence and correlation by immunofluorescence:

Orthogonal projections of colony optimal slice generated image stacks were taken at 40x
and 63x immersed in oil by a Zeiss LSM800 confocal microscope. Thresholds were set
by optimized single stain samples (channel 488 - OCT4, GAPDH and channel 555 PKM1, PKM2) exposed to all tested lasers and exposures. These exposures and laser
intensities were tested against secondary antibody only controls. Double stains
(PKM1/OCT4, PKM1/GAPDH, PKM2/OCT4 and PKM2/GAPDH) were taken in stacks
containing full colonies and processed into orthogonal projections. The projections were
then set to the predetermined co-localization thresholds (Costes thresholds were set when
applicable) as set from the single stain controls. Each treatment was analysed in at least
biological triplicate and each biological replicate was examined for several technical
replicates of different colonies within their respective samples. Double stained treatments
were compared for co-occurrence and correlation using Manders’s Overlap Coefficient
(MOC) and Pearson’s Correlation Coefficient (PCC) respectively. MOC and PCC
represent areas of spatial overlap and correlation between two controlled fluorophores
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within regions of interest respectively. Areas of interest and negation of background
information was completed using the outline tool to circle colonies and cells of interest
while removing staining on MEFs and potential sources of non-specific binding.
Additionally, individual cells were compared to whole colonies using airyscan processing
under 63x magnification by confocal microscopy. This process increased the signal-tonoise ratio thus increasing signal resolution. Due to the intensity of light during an
airyscan process, photobleaching prevented stacks of colonies at 63x when examining the
individual cells. PCC values were categorised within set ranges to a classification, that
included: correlation: very weak: -1 – -0.27, weak: -0.26 - 0.09, moderate: 0.1 – 0.48,
strong: 0.49 – 0.84, and very strong: 0.85 – 1.0 (Zinchuk, Wu, and GrossenbacherZinchuk 2013). MOC values fall into set ranges of: overlap: very weak: 0 – 0.49, weak:
0.50 – 0.70, moderate: 0.71 – 0.88, strong: 0.89 – 0.97, very strong: 0.98 – 1.0 (Zinchuk,
Wu, and Grossenbacher-Zinchuk 2013). Statistical analysis included application of a two
tailed Mann-Whitney test of mean ±SEM MOC and PCC scores run in at least three
biological and technical replicates. All tested samples were stained and treated in the
same manner and processed in the same session. Between microscopy sessions, single
stain laser thresholds were retaken to account for any potential photobleaching. Statistics
of PCC and MOC treatments relative to the positive reference represent a two-way
ANOVA with Sidak’s multiple comparisons test of mean±SEM PCC and MOC scores
where ∝=0.05, n=3 biological replicates.
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3.3.8. Nuclear and cytoplasmic fractionation.
Rapid isolation of nuclei from cells was completed using the REAP protocol (Nabbi and
Riabowol 2015). mESCs were grown to 90% confluency on 10 cm dishes. Prior to
collection, culture medium was aspirated, and the cells were washed with ice-cold PBS(/-) with 1X Protease Inhibitor Cocktail Set 1 (Calbiochem 539131). The PBS was
aspirated, and the dish was placed on ice where 1 mL of PBS was added, and the cells
were scraped and centrifuged for 10 seconds at 10,000 rpm. The supernatant was
aspirated and resuspended in 900 µL of ice-cold 0.1% Tergitol-NP-40 (Sigma NP-40S) in
PBS(-/-) before being triturated 5 times. At this point a 300 µL total lysate sample was
removed and stabilized in Laemmli buffer and vortexed. This sample was sonicated at 20
kHz for 2 pulses each 8 seconds long and the sample was then boiled for 1 minute and
frozen prior to western blotting. The remaining NP-40 suspended sample was then
centrifuged at 10,000 rpm for 10 seconds and 300 µL was removed as the cytoplasmic
fraction. This fraction was stabilized in Laemmli buffer, vortexed and boiled for 1 minute
before being frozen prior to western blotting. The remaining NP-40 suspended sample
was aspirated and resuspended in 1 mL 0.1% NP-40 in PBS(-/-) with 1X Protease
Inhibitor Cocktail Set 1 before centrifuged at 10,000 rpm. The supernatant was
discarded, and the pellet resuspended in water and Laemmli buffer before sonication at 20
kHz for 2 pulses at 8 seconds per pulse. This nuclear fraction was boiled for 1 minute
and frozen for future western blotting as described above. Antibody staining for control
markers LAMIN A and ∝-TUBULIN and the markers of interest PKM1, pPKM2, and
PKM2 were compared relative to total lane protein content by Ponceau staining (0.1%
Ponceau, 5% acetic acid). Each cell type’s mean densitometry ± SEM was analyzed by
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applying a one-way ANOVA with Tukey’s multiple comparison test or unpaired, two
tailed t-test respectively with 3 biological replicates.

3.4.0. Results:

3.4.1. Characterization of naïve mESCs transitioning towards a primed pluripotent
state.

By 72 hours following the removal of mouse LIF and 2i supplementation with the
addition of Fgf-2/Activin A (FA media), mESCs approximating a primed-like pluripotent
state underwent an apoptotic event with the resulting colonies transitioning to a flattened
morphology (Supplementary Figure 3.01.). The mESCs by 72 hours had transitioned to
mEpiLCs (primed-like state) and the mESCs, mEpiLCs, and mEpiSCs showed
homogenous colony expression of the pluripotency associated genes NANOG, OCT4,
and SOX2 (Figure 3.01.A). Secondary antibody only controls confirmed the specificity
of the immunofluorescence staining (Supplementary Figure 3.02.).
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Supplementary Figure 3.01. mEpiLC generation and mPSC cell morphology.
(A) Schematic depicting the generation of mEpiLCs from mESCs and the associated
pluripotent states. (B) Phase contrast microscopy of mESCs, mEpiLCs (24, 48, 72, 96,
and 120 hours) and mEpiSCs grown on MEFs. Images take using 10x Magnification and
scale bars represent 250 and 300 𝜇𝑚 (as indicated).
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Supplementary Figure 3.02. Secondary antibody only immunofluorescence controls
for pluripotency markers.
Immunofluorescence of mESC, mEpiLC, and mEpiSC stained for Hoechst, phalloidin
and the secondary antibodies (Table 3.3.) used throughout this study, assessed by
confocal microscopy. Images taken using 40x magnification and scale bars represent 20
𝜇𝑚.
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Assessment of stage specific transcript abundance of naïve, formative, and primed
markers verified the pluripotent state of mESCs, mEpiLCs, and mEpiSCs, respectively
(Figure 3.01.). The naïve pluripotent associated genes: Rex1, Esrrb, Pecam, Tcfcp2l1,
Klf2, Klf4, Dppa3, and Klf5 all underwent a significant (p<0.05) reduction in transcript
abundance in mEpiLCs and mEpiSCs relative to mESCs (Figure 3.01.B). The transcript
abundance of formative pluripotent associated genes; Lef1, Dnmt3, and Pou1fc were
significantly (p<0.05) increased in mEpiLCs compared to mESCs with Dnmt3 and
Pou1fc mRNAs also significantly (p<0.05) elevated in mEpiLCs over that observed in
mEpiSCs (Figure 3.01.B). The transcript abundance of primed pluripotent state
associated markers Zic2, T(Brachyury), and Cer1 were significantly (p<0.05) increased in
the mEpiSCs relative to the mESCs (Figure 3.01.B).
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Figure 3.01. mESC, mEpiLC, and mEpiSC populations transcript abundance for
pluripotency genes.
(A) Immunofluorescence of mESC, mEpiLC, and mEpiSC stained with Hoechst (blue),
phalloidin (red) and the core pluripotency associated markers (green): NANOG, OCT4,
SOX2 assessed by confocal microscopy. Images taken using 40x magnification and scale
bars represent 20 𝜇𝑚. (B) Histogram of transcript abundance of naïve, formative, and
primed pluripotent associated genes relative to Tbp and normalized to mESCs. Error bars
represent standard error of the mean (SEM), n=3, *p<0.05. Statistics for the transcript
abundance study represent a two-way ANOVA with Tukey’s multiple comparisons of
mean±SEM where ∝=0.05, n=3 biological replicates run in technical triplicate.
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3.4.2. PKM1/2 protein abundance and localization fluctuate in naïve mESCs,
primed-like mEpiLCs, and primed mEpiSCs.

There was a significant (p<0.05) increase in PKM1 and PKM2 protein abundance relative
to 𝛽-ACTIN in formative primed-like mEpiLCs cultured in Fgf-2/Activin A (FA
medium) compared to naïve mESCs or primed mEpiSCs (Figure 3.02.A). The ratio of
phosphorylated (Tyr105), homodimeric conformation of PKM2 to total PKM2 protein
abundance relative to 𝛽-ACTIN significantly (p<0.05) decreased when naïve mESCs
were transitioned to formative, primed-like mEpiLCs. However, no significant (p>0.05)
difference in the ratio of PKM1 to PKM2 protein abundance relative to 𝛽-ACTIN was
observed in any pluripotency cell state cultures investigated. PKM1 and PKM2 protein
fluorescence were detected in the cytoplasm and nuclei of mESCs, mEpiLCs, and
mEpiSCs as demonstrated by morphological comparison with Hoechst and rhodamine
phalloidin stains representing nuclear and cytoskeletal compartments respectively (Figure
3.02.B). Secondary antibody only controls confirmed the specificity of the PKM1/2
immunofluorescence staining (Supplementary Figure 3.04.).
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Figure 3.02. Distinct PKM1 and PKM2 protein profiles in mESCs, mEpiLCs, and
mEpiSCs.
A) Histogram comparing protein abundance of PKM1, PKM2, and pPKM2 relative to 𝛽ACTIN in mESCs, mEpiLCs, and mEpiSCs in total protein lysates. Error bars represent
SEM, n=3, *p<0.05. B) Immunofluorescence of mESC, mEpiLC, and mEpiSC stained
for Hoechst (blue), phalloidin (red) and the metabolic markers: PKM1 and PKM2 (green)
assessed by confocal microscopy. Images taken using 40x magnification and scale bars
represent 20 𝜇𝑚. Error bars represent SEM, n=3, *p<0.05. Statistics represent a one-way
ANOVA with Tukey’s multiple comparisons of mean±SEM MOC and PCC scores run in
n=3 biological replicates.
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3.4.3. Qualitative PKM1/2 nuclear translocation in naïve mESCs, formative
mEpiLCs, and primed mEpiSCs

Following the first indication of nuclear PKM1/2 in naïve mESCs, a series of precolocalization imaging studies were completed as a precursor for Chapters 2 and 3.
Nuclear PKM1/2 was not always clearly visible in colonies or individual cells, this led us
to taking a 3-dimension (3D) approach to imaging. Using a confocal microscope,
individual slices of fluorescent images were stacked to generate a 3D structure of entire
colonies of mESCs and mEpiSCs for PKM1 and PKM2 (Figure 3.03.). Visually
examining the 3D architecture of mESCs stained for PKM1 provide our first truly
promising evidence of nuclear PKM1 translocation as cells closer to the upper layers of
the colony exhibit clear nuclear localization.
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Figure 3.03. 3D rendered immunofluorescence imaging of mESC and mEpiSC
PKM1 and PKM2 indicate potential nuclear localization patterns.
Colonies of mESCs and mEpiSCs stained for PKM1 and PKM2 demonstrate a 3D
rendering of localization patterns within cells. Nuclear localization of PKM1 in mESCs
is visually demonstrated in cells of the upper layers of the colony. Scale bars are depicted
on all 3 axes and imaging was completed at 40x objective; scale bars depict
measurements in m.
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To further promote the notion of nuclear translocation of PKM1/2 in mESCs and
mEpiSCs, I utilized the pharmacological agent Leptomycin B. Leptomycin B is an
antibiotic and the first agent found that works to block nuclear export in cells (Wolff,
Sanglier, and Wang 1997). As Leptomycin B doesn’t impede nuclear import, it served as
a useful tool in the study of nuclear PKM1/2 translocation. Leptomycin was first
assessed in a time course (Supplementary Figure 3.03, Figures 3.04., and 3.05.). As small
colonies visually appeared to show the most consistent nuclear PKM1, I examined the
influence of adding the nuclear export blocking agent Leptomycin B in mESCs over 3, 6,
9, and 12 hours comparing no Leptomycin to 2 ng/mL treatments by fluorescence
imaging. Based on these images, there is a qualitative increase in nuclear PKM2 at 12
hours (Figure 3.04.) and PKM1 throughout the series (Figure 3.05.).
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Figure 3.04. Nuclear translocation of PKM2 following Leptomycin B treatment.
Elevated PKM2 nuclear translocation in naïve mESCs were treated with Leptomycin B to
block nuclear export over 12 hours. Cells were stained for the nuclear localized
pluripotency marker SOX2, DAPI, PKM2, and Phalloidin. Scale bars represent 10 m.
Imaging was completed at 63x objective.
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3 Hours

0 Hours
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Figure 3.05. Nuclear translocation of PKM1 following Leptomycin B treatment time
course.
Progression of nuclear translocation of PKM1 in mESCs with the addition of Leptomycin
B to hinder nuclear export over 12 hours. Cells were stained for the nuclear localized
pluripotency marker SOX2, DAPI, PKM1, and Phalloidin. Scale bars represent 10 m.
Imaging was completed at 63x objective.
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Supplementary Figure 3.03. No Primary controls for small colony nuclear
localization imaging.
No primary controls of mESCs grown in small colonies stained with DAPI and
Phalloidin. Scale bars represent 10 m. Imaging was completed at 63x objectives.
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The concentration of Leptomycin B was then increased to better demonstrate nuclear
localization in larger colonies. Examining mESCs at 5 and 10 hours following the
addition of 20 µg/mL of Leptomycin B showed clearer nuclear translocation of PKM1 at
10 hours relative to no leptomycin B treatment (Figure 3.06.). The addition of nuclear
and cytoplasmic markers further allowed for a comparison of nuclear translocation.
SOX2, Hoechst, and Phalloidin made comparing nuclear PKM1 substantially more
evident and further promoted the idea of adding nuclear references to (see Chapter 2
colocalization methodology). It was clear that blocking nuclear export in these cells was
detrimental to their viability and not a long-term solution.
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Supplementary Figure 3.04. Secondary antibody only immunofluorescence controls
for PKM1 and PKM2 and colocalization study.
Immunofluorescence microscopy of mESC, mEpiLC and mEpiSC stained for Hoechst,
phalloidin and the secondary antibodies (Table 3.3.) used throughout this study, assessed
by confocal microscopy. Images taken using 40x magnification and scale bars represent
20 𝜇𝑚.
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Supplementary Figure 3.05. mESC PKM1, PKM2, OCT4, and GAPDH
colocalization settings.
Immunofluorescence microscopy of mESCs demonstrating single fluorescence images for
PKM1, PKM2, OCT4, and GAPDH along with their respective thresholds. Images taken
using 40x magnification and scale bars represent 20 𝜇𝑚. Confocal laser channels
labelled as 488 and 555 corresponding to treatments incubated with OCT4/GAPDH and
PKM1/PKM2 respectively.
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Figure 3.06. Time course fluorescence imaging of mESCs treated with Leptomycin
B prevent nuclear export of PKM1.
The addition of the nuclear export blocking agent Leptomycin B to mESCs at 20 µg/mL
over 5 and 10 hours demonstrates that PKM1 translocated to the nuclei. Scale bars
represent 20 m and microscopic imaging was completed using a 63x objective.
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Finally, I examined both naïve mESCs and primed mEpiSCs for PKM1 and PKM2
protein localization by fluorescence imaging with the addition of 20 µg/ml Leptomycin B
(Figure 3.07.). This imaging provided evidence that not only naïve mESCs experience
nuclear translocation, but primed mEpiSCs, exhibiting the aerobic glycolytic metabolic
preference also have a degree of nuclear PKM1 and PKM2 nuclear translocation. I
originally hypothesized that primed mEpiSCs would have nuclear PKM2 as this
localization pattern is indicative of dimeric pPKM2 and the Warburg Effect (Weiwei
Yang et al. 2012; W. Zhou et al. 2012). Nuclear translocation of PKM1 and PKM2 in
either end of the pluripotent continuum naturally led us to investigate what happens in
between the naïve and primed states, and ultimately devise a better system of
colocalization methodology.
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Figure 3.07. Initial results indicating potential nuclear localization of PKM1 in
mESCs.
Naïve and primed mPSCs appear to show nuclear localization of the metabolic proteins
PKM1 and PKM2. This was an early finding following the addition of Leptomycin B for
a nuclear export blockade to demonstrate nuclear translocation of PKM1. Cultured
mESCs and mEpiSCs treated with 20 g/mL of Leptomycin B for 5 hours, stained for
PKM1 and PKM2. Scale bars represent 5 m and imaged at 40x and 63x objectives.
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3.4.4. Subnuclear localization of PKM1 and PKM2 with OCT4 within naïve
mESCs.

To authenticate the subcellular immunofluorescence results (Figure 3.02.B), a
colocalization study investigating spatial co-occurrence or overlap and correlation of
PKM1 and PKM2 with the nuclear localized marker OCT4 and the cytoplasmic localized
marker GAPDH using confocal microscopy was conducted. Colocalization of
immunofluorescent spatial overlap and correlation was compared using Manders’s
overlap coefficient (MOC) and Pearson’s correlation coefficient (PCC), respectively on
orthogonal projections with background pixels removed from quantification (Dunn,
Kamocka, and McDonald 2011). Using these methods, total mESC colony colocalization
of PKM1 and PKM2 with OCT4 and GAPDH showed a high instance of spatial overlap
to both marker proteins with a significantly (p<0.05) greater overlap to nuclear OCT4
(Figure 3.08.A, B). However, PKM1 displayed significantly (p<0.05) higher correlation
to OCT4 localization compared to GAPDH (Figure. 3.08. B). Using the standards set by
Zinchuk et al., PKM1 and PKM2 exhibited a ‘moderate’ correlation and a ‘strong’
overlap to both OCT4 and GAPDH localization (PCC range: moderate = 0.1-0.48, MOC
range: strong = 0.89-0.97) (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013). By
increasing the signal-to-noise ratio through airyscan processing, the colocalization
resolution was improved and the analysis was applied to individual mESCs. Individual
cell analysis aligned closely with the colony analysis by indicating a strong correlation for
spatial co-occurrence for PKM1 and PKM2 in mESCs (Supplementary Figure 3.06.A, B).
Immunofluorescence controls and colocalization thresholds are shown in Supplementary
Figure 3.05.
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Figure 3.08. PKM1 and PKM2 are translocated to the nuclei of mESCs and both
PKM1 and PKM2 are associated with OCT4 and GAPDH localization.
(A) Immunofluorescence of mESCs stained for OCT4 (green), GAPDH (green), and
PKM2 (orange) for a confocal, colocalization analysis. Images taken using 40x
magnification and scale bars represent 20 𝜇𝑚. Histogram comparing PKM2 to OCT4
and GAPDH spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s
Correlation Coefficient (PCC). Error bars represent SEM, n=3, *p<0.05. (B)
Immunofluorescence of mESCs stained for OCT4 (green), GAPDH (green), and PKM1
(orange) for a confocal, colocalization analysis. Images taken using 40x magnification
and scale bars represent 20 𝜇𝑚. Histogram comparing PKM1 to OCT4 and GAPDH
spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s Correlation
Coefficient (PCC). Error bars represent SEM, n=3, *p<0.05. Statistics represent a two
tailed Mann-Whitney test of mean±SEM MOC and PCC scores run in n=4 biological
replicates and at least a technical triplicate.
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Supplementary Figure 3.06. PKM1/2 colocalization within individual cells of mESC
colonies.
Immunofluorescence microscopy of mESC colonies, colocalization analysis compared
MOC and PCC of the total colony to that of a single cell. (A) PKM2 staining versus
OCT4 and GAPDH in mESCs comparing orthogonal projections of whole colonies to
individual cells by airyscan processing. (B) PKM1 staining versus OCT4 and GAPDH in
mESCs comparing orthogonal projections of whole colonies to individual cells by
airyscan processing. Images taken using 40x magnification with scale bars represent 20
𝜇𝑚 and 63x magnification with scale bars representing 5 𝜇𝑚. Square boxes indicate
areas of interest from the 40x for 63x magnification. White outlines around cells
represents the area of analysis of the airyscanned images.
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3.4.5. Subnuclear localization of PKM1 and PKM2 with Oct4 in mEpiLCs.

Immunofluorescence colocalization was quantified in mEpiLCs cultured in transitioning
FA medium at 48 hours via confocal microscopy of orthogonal projections and airyscan
processing. These cells represent the formative pluripotent state. I applied total colony
and single cell colocalization analysis as described above, and observed co-occurrence of
PKM1 and PKM2 compared to OCT4 and GAPDH with a significantly (p<0.05) greater
PKM1 spatial co-occurrence to OCT4 (Figure 3.09.A, B). Only PKM1 localization was
correlated with both OCT4 and GAPDH localization in these cultures (Figure 3.09.B).
PKM1 exhibited a ‘strong’ correlation and a ‘strong’ overlap with OCT4 localization, a
‘moderate’ correlation and a ‘strong’ overlap to GAPDH localization (PCC range: strong
= 0.49-0.84, MOC range: strong = 0.89-0.97) (Zinchuk, Wu, and Grossenbacher-Zinchuk
2013). PKM2 displayed a ‘weak’ correlation to both OCT4 and GAPDH with a ‘strong’
overlap to OCT4 and a ‘moderate’ overlap to GAPDH (PCC range: weak = -0.26-0.09,
MOC range: moderate = 0.71-0.88, strong = 0.89-0.97). Using airyscan processing,
individual cells of mEpiLC colonies displayed consistent correlation and spatial overlap
compared to the colony (Supplementary Figure 3.08. A, B). Immunofluorescence
controls and colocalization thresholds are shown in Supplementary Figure 3.07.
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Figure 3.09. PKM1 and PKM2 are translocated to the nuclei of mEpiLCs and
PKM1 is associated with OCT4 and GAPDH localization.
A) Immunofluorescence of mEpiLCs stained for OCT4 (green), GAPDH (green), and
PKM2 (orange) for a confocal, colocalization analysis. Images taken using 40x
magnification and scale bars represent 20 𝜇𝑚. Histogram comparing PKM2 to OCT4
and GAPDH spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s
Correlation Coefficient (PCC). Error bars represent SEM, n=3. (B) Immunofluorescence
of mEpiLCs stained for OCT4 (green), GAPDH (green) and PKM1 (orange) for a
confocal, colocalization analysis. Images taken using 40x magnification and scale bars
represent 20 𝜇𝑚. Histogram comparing PKM1 to OCT4 and GAPDH spatial localization
by Manders’s Overlap Coefficient (MOC) and Pearson’s Correlation Coefficient (PCC).
Error bars represent SEM, n=3, *p<0.05. Statistics represent a two tailed Mann-Whitney
test of mean±SEM MOC and PCC scores run in at least n=3 biological replicates and at
least technical triplicate.
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Supplementary Figure 3.07. mEpiLC PKM1, PKM2, OCT4 and GAPDH
colocalization settings.
Immunofluorescence microscopy of mEpiLCs demonstrating single fluorescence images
for PKM1, PKM2, OCT4, and GAPDH along with their respective thresholds. Images
taken using 40x magnification and scale bars represent 20 𝜇𝑚. Confocal laser channels
labelled as 488 and 555 corresponding to treatments incubated with OCT4/GAPDH and
PKM1/PKM2 respectively.
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Supplementary Figure 3.08. PKM1/2 colocalization within individual cells of
mEpiLC colonies.
Immunofluorescence microscopy of mEpiLC colonies, colocalization analysis compared
MOC and PCC of the total colony to that of a single cell. (A) PKM2 staining versus
OCT4 and GAPDH in mEpiLCs comparing orthogonal projections of whole colonies to
individual cells by airyscan processing. (B) PKM1 staining versus OCT4 and GAPDH in
mEpiLCs comparing orthogonal projections of whole colonies to individual cells by
airyscan processing. Images taken using 40x magnification with scale bars represent 20
𝜇𝑚 and 63x magnification with scale bars representing 5 𝜇𝑚. Square boxes indicate
areas of interest from the 40x for 63x magnification. White outlines around cells
represents the area of analysis of the airyscanned images.
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3.4.6. Subnuclear Localization of PKM1 and PKM2 with Oct4 in mEpiSCs.

As observed for the naïve mESCs and the formative mEpiLCs, a high degree of PKM1
and PKM2 spatial overlap to both OCT4 and GAPDH in mEpiSCs was observed (Figure
3.10.A, B). However, unlike the mESCs and mEpiLCs, there were only low levels
representing no meaningful correlation of PKM1 or PKM2 with OCT4 or GAPDH in
these cultures (Figure 3.10.A, B). PKM1 and PKM2 immunofluorescence each showed a
‘strong’ overlap to both OCT4 and GAPDH immunolocalizations (MOC range: 0.890.97) (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013). PKM1 and PKM2 displayed a
‘weak’ correlation to OCT4 and a ‘moderate’ correlation to GAPDH (PCC range: weak =
-0.26-0.09, moderate = 0.1-.48). Using airyscan processing, individual cells of mEpiLC
colonies displayed consistent correlation and spatial overlap compared to the colony
(Supplementary Figure 3.10.A, B). Immunofluorescence controls and colocalization
thresholds are shown in Supplementary Figure 3.09.
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Figure 3.10. PKM1 and PKM2 are translocated to the nuclei of mEpiSCs and
neither isoform is associated with OCT4 or GAPDH localization.
(A) Immunofluorescence of mEpiSCs stained for OCT4 (green), GAPDH (green), and
PKM2 (orange) for a confocal, colocalization analysis. Images taken using 40x
magnification and scale bars represent 20 𝜇𝑚. Histogram comparing PKM2 to OCT4
and GAPDH spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s
Correlation Coefficient (PCC). Error bars represent SEM, n=3. (B) Immunofluorescence
of mEpiSCs stained for OCT4 (green), GAPDH (green) and PKM1 (orange) for a
confocal, colocalization analysis. Images taken using 40x magnification and scale bars
represent 20 𝜇𝑚. Histogram comparing PKM1 to OCT4 and GAPDH spatial localization
by Manders’s Overlap Coefficient (MOC) and Pearson’s Correlation Coefficient (PCC).
Error bars represent SEM, n=3. Statistics represent a two tailed Mann-Whitney test of
mean±SEM MOC and PCC scores run in at least n=3 biological replicates and at least
technical triplicate.
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Supplementary Figure 3.09. mEpiSC PKM1, PKM2, OCT4, and GAPDH
colocalization settings.
Immunofluorescence microscopy of mEpiSCs demonstrating single fluorescence images
for PKM1, PKM2, OCT4, and GAPDH along with their respective thresholds. Images
taken using 40x magnification and scale bars represent 20 𝜇𝑚. White outlines represent
area of analysis to exclude areas of MEF staining. Confocal laser channels labelled as
488 and 555 corresponding to treatments incubated with OCT4/GAPDH and
PKM1/PKM2 respectively.
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Supplementary Figure 3.10. PKM1/2 colocalization within individual cells of
mEpiSC colonies.
Immunofluorescence microscopy of mEpiSC colonies, colocalization analysis compared
MOC and PCC of the total colony to that of a single cell. (A) PKM2 staining versus
OCT4 and GAPDH in mEpiSCs comparing orthogonal projections of whole colonies to
individual cells by airyscan processing. (B) PKM1 staining versus OCT4 and GAPDH in
mEpiSCs comparing orthogonal projections of whole colonies to individual cells by
airyscan processing. Images taken using 40x magnification with scale bars represent 20
𝜇𝑚 and 63x magnification with scale bars representing 5 𝜇𝑚. Square boxes indicate
areas of interest from the 40x for 63x magnification. White outlines around cells
represents the area of analysis of the airyscanned images.
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3.4.7. PKM1 and PKM2 are differentially localized to OCT4 and GAPDH between
naïve, formative, and primed pluripotent states.
To obtain a deeper understanding of the cellular co-occurrence of nuclear PKM1 and
PKM2 during the transition from mESCs, mEpiLCs, and mEpiSCs cultures, I contrasted
the outcomes between overall co-occurrence (MOC) with Hoechst and OCT4 (positive
reference) and Hoechst and GAPDH (negative reference). Relative to the positive
reference, there was no significant (p>0.05) changes to MOC of PKM1 or PKM2
localization to OCT4 localization in mESCs, mEpiLCs, or mEpiSCs, indicating that
PKM1 and PKM2 do indeed occupy nuclear associated regions in these pluripotent cells
(Figure 3.12.B). Relative to the positive reference, there was a no significant (p>0.5)
changes to the MOC of PKM1 or PKM2 localization to GAPDH localization in mESCs
and mEpiSCs, indicating that PKM1 and PKM2 do indeed occupy cytoplasmic regions in
these cells as well (Figure 3.12.B). However, relative to the positive reference, there was
a significant (p<0.05) decrease in MOC of PKM1 and PKM2 localization to GAPDH
localization in the mEpiLCs, indicating a decreased cytoplasmic presence in these cells
(Figure 3.12.B).

To further interrogate the subnuclear association of nuclear PKM1 and PKM2 during
transitioning mESCs, mEpiLCs, and mEpiSCs cultures, I compared the outcomes
between overall correlation (PCC) with Hoechst and OCT4 (positive reference) and
Hoechst and GAPDH (negative reference). Each mPSC state examined showed
differential PKM1/2 subnuclear expression correlation to OCT4 and GAPDH compared
to the positive reference. Relative to the positive reference indicating nuclear OCT4
association, there was no significant (p>0.05) difference in PCC of PKM1 or PKM2
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localization to OCT4 or GAPDH in mESCs (Figure. 3.11.B). In contrast, mEpiLCs and
mEpiSC displayed significantly (p<0.05) less PCC of PKM2 localization to OCT4
relative to the positive reference, however, these values did not reach a meaningful linear
correlation level (Figure 3.11.B). Relative to the positive reference indicating nuclear
association, there was no significant (p>0.05) PCC difference in PKM1 and a significant
(p<0.05) decrease in correlation of PKM2 localization to OCT4 and GAPDH localization
relative to the positive reference in mEpiLCs, suggesting nuclear association of PKM1
and reduced nuclear association of PKM2 with OCT4 (Figure 3.11.B). Relative to the
positive reference indicating nuclear association, there was a significant (p<0.05)
decrease in PCC of PKM1 and PKM2 localization to OCT4 and GAPDH localization
relative to the positive reference in mEpiSCs (Figure 3.11.B). However, in the case of
mEpiLCs and mEpiSCs, values with PCC = 0 reflect no meaningful linear correlation and
a meaningful association of PKM1 or PKM2 localization to these fluorophores of interest
cannot be conclusively inferred.

Using the standard ranges set by Zinchuk et. al. to describe these values with qualifying
terms, there is an observed ‘strong correlation’ and ‘strong overlap’ in the Hoechst/OCT4
positive reference (PCC = 0.49±0.06, MOC = 0.95± 0.00) and a ‘very weak correlation’
and ‘strong overlap’ in the GAPDH/Hoechst negative reference (PCC = -0.07±0.08,
MOC =0.89±0.01) (Figure 3.11.A) (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).
These standards promote the superiority of the PCC over the MOC, however, there was a
significant difference between the positive and negative references and our sample data
indicating a valuable role for the MOC comparison as well.
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In summary, PKM1 and PKM2 occupy the same spatial localization as OCT4 nuclear
regions and differentially correlate to subnuclear localizations relative to OCT4 and
GAPDH localization in mESCs, mEpiLCs, and mEpiSCs. I demonstrate that both the
PCC and MOC metrics are valuable in comparison to known positive nuclear references,
in this case Hoechst staining. Reference stains and colocalization thresholds are available
in Supplementary Figure 3.11.
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Figure 3.11. PKM1/2 are moderately associated with OCT4 localization in mESC,
PKM1 is strongly associated with OCT4 localization in mEpiLCs, and PKM1/2
overlap in nuclear regions of mESCs, mEpiLCs, and mEpiSCs.
(A) Immunofluorescence of mESCs immuno-stained for OCT4 (green), GAPDH (green),
and Hoechst (blue) for a confocal, colocalization analysis. Images taken using 40x
magnification and scale bars represent 20 𝜇𝑚. Histogram comparing Hoechst to OCT4
and GAPDH spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s
Correlation Coefficient (PCC). Error bars represent SEM, n=3. (B) Total results of
colocalization study comparing positive and negative references to mESCs, mEpiLCs,
and mEpiSC MOC and PCC values. Standard range qualifiers set by Zinchuk et al.
(2013) compare overlap and correlation differences. Error bars represent SEM, n=3.
Statistics of PCC and MOC treatments relative to the positive reference represent a twoway ANOVA with Sidak’s multiple comparisons test of mean±SEM PCC and MOC
scores where ∝=0.05, n=3 biological replicates.
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Supplementary Figure 3.11. mESC positive and negative colocalization controls.
Immunofluorescence microscopy of mESCs demonstrating single and double stains for
Hoechst, OCT4 and GAPDH along with their respective thresholds. Images taken using
40x magnification and scale bars represent 20 𝜇𝑚. Confocal laser channels labelled as
405 nm and 488 nm corresponding to treatments incubated with Hoechst and
OCT4/GAPDH respectively.
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Nuclear localization of PKM1 and PKM2 in naïve mESCs by cell fractionation
To validate the results of the orthogonal projection immunofluorescence analysis, a
nuclear and cytoplasmic fractionation of naïve mESCs using the REAP protocol was
conducted (Nabbi and Riabowol 2015). Naïve mESCs were selected as they were the
only mPSC that exhibited both a nuclear co-occurrence and correlation of PKM1 and
PKM2 with OCT4 immunofluorescence from our colocalization study. The REAP
protocol was validated by comparing the nuclear and cytoplasmic fractions with the
nuclear marker LAMIN A and the cytoplasmic marker ∝-TUBULIN. A significant
(p<0.05) increase in ∝-TUBULIN in the cytoplasmic fraction compared to the nuclear
fraction validating successful fractionation was observed (Supplementary Figure 3.12. A,
B, C). The results effectively demonstrated the nuclear localization of PKM1 from naïve
mESC protein lysates (Supplementary Figure 3.12. C). This was evident as the ratio of
nuclear-to-cytoplasmic fraction PKM1 trended towards elevated levels of nuclear PKM1
in the mESC, however, this did not reach statistical significance (Supplementary Figure
3.12. C).
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Supplementary Figure 3.12. PKM1 is translocated to the nuclei of mESCs.
(A) Histogram comparing protein abundance of nuclear and cytoplasmic fractioned
lysates of pPKM2, ∝-TUBULIN, and LAMIN A relative to total protein Ponceau staining
in mESCs. Error bars represent SEM, n=3, *p<0.05. (B) Histogram comparing protein
abundance of nuclear and cytoplasmic fractioned lysates of PKM2, ∝-TUBULIN, and
LAMIN A relative to total protein Ponceau staining in mESCs. Error bars represent SEM,
n=3, *p<0.05. (C) Histogram comparing protein abundance of nuclear and cytoplasmic
fractioned lysates of PKM1, ∝-TUBULIN, and LAMIN A relative to total protein
Ponceau staining in mESCs. Error bars represent SEM, n=3, *p<0.05.
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3.5.0. Discussion:
Despite traditionally being considered a passive trait of cell-fate determination, mounting
evidence now supports metabolism as having a direct role in self-renewal, cell fate and
differentiation (Dahan et al. 2019). Our study investigated differences in pyruvate kinase
muscle isoforms 1 and 2 (PKM1/2) in naïve, formative, and primed pluripotent stem cells
and found differential expression and nuclear localization of these metabolic isoforms
during pluripotent state transitioning. Densitometry of total protein lysates indicated that
over the course of pluripotent progression there is an increase protein abundance of
PKM1, PKM2, and phosphorylated PKM2 in the formative state. Despite this increase in
protein abundance, the ratio of PKM1 to PKM2, a common ratio used to examine aerobic
glycolytic preferential cancer cells, was not different between each pluripotent state,
indicating that a stable PKM1/2 ratio is likely required for maintaining pluripotency,
which one differentiation occurs is not observed (Qin et al. 2017). There was an observed
nuclear immunofluorescence for both PKM1/2 isoforms in naïve mouse embryonic stem
cells (mESCs), formative mouse epiblast-like stem cells (mEpiLCs), and primed mouse
epiblast stem cells (mEpiSCs). To verify this observation, I conducted an improved
confocal colocalization approach to compare differences in nuclear and cytoplasmic
localization by contrasting orthogonal projections with well-established reference
markers. Using this technique, I determined that in each pluripotent state, PKM1 and
PKM2 both reside in nuclear regions and that PKM1 and PKM2 are moderately
associated with OCT4 localization patterns in mESCs. PKM1 is strongly associated with
OCT4 localization patterns in mEpiLCs and both isoforms have a weak association to
OCT4 immunolocalization in mEpiSCs showing a progressive decline in association to
the pluripotency gene OCT4 during mouse ES cell pluripotency transitioning.
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The measurement of colocalization is a complicated and hotly debated area of biology
(Adler and Parmryd 2010; Aaron, Taylor, and Chew 2019). The term colocalization is
largely used to measure two main components with different applications, namely
correlation or co-occurrence of two fluorophores to each other based on pixel distribution
(Aaron, Taylor, and Chew 2018). Co-occurrence in immunofluorescence is the
presentation of fluorescent pixels existing in the same spatial distribution, and it is an
indicator of overlap between markers (Manders, Verbeek, and Aten 1993). Correlation is
a measurement of the relationship between the pixel intensities and may indicate a
biochemical interaction (Manders, Verbeek, and Aten 1993). Both the Manders’s overlap
coefficient (MOC) and Pearson’s correlation coefficient (PCC) are valid measures of
colocalization, but they inform different biological questions (Aaron, Taylor, and Chew
2019). Immunofluorescence microscopy is commonly thought of as a qualitative
technique and the literature into colocalization often uses descriptors such as moderate or
strong association within PCC ranges. Zinchuk et al. (Zinchuk, Wu, and GrossenbacherZinchuk 2013) developed a method of colocalization range descriptors to bring greater
consistency to the field and offer more validity to the quantitative nature of
colocalization. I implemented a quantitative designate to the colocalization of PKM1 and
PKM2 within the mPSCs of this study. This study supports claims that the MOC is a
valuable metric of colocalization. By comparing MOC and PCC values to a positive and
negative biological reference, I demonstrate that this methodology sets a stronger baseline
than using only improved descriptors. OCT4 and GAPDH were used as nuclear and
cytoplasmic reference proteins control markers to compare to another known nuclear
stain, Hoechst, which set a positive and negative reference to nuclear colocalization that
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allowed us to directly compare MOC and PCC values to. Comparing known positive and
negative references to the qualifying range standards set by Zinchuk et al. this studies
data supports comparing colocalization by correlation being superior to spatial overlap
(Zinchuk, Wu, and Grossenbacher-Zinchuk 2013). However, while MOC still provided
valuable knowledge, the PCC data showed an improved distinction between internal
reference controls. These findings demonstrate that it is critical to run positive and
negative references relative to dual fluorophore colocalization and that in the case of
mouse embryonic stem cells, the spatial overlap data may not be sufficient to reach
quality colocalization assessment compared to correlation data when considering the
qualifying standards set by Zinchuk et al. I observed that the MOC metric in mPSCs did
not delineate nuclear and cytoplasmic distinctions by colocalization and that the PCC
metric was a highly effective and viable tool for such distinction and analysis. To
increase the power of our colocalization study, a simple analysis single images was not
employed, instead, I investigated orthogonal projections of stacks examining the data of
individual slices to characterize the localization patterns of a true three-dimensional
structure. I also accounted for the inherent flaws of the MOC calculation by examining
only the individual colonies and individual cells in the orthogonal and airyscanned images
respectively to prevent autofluorescence or background pixel offset to influence the
algorithm.

Naïve mESCs, in the metabolically bivalent state, proved to be a unique and attractive
cell type for colocalization analysis. By examining the correlation of PKM1 and PKM2
immunolocalizations to OCT4 and GAPDH immunolocalizations, not only was an
assessment of PKM isoforms occupying similar spaces completed, but the trends in
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subnuclear pixel intensity were related was as well. Additonally, both isoforms occupy
the same spatial regions in comparison to the controls, and both PKM1 and PKM2 were
clearly associated with the localization patterns of both OCT4 and GAPDH. Together,
these results promote the concept that PKM1 and PKM2 both translocate to the nuclei of
mESCs. A recent study using mass spectroscopy of human lung carcinoma cells
determined that PKM1 and PKM2 interact with each other (Prakasam et al. 2017)
suggesting a possible PKM1/2 interaction in the nuclei of mouse ESCs. Supporting this
claim, I completed a REAP fractionation for nuclear and cytoplasmic protein abundance
in mESCs and demonstrate the presence of both PKM1 and PKM2 in nuclear fractions
(Nabbi and Riabowol 2015). This methodology was able to cleanly discriminate
cytoplasmic fractions from nuclear proteins as controlled by LAMIN A, however, nuclear
fractions were not fully separated from cytoplasmic proteins, likely due to the high ratio
of nuclear-to-cytoplasm in PSCs.

In the initial PKM protein abundance characterization of total cell lysate, I found that
there was an increase of PKM1 and PKM2 levels in mEpiLCs. Despite this increase in
protein abundance, the ratio of PKM1 to PKM2 protein abundance did not change
between any of the pluripotent cell types examined. As PKM2 switches to increased
PKM1 expression during differentiation and development, with the reverse occurring
during tumor formation, the role of the PKM1 to PKM2 ratio has become a focus of
interest (Morita et al. 2018). It may be more pertinent to examine the nuclear-tocytoplasmic ratio of PKM1/2 including the dimer to tetramer conformations of PKM2 in
various pluripotent states. Surprisingly, the formative state mEpiLCs had significantly
decreased in PKM1 and PKM2 colocalization spatial overlap to GAPDH compared with
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the positive reference. This demonstrates very low amounts of either isoform occupying
the traditional cytoplasmic region occupied by GAPDH for both isoforms. When
examining mEpiLCs for correlation of PKM1 and PKM2 colocalization to OCT4 and
GAPDH, I determined that PKM1 was associated with both OCT4 and GAPDH
compared to the controls. Coupling this finding with the results of the colocalization
overlap findings, the formative state mEpiLCs were unique in primarily localizing PKM1
in the nucleus, suggesting that PKM1 may be key in the transition of bivalent metabolism
to preferential aerobic glycolysis. Previous studies have shown that the transcription
factor promyelocytic leukemia protein (PML), a known PKM2 mediator that maintains
the homotetrameric conformation and suppresses the Warburg Effect, interacts with
OCT4 and NANOG and is necessary for maintaining naïve pluripotency (Hadjimichael et
al. 2017; Jiancong Liang et al. 2008; Shimada, Shinagawa, and Ishii 2008). Knocking
down or deleting PML resulted in flat, slower growing mESC colonies with reduced
OCT4, SOX2, cMYC and NR0B1 and diminished naïve-associated BMP, LIF/STAT3
and PI3K signaling whereas Activin A and FGF signalling increased (Hadjimichael et al.
2017). Overexpression of PML resists mESC transitioning towards primed pluripotency
and is required for efficient iPSC generation (Hadjimichael et al. 2017). Future studies
should examine the influence of PML in the generation of formative state mEpiLCs. As
mEpiLCs are the only cells currently described that can efficiently give rise to primordial
germ-like cells, PML and PKM1/2 may be important targets for controlling cell fate to
efficiently produce mEpiLCs (Hayashi et al. 2011).

I determined that of all the mPSCs studied, the primed mEpiSCs had the greatest spatial
overlap as assessed by Manders’s overlap coefficient (MOC) of PKM1 and PKM2
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colocalization to OCT4 and GAPDH yet significantly lower PKM1 and PKM2
correlation (PCC) to OCT4 and GAPDH. This was unexpected as other aerobic
glycolytic cells, such as, glioma stem cells display an interaction between PKM2 and
OCT4 (Morfouace et al. 2014). The reduced association as assessed by the Pearson
correlation coefficient (PCC) of PKM2 and OCT4 may reflect differential chromatin
targets in the primed pluripotent state and may be associated with lineage priming and
reduced differentiation potential (Morfouace et al. 2014). Interestingly, there is also a
decrease in PKM1 correlation to OCT4 as assessed by PCC, but only in the primed
mEpiSCs. Using the refined colocalization analysis, I demonstrated that PKM1 and
PKM2 co-occur (MOC) in the nuclei of mPSCs across the pluripotent continuum and that
PKM1 and PKM2 are differentially correlated (PCC) with OCT4 and GAPDH in each
examined pluripotent state. This data suggests that ChIP-sequencing of PKM1 and
PKM2 targets should be examined in mPSC varieties encompassing the pluripotent
continuum. Further, the correlation of PKM2 colocalization to OCT4 decreases from
naïvety through the formative state and into primed pluripotency. As such, I conclude
that nuclear PKM1 and PKM2 are implicated as contributors to the maintenance and
progression of embryonic stem cell pluripotency.

Recent literature has reported instances of nuclear and mitochondrial translocation of
PKM2 (Qi et al. 2019; Ji Liang et al. 2017). The nuclear translocation of PKM2 is
implicated in the regulation of the master glycolysis regulator HIF-1 (Wang et al. 2014).
Jumonji C Domain-containing dioxygenase 5 (JMJD5)-PKM2 interaction hinders PKM2
tetramer formation, blocks pyruvate kinase activity and promotes translocation of PKM2
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into the nucleus to regulate HIF-1-mediated gene transcription (Wang et al. 2014).
JMJD5 regulates the cell cycle and maintains pluripotency in human embryonic stem
cells (Zhu, Hu, and Baker 2014), however, its role in the nuclear translocation of PKM2
and regulating metabolism in pluripotent stem cells has not been explored.
Overexpression of PKM2 maintains the undifferentiated state by fine tuning redox control
in naïve mESCs grown as embryoid bodies (Konno et al. 2015). Future studies treating
naïve stem cells with pharmacological agents such as shikonin or DASA-58, which
promote the tetrameric conformation of PKM2, may resist formative state transitioning by
maintaining the naïve state (J. Chen et al. 2011; Giannoni et al. 2015). Adjusting PKM2
levels has been completed in mESCs and a complete knockout should be feasible as
PKM2-null mice are viable though they experience some metabolic distress and have a
reliance on PKM1 (Jacks et al. 2016). However, these mice show induction of late onset
formation of spontaneous hepatocellular carcinomas (Jacks et al. 2016). PKM2 is
certainly a potential target for cancer treatments and likely a key player in cellular
reprogramming and differentiation (Jacks et al. 2016; Qin et al. 2017). Despite several
non-canonical roles being characterized, it is likely that other roles exist and have yet to
be discovered (Weiwei Yang et al. 2011).

While PKM2 has been extensively studied in cancers and stem cells (Morita et al. 2018;
Jacks et al. 2016; Konno et al. 2015; Wei et al. 2018; C. C. L. Wong et al. 2014;
Taniguchi et al. 2015; N. Wong, De Melo, and Tang 2013), the PKM1 isoform has not
been investigated to the same extent. There is a growing body of evidence to suggest that
PKM1 may play an important role in early differentiation and within specific cancer
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subtypes. Until recently, PKM1 was thought to be only expressed with spatial
heterogeneity in non-proliferative cells of tumors, however, recent publications have
found this is not always the case (Israelsen et al. 2013; Morita et al. 2018). PKM1 is
essential for the proliferation and tumor-promoting capabilities of small cell lung cancer
(SCLCs) and other net endocrine tumors (Morita et al. 2018). Oxygen consumption in
PKM1 overexpressed cancer cells does not change although there are more mitochondria
with a greater rate of mitochondria dysfunction, while there are more reactive oxygen
species generated in the PKM2 overexpressed cells compared to the PKM1 overexpressed
cells (Morita et al. 2018). These characteristics of PKM1 overexpressed cells are
accompanied with increased autophagic flux and increased tumor growth with increased
autophagy and mitophagy (Morita et al. 2018). PKM1 could play a non-canonical role in
promoting autophagic and mitophagic roles during pluripotent stem cell state
transitioning. When either PKM1 or PKM2 was overexpressed in mESCs, it was found
that the pluripotency markers Nanog, Eras, and Rex1 were upregulated and an embryoid
body formation assay showed that overexpression did not influence differentiation (W.
Zhou et al. 2012). Taken together, these results indicate that PKM1 contributes to
proliferation, stemness, and pluripotency. Based on this investigation’s protein
abundance analysis, PKM2 or both isoforms may promote the generation of mEpiLCs
and the formative pluripotent state (Qin et al. 2017). The results suggest that preserving
an equal ratio of PKM1 to PKM2 may be necessary to maintain mouse pluripotency.
Such a trend is not found following lineage specialization into various somatic cells (Qin
et al. 2017). I also report a unique localization of PKM1 that suggests a novel, noncanonical role just as nuclear, dimeric pPKM2 has been implicated in several nonmetabolic roles associated with stemness and cell growth (W. Yang and Lu 2015).
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Recently, the role of PKM1 in highly proliferative cells has been highlighted (Morita et
al. 2018). These results along with our current data questions PKM2’s role as the
traditional prototypic isozyme of development as it is now clear that PKM1 is expressed
and likely has non-canonical roles (Morita et al. 2018). Nuclear PKM1 has recently been
reported in other highly proliferative cell types such as human liver cancer cells (HepG2
and SMMC-7721) (Wei et al. 2017). Following treatment with drug Oroxylin A (OA), an
O-methylated flavonoid derived from the Oroxylum indicum tree, PKM1 is translocated
to the nucleus with hepatocyte nuclear factor 4 α (HNF4α), and increases the PKM1 to
PKM2 ratio resulting in hepatoma differentiation (Wei et al. 2017). PKM1 overexpressed
in embryoid bodies generated from mESCs resulted in increased endoderm transcript
abundance of FOXA2, AFP, and HINF1B, implicating PKM1 in endoderm differentiation
(Konno et al. 2015). Given the colocalization findings, nuclear localization of PKM1 is
certainly implicated in formative state generation, and the addition of a drug such as OA
may modulate the occurrence of this transient pluripotent state.

To fully validate to the colocalization study, I examined nuclear and cytoplasmic
fractionation protein abundance in the mESCs. Due to the inherent difficulty of nuclear
and cytoplasmic extraction and the exceptionally high nuclear-to-cytoplasmic ratio of
mESCs, the most successful method of extraction was the REAP ( Rapid, Efficient and
Practical) method of extraction (Y. Zhou et al. 2016; Nabbi and Riabowol 2015). While
nuclear extraction of PSCs is generally considered a challenging technique, clean
extractions have been published (Bechard and Dalton 2009). Using this technique,
protein densitometry demonstrates PKM1 and PKM2 do have increased nuclear lysate
protein abundance. The most important finding of this study was that PKM1 is enriched
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in the nuclear fraction compared to the cytoplasmic fraction of mESCs, further supporting
that PKM1 is being translocated to the nuclei of naïve mESCs.

In summary, the data supports differential nuclear and subnuclear localization of both
PKM1 and PKM2 in mouse pluripotent stem cells and suggest a novel regulatory role for
nuclear PKM1. These results establish differential nuclear, subnuclear, and cytoplasmic
association of PKM1 and PKM2 in mESC cells as they transition from naïve
pluripotency, through formative state (primed-like mEpiLCs) towards primed mEpiSCs
(Figure 3.12.). Protein colocalization studies applied to PSCs should give greater weight
to their correlation data and not their spatial overlap findings especially if the standards
set by Zinchuk et al. are implemented (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).
The presence of nuclear PKM1/2 and the dynamic redistribution of PKM1 and PKM2
during pluripotency continuum suggests potential non-canonical roles for both isoforms
in maintaining and directing varying pluripotent states.
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Figure 3.12. PKM1/2 are differentially localized to subcellular regions with
potential interaction with OCT4 and GAPDH in naïve, formative, and primed
mouse embryonic stem cells.
Pyruvate kinase muscle isoforms are localized to nuclear regions in mESCs, mEpiLCs,
and mEpiSCs. There is indication of potential biomolecular interaction of PKM with
OCT4 or GAPDH denoted by circled proteins overlapping in the schematic. As mESCs
become more developmentally lineage primed for differentiation (mEpiSCs), the
correlation of PKM1/2 with OCT4 and GAPDH decreases. This could mean decreased
potential for biomolecular interaction of the isoforms with OCT4 and a potential
rearrangement of subcellular localization patterns in the cytosol such as mitochondrial
colocalization as demonstrated in previous studies (Ji Liang et al. 2017). This illustration
was completed using BioRender.

128
3.6.0. Acknowledgments:
Technical expertise and advisement from Courtney Brooks and Drs. Lin Zhao, Christie
Vanderboor, Nicole Edwards, Ian Tobias, Jodi Garner, Amy Wong, and Cheryle Séguin
aided to the progress of this work. Confocal and colocalization tips were graciously
shared by Dr. Julia Abitbol. Pluripotent cell lines were gifted from Dr. Janet Rossant.
This research was funded by a Canadian Institutes of Health Research operating grant to
A.J.W. and D.H.B. and Natural Sciences and Engineering Research Council of Canada
grant to D.H.B. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.

129
3.7.0. References:
Aaron, Jesse S, Aaron B Taylor, and Teng-Leong Chew. 2018. “Image Co-Localization –
Co-Occurrence versus Correlation.” Journal of Cell Science 131 (3): jcs211847.
https://doi.org/10.1242/jcs.211847.
———. 2019. “The Pearson’s Correlation Coefficient Is Not a Universally Superior
Colocalization Metric. Response to ‘Quantifying Colocalization: The MOC Is a
Hybrid Coefficient – an Uninformative Mix of Co-Occurrence and Correlation.’”
Journal of Cell Science 132 (1): jcs227074. https://doi.org/10.1242/jcs.227074.
Adler, Jeremy, and Ingela Parmryd. 2010. “Quantifying Colocalization by Correlation:
The Pearson Correlation Coefficient Is Superior to the Mander’s Overlap
Coefficient.” Cytometry Part A 77A (8): 733–42.
https://doi.org/10.1002/cyto.a.20896.
———. 2012. “Colocalization Analysis in Fluorescence Microscopy.” Methods in
Molecular Biology 931: 97–109. https://doi.org/10.1007/978-1-62703-56-4_5.
Bechard, Matthew, and Stephen Dalton. 2009. “Subcellular Localization of Glycogen
Synthase Kinase 3β Controls Embryonic Stem Cell Self-Renewal.” Molecular and
Cellular Biology 29 (8): 2092 LP – 2104. https://doi.org/10.1128/MCB.01405-08.
Boles, Eckhard, Frank Schulte, Thomas Miosga, Kerstin Freidel, Elke Schlüter, Friedrich
K. Zimmermann, Cornelis P. Hollenberg, and Jürgen J. Heinisch. 1997.
“Characterization of a Glucose-Repressed Pyruvate Kinase (Pyk2p) in
Saccharomyces Cerevisiae That Is Catalytically Insensitive to Fructose-1,6Bisphosphate.” Journal of Bacteriology 179 (9): 2987–93.
https://doi.org/10.1128/jb.179.9.2987-2993.1997.
Brons, I Gabrielle M, Lucy E Smithers, Matthew W B Trotter, Peter Rugg-Gunn, Bowen
Sun, Susana M Chuva de Sousa Lopes, Sarah K Howlett, et al. 2007. “Derivation of
Pluripotent Epiblast Stem Cells from Mammalian Embryos.” Nature 448 (June):
191. https://doi.org/10.1038/nature05950.
Chambers, Ian, Douglas Colby, Morag Robertson, Jennifer Nichols, Sonia Lee, Susan
Tweedie, and Austin Smith. 2003. “Functional Expression Cloning of Nanog, a
Pluripotency Sustaining Factor in Embryonic Stem Cells.” Cell 113 (5): 643–55.
https://doi.org/10.1016/S0092-8674(03)00392-1.
Chen, J., J. Xie, Z. Jiang, B. Wang, Y. Wang, and X. Hu. 2011. “Shikonin and Its
Analogs Inhibit Cancer Cell Glycolysis by Targeting Tumor Pyruvate Kinase-M2.”
Oncogene 30 (42): 4297–4306. https://doi.org/10.1038/onc.2011.137.
Chen, Jianan, Yan Yu, Xiaolong Chen, Yuting He, Qiuyue Hu, Hongqiang Li, Qicai Han,
et al. 2018. “MiR-139-5p Is Associated with Poor Prognosis and Regulates
Glycolysis by Repressing PKM2 in Gallbladder Carcinoma.” Cell Proliferation 51
(6): e12510. https://doi.org/10.1111/cpr.12510.
Christensen, David R, Philip C Calder, and Franchesca D Houghton. 2015. “GLUT3 and
PKM2 Regulate OCT4 Expression and Support the Hypoxic Culture of Human
Embryonic Stem Cells.” Scientific Reports 5 (December): 17500.
https://doi.org/10.1038/srep17500.
Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M. & Cantley, L. C. 2008.
“Pyruvate Kinase M2 Is a Phosphotyrosine Binding Protein.” Nature 452 (March):
181–89. https://doi.org/10.1038/nature06667.
Christofk, Heather R., Matthew G. Vander Heiden, Marian H. Harris, Arvind

130
Ramanathan, Robert E. Gerszten, Ru Wei, Mark D. Fleming, Stuart L. Schreiber,
and Lewis C. Cantley. 2008. “The M2 Splice Isoform of Pyruvate Kinase Is
Important for Cancer Metabolism and Tumour Growth.” Nature 452 (7184): 230–33.
https://doi.org/10.1038/nature06734.
Dahan, Perrine, Vivian Lu, Robert M T Nguyen, Stephanie A L Kennedy, and Michael A
Teitell. 2019. “Metabolism in Pluripotency: Both Driver and Passenger?” The
Journal of Biological Chemistry 294 (14): 5420–29.
https://doi.org/10.1074/jbc.TM117.000832.
David, Charles J, Mo Chen, Marcela Assanah, Peter Canoll, and James L Manley. 2010.
“HnRNP Proteins Controlled by C-Myc Deregulate Pyruvate Kinase MRNA
Splicing in Cancer.” Nature 463 (7279): 364–68.
https://doi.org/10.1038/nature08697.
DeBerardinis, Ralph J, and Navdeep S Chandel. 2016. “Fundamentals of Cancer
Metabolism.” Science Advances 2 (5): e1600200.
https://doi.org/10.1126/sciadv.1600200.
Desai, Shruti, Minming Ding, Bin Wang, Zhimin Lu, Qi Zhao, Kenna Shaw, W K Alfred
Yung, John N Weinstein, Ming Tan, and Jun Yao. 2013. “Tissue-Specific Isoform
Switch and DNA Hypomethylation of the Pyruvate Kinase PKM Gene in Human
Cancers.” Oncotarget 5 (18): 1–9. https://doi.org/10.18632/oncotarget.1159.
Dunn, Kenneth W, Malgorzata M Kamocka, and John H McDonald. 2011. “A Practical
Guide to Evaluating Colocalization in Biological Microscopy.” American Journal of
Physiology-Cell Physiology 300 (4): C723–42.
https://doi.org/10.1152/ajpcell.00462.2010.
Evans, M. J., and M. H. Kaufman. 1981. “Establishment in Culture of Pluripotential Cells
from Mouse Embryos.” Nature. https://doi.org/10.1038/292154a0.
Feron, Olivier. 2009. “Pyruvate into Lactate and Back: From the Warburg Effect to
Symbiotic Energy Fuel Exchange in Cancer Cells.” Radiotherapy and Oncology 92
(3): 329–33. https://doi.org/10.1016/j.radonc.2009.06.025.
Gafni, Ohad, Leehee Weinberger, Abed Alfatah Mansour, Yair S. Manor, Elad Chomsky,
Dalit Ben-Yosef, Yael Kalma, et al. 2013. “Derivation of Novel Human Ground
State Naive Pluripotent Stem Cells.” Nature 504 (7479): 282–86.
https://doi.org/10.1038/nature12745.
Giannoni, Elisa, Maria Letizia Taddei, Andrea Morandi, Giuseppina Comito, Maura
Calvani, Francesca Bianchini, Barbara Richichi, et al. 2015. “Targeting StromalInduced Pyruvate Kinase M2 Nuclear Translocation Impairs Oxphos and Prostate
Cancer Metastatic Spread.” Oncotarget 6 (27): 24061–74.
https://doi.org/10.18632/oncotarget.4448.
Guo, G., J. Yang, J. Nichols, J. S. Hall, I. Eyres, W. Mansfield, and A. Smith. 2009. “Klf4
Reverts Developmentally Programmed Restriction of Ground State Pluripotency.”
Development 136 (7): 1063–69. https://doi.org/10.1242/dev.030957.
Guo, Ge, Ferdinand Von Meyenn, Fatima Santos, Yaoyao Chen, Wolf Reik, Paul
Bertone, Austin Smith, and Jennifer Nichols. 2016. “Naive Pluripotent Stem Cells
Derived Directly from Isolated Cells of the Human Inner Cell Mass.” Stem Cell
Reports 6 (4): 437–46. https://doi.org/10.1016/j.stemcr.2016.02.005.
Guppy, Michael, Erich Greiner, and Karl Brand. 1993. “The Role of the Crabtree Effect
and an Endogenous Fuel in the Energy Metabolism of Resting and Proliferating
Thymocytes.” European Journal of Biochemistry 212 (1): 95–99.

131
https://doi.org/10.1111/j.1432-1033.1993.tb17637.x.
Hadjimichael, Christiana, Konstantina Chanoumidou, Christoforos Nikolaou, Antonios
Klonizakis, Gesthimani Ioanna Theodosi, Takis Makatounakis, Joseph
Papamatheakis, and Androniki Kretsovali. 2017. “Promyelocytic Leukemia Protein
Is an Essential Regulator of Stem Cell Pluripotency and Somatic Cell
Reprogramming.” Stem Cell Reports 8 (5): 1366–78.
https://doi.org/10.1016/j.stemcr.2017.03.006.
Hawkins, Kate E., Shona Joy, Juliette M.K.M. Delhove, Vassilios N. Kotiadis, Emilio
Fernandez, Lorna M. Fitzpatrick, James R. Whiteford, et al. 2016. “NRF2
Orchestrates the Metabolic Shift during Induced Pluripotent Stem Cell
Reprogramming.” Cell Reports 14 (8): 1883–91.
https://doi.org/10.1016/j.celrep.2016.02.003.
Hayashi, Katsuhiko, Hiroshi Ohta, Kazuki Kurimoto, Shinya Aramaki, and Mitinori
Saitou. 2011. “Reconstitution of the Mouse Germ Cell Specification Pathway in
Culture by Pluripotent Stem Cells.” Cell 146 (4): 519–32.
https://doi.org/10.1016/j.cell.2011.06.052.
Heard, Edith. 2004. “Recent Advances in X-Chromosome Inactivation.” Current Opinion
in Cell Biology 16 (3): 247–55. https://doi.org/10.1016/j.ceb.2004.03.005.
Hensley, Christopher T., Brandon Faubert, Qing Yuan, Naama Lev-Cohain, Eunsook Jin,
Jiyeon Kim, Lei Jiang, et al. 2016. “Metabolic Heterogeneity in Human Lung
Tumors.” Cell 164 (4): 681–94. https://doi.org/10.1016/j.cell.2015.12.034.
Hitosugi, Taro, Sumin Kang, Matthew G Vander Heiden, Tae-Wook Chung, Shannon
Elf, Katherine Lythgoe, Shaozhong Dong, et al. 2009. “Tyrosine Phosphorylation
Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth.” Science
Signaling 2 (97): ra73 LP-ra73. https://doi.org/10.1126/scisignal.2000431.
Horiuchi, Yuta, Daiki Nakatsu, Fumi Kano, and Masayuki Murata. 2017. “Pyruvate
Kinase M1 Interacts with A-Raf and Inhibits Endoplasmic Reticulum Stress-Induced
Apoptosis by Activating MEK1/ERK Pathway in Mouse Insulinoma Cells.” Cellular
Signalling 38: 212–22. https://doi.org/https://doi.org/10.1016/j.cellsig.2017.07.017.
Imamura, Kuchi, and Takehiko Tanaka. 1982. “[25] Pyruvate Kinase Isozymes from
Rat.” Methods in Enzymology 90 (C): 150–65. https://doi.org/10.1016/S00766879(82)90121-5.
Israelsen, William J., Talya L. Dayton, Shawn M. Davidson, Brian P. Fiske, Aaron M.
Hosios, Gary Bellinger, Jie Li, et al. 2013. “PKM2 Isoform-Specific Deletion
Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells.” Cell 155
(2): 397–409. https://doi.org/10.1016/j.cell.2013.09.025.
Jacks, Tyler E., Alba Luengo, Arjun Bhutkar, Talya L. Dayton, Kathryn M. Miller,
Matthew G. Vander Heiden, William J. Israelsen, Shawn M. Davidson, Vasilena
Gocheva, and Clary B. Clish. 2016. “Germline Loss of PKM2 Promotes Metabolic
Distress and Hepatocellular Carcinoma.” Molecular Cancer Research 14 (4
Supplement): PR04–PR04. https://doi.org/10.1158/1557-3125.devbiolca15-pr04.
Jiang, Yuhui, Xinjian Li, Weiwei Yang, David H. Hawke, Yanhua Zheng, Yan Xia,
Kenneth Aldape, et al. 2014. “PKM2 Regulates Chromosome Segregation and
Mitosis Progression of Tumor Cells.” Molecular Cell 53 (1): 75–87.
https://doi.org/10.1016/j.molcel.2013.11.001.
Jiang, Yuhui, Yugang Wang, Ting Wang, David H Hawke, Yanhua Zheng, Xinjian Li,
Qin Zhou, et al. 2014. “PKM2 Phosphorylates MLC2 and Regulates Cytokinesis of

132
Tumour Cells.” Nature Communications 5 (1): 5566.
https://doi.org/10.1038/ncomms6566.
Joo, Jin Young, Hyun Woo Choi, Min Jung Kim, Holm Zaehres, Natalia Tapia, Martin
Stehling, Koo Sung Jung, Jeong Tae Do, and Hans R. Schöler. 2014. “Establishment
of a Primed Pluripotent Epiblast Stem Cell in FGF4-Based Conditions.” Scientific
Reports 4: 7477. https://doi.org/10.1038/srep07477.
Jurica, Melissa S, Andrew Mesecar, Patrick J Heath, Wuxian Shi, Thomas Nowak, and
Barry L Stoddard. 1998. “The Allosteric Regulation of Pyruvate Kinase by Fructose1,6-Bisphosphate.” Structure 6 (2): 195–210. https://doi.org/10.1016/S09692126(98)00021-5.
Kalkan, Tüzer, Susanne Bornelöv, Carla Mulas, Evangelia Diamanti, Tim Lohoff,
Meryem Ralser, Sjors Middelkamp, Patrick Lombard, Jennifer Nichols, and Austin
Smith. 2019. “Complementary Activity of ETV5, RBPJ, and TCF3 Drives
Formative Transition from Naive Pluripotency.” Cell Stem Cell 24 (5): 785-801.e7.
https://doi.org/10.1016/j.stem.2019.03.017.
Kalkan, Tüzer, and Austin Smith. 2014. “Mapping the Route from Naive Pluripotency to
Lineage Specification.” Philosophical Transactions of the Royal Society B:
Biological Sciences 369 (1657): 20130540-. https://doi.org/10.1098/rstb.2013.0540.
Kinoshita, Masaki, and Austin Smith. 2018. “Pluripotency Deconstructed.” Development,
Growth & Differentiation 60 (1): 44–52. https://doi.org/10.1111/dgd.12419.
Kojima, Yoji, Keren Kaufman-Francis, Joshua B. Studdert, Kirsten A. Steiner, Melinda
D. Power, David A.F. Loebel, Vanessa Jones, et al. 2014. “The Transcriptional and
Functional Properties of Mouse Epiblast Stem Cells Resemble the Anterior Primitive
Streak.” Cell Stem Cell 14 (1): 107–20. https://doi.org/10.1016/j.stem.2013.09.014.
Kondoh, Hiroshi, Matilde E Lleonart, Yasuhiro Nakashima, Masayuki Yokode, Makoto
Tanaka, David Bernard, Jesus Gil, and David Beach. 2007. “A High Glycolytic Flux
Supports the Proliferative Potential of Murine Embryonic Stem Cells.” Antioxidants
& Redox Signaling 9 (3): 293–99. https://doi.org/10.1089/ars.2006.1467.
Konno, Masamitsu, Hideshi Ishii, Jun Koseki, Nobuhiro Tanuma, Naohiro Nishida,
Koichi Kawamoto, Tatsunori Nishimura, et al. 2015. “Pyruvate Kinase M2, but Not
M1, Allele Maintains Immature Metabolic States of Murine Embryonic Stem Cells.”
Regenerative Therapy 1: 63–71. https://doi.org/10.1016/j.reth.2015.01.001.
Lee, Jungwoon, Hye Kyoung Kim, Yong-Mahn Han, and Jungho Kim. 2008. “Pyruvate
Kinase Isozyme Type M2 (PKM2) Interacts and Cooperates with Oct-4 in
Regulating Transcription.” The International Journal of Biochemistry & Cell
Biology 40 (5): 1043–54.
https://doi.org/https://doi.org/10.1016/j.biocel.2007.11.009.
Levine, Arnold J, and Anna M Puzio-Kuter. 2010. “The Control of the Metabolic Switch
in Cancers by Oncogenes and Tumor Suppressor Genes.” Science 330 (6009): 1340
LP – 1344. https://doi.org/10.1126/science.1193494.
Liang, Ji, Ruixiu Cao, Xiongjun Wang, Yajuan Zhang, Pan Wang, Hong Gao, Chen Li, et
al. 2017. “Mitochondrial PKM2 Regulates Oxidative Stress-Induced Apoptosis by
Stabilizing Bcl2.” Cell Research 27 (3): 329–51.
https://doi.org/10.1038/cr.2016.159.
Liang, Jiancong, Ma Wan, Yi Zhang, Peili Gu, Huawei Xin, Sung Yun Jung, Jun Qin, et
al. 2008. “Nanog and Oct4 Associate with Unique Transcriptional Repression
Complexes in Embryonic Stem Cells.” Nature Cell Biology 10 (6): 731–39.

133
https://doi.org/10.1038/ncb1736.
Ma, Rong, Qing Liu, Shutao Zheng, Tao Liu, Doudou Tan, and Xiaomei Lu. 2019.
“PKM2-Regulated STAT3 Promotes Esophageal Squamous Cell Carcinoma
Progression via TGF-Β1-Induced EMT.” Journal of Cellular Biochemistry 120 (7):
11539–50. https://doi.org/10.1002/jcb.28434.
Manders, EMM, FJ Verbeek, and JA Aten. 1993. “Measurement of Co-Localization of
Objects in Dual-Colour Confocal Images.” Journal of Microscopy 169 (3): 375–82.
https://doi.org/10.1111/j.1365-2818.1993.tb03313.x.
Martin, G R. 1981. “Isolation of a Pluripotent Cell Line from Early Mouse Embryos
Cultured in Medium Conditioned by Teratocarcinoma Stem Cells.” Proceedings of
the National Academy of Sciences 78 (12): 7634 LP – 7638.
https://doi.org/10.1073/pnas.78.12.7634.
Morfouace, M., L. Lalier, L. Oliver, M. Cheray, C. Pecqueur, P. F. Cartron, and F. M.
Vallette. 2014. “Control of Glioma Cell Death and Differentiation by PKM2-Oct4
Interaction.” Cell Death and Disease 5 (1): e1036-8.
https://doi.org/10.1038/cddis.2013.561.
Morgani, Sophie, Jennifer Nichols, and Anna Katerina Hadjantonakis. 2017. “The Many
Faces of Pluripotency: In Vitro Adaptations of a Continuum of in Vivo States.” BMC
Developmental Biology 17 (1): 10–12. https://doi.org/10.1186/s12861-017-0150-4.
Morita, Mami, Taku Sato, Miyuki Nomura, Yoshimi Sakamoto, Yui Inoue, Ryota
Tanaka, Shigemi Ito, et al. 2018. “PKM1 Confers Metabolic Advantages and
Promotes Cell-Autonomous Tumor Cell Growth.” Cancer Cell 33 (3): 355-367.e7.
https://doi.org/10.1016/j.ccell.2018.02.004.
Nabbi, Arash, and Karl Riabowol. 2015. “Rapid Isolation of Nuclei from Cells in Vitro.”
Cold Spring Harbor Protocols 2015 (8): 769–72.
https://doi.org/10.1101/pdb.prot083733.
Nakatsu, Daiki, Yuta Horiuchi, Fumi Kano, Yoshiyuki Noguchi, Taichi Sugawara, Iseki
Takamoto, Naoto Kubota, Takashi Kadowaki, and Masayuki Murata. 2015. “LCysteine Reversibly Inhibits Glucose-Induced Biphasic Insulin Secretion and ATP
Production by Inactivating PKM2.” Proceedings of the National Academy of
Sciences of the United States of America 112 (10): E1067–76.
https://doi.org/10.1073/pnas.1417197112.
Nichols, Jennifer, and Austin Smith. 2009. “Naive and Primed Pluripotent States.” Cell
Stem Cell 4 (6): 487–92. https://doi.org/10.1016/j.stem.2009.05.015.
Niwa, Hitoshi, Jun Ichi Miyazaki, and Austin G. Smith. 2000. “Quantitative Expression
of Oct-3/4 Defines Differentiation, Dedifferentiation or Self-Renewal of ES Cells.”
Nature Genetics 24 (4): 372–76. https://doi.org/10.1038/74199.
Noguchi, T, K Yamada, H Inoue, T Matsuda, and T Tanaka. 1987. “The L- and R-Type
Isozymes of Rat Pyruvate Kinase Are Produced from a Single Gene by Use of
Different Promoters.” Journal of Biological Chemistry 262 (29): 14366–71.
http://www.jbc.org/content/262/29/14366.abstract.
Ohinata, Yasuhide, Hiroshi Ohta, Mayo Shigeta, Kaori Yamanaka, Teruhiko Wakayama,
and Mitinori Saitou. 2009. “A Signaling Principle for the Specification of the Germ
Cell Lineage in Mice.” Cell 137 (3): 571–84.
https://doi.org/10.1016/j.cell.2009.03.014.
Ohtsuka, Satoshi, Yoko Nakai-Futatsugi, and Hitoshi Niwa. 2015. “LIF Signal in Mouse
Embryonic Stem Cells.” JAK-STAT 4 (2): 1–9.

134
https://doi.org/10.1080/21623996.2015.1086520.
Ohtsuka, Satoshi, Satomi Nishikawa-Torikai, and Hitoshi Niwa. 2012. “E-Cadherin
Promotes Incorporation of Mouse Epiblast Stem Cells into Normal Development.”
PLoS ONE 7 (9). https://doi.org/10.1371/journal.pone.0045220.
Otsu, Nobuyuki. 1979. “A Threshold Selection Method from Gray-Level Histograms.”
IEEE Transactions on Systems, Man and Cybernetics 20 (1): 62–66.
https://doi.org/0018-9472/79/0100-0062$00.75.
Pearson, Karl, and Olaus Magnus Friedrich Erdmann Henrici. 1896. “VII. Mathematical
Contributions to the Theory of Evolution.—III. Regression, Heredity, and
Panmixia.” Philosophical Transactions of the Royal Society of London. Series A,
Containing Papers of a Mathematical or Physical Character 187 (January): 253–
318. https://doi.org/10.1098/rsta.1896.0007.
Prakasam, Gopinath, Rajnish Kumar Singh, Mohammad Askandar Iqbal, Sunil Kumar
Saini, Ashu Bhan Tiku, and Rameshwar N K Bamezai. 2017. “Pyruvate Kinase M
Knockdown–Induced Signaling via AMP-Activated Protein Kinase Promotes
Mitochondrial Biogenesis, Autophagy, and Cancer Cell Survival.” Journal of
Biological Chemistry 292 (37): 15561–76.
https://doi.org/10.1074/jbc.M117.791343.
Prigione, Alessandro, Beatrix Fauler, Rudi Lurz, Hans Lehrach, and James Adjaye. 2010.
“The Senescence-Related Mitochondrial/Oxidative Stress Pathway Is Repressed in
Human Induced Pluripotent Stem Cells.” STEM CELLS 28 (4): 721–33.
https://doi.org/10.1002/stem.404.
Qi, Hailong, Xianling Ning, Chang Yu, Xin Ji, Yan Jin, Michael A McNutt, and Yuxin
Yin. 2019. “Succinylation-Dependent Mitochondrial Translocation of PKM2
Promotes Cell Survival in Response to Nutritional Stress.” Cell Death & Disease 10
(3): 170. https://doi.org/10.1038/s41419-018-1271-9.
Qin, Shengtang, Danli Yang, Kang Chen, Haolan Li, Liqiang Zhang, Yuan Li, Rongrong
Le, Xiaojie Li, Shaorong Gao, and Lan Kang. 2017. “Pkm2 Can Enhance
Pluripotency in ESCs and Promote Somatic Cell Reprogramming to IPSCs.”
Oncotarget 8 (48): 84276. https://doi.org/10.18632/ONCOTARGET.20685.
Rodrigues, Ana Sofia, Marcelo Correia, Andreia Gomes, Sandro L. Pereira, Tânia
Perestrelo, Maria Inês Sousa, and João Ramalho-Santos. 2015. “Dichloroacetate, the
Pyruvate Dehydrogenase Complex and the Modulation of MESC Pluripotency.”
PLoS ONE 10 (7): e0131663. https://doi.org/10.1371/journal.pone.0131663.
Shi, Xiangguang, Lingchong You, and Ruo-yu Luo. 2019. “Glycolytic Reprogramming in
Cancer Cells: PKM2 Dimer Predominance Induced by Pulsatile PFK-1 Activity.”
Physical Biology 16 (6): 66007. https://doi.org/10.1088/1478-3975/ab3f5a.
Shimada, Nobukazu, Toshie Shinagawa, and Shunsuke Ishii. 2008. “Modulation of M2Type Pyruvate Kinase Activity by the Cytoplasmic PML Tumor Suppressor
Protein.” Genes to Cells 13 (3): 245–54. https://doi.org/10.1111/j.13652443.2008.01165.x.
Silva, Jose, and Austin Smith. 2008. “Capturing Pluripotency.” Cell 132 (4): 532–36.
https://doi.org/10.1016/j.cell.2008.02.006.
Smith, Austin. 2017. “Formative Pluripotency: The Executive Phase in a Developmental
Continuum.” Development 144 (3): 365–73. https://doi.org/10.1242/dev.142679.
Takahashi, Saori, Shin Kobayashi, and Ichiro Hiratani. 2018. “Epigenetic Differences
between Naïve and Primed Pluripotent Stem Cells.” Cellular and Molecular Life

135
Sciences 75 (7): 1191–1203. https://doi.org/10.1007/s00018-017-2703-x.
Taniguchi, Kohei, Nobuhiko Sugito, Minami Kumazaki, Haruka Shinohara, Nami
Yamada, Yoshihito Nakagawa, Yuko Ito, et al. 2015. “MicroRNA-124 Inhibits
Cancer Cell Growth through PTB1/PKM1/PKM2 Feedback Cascade in Colorectal
Cancer.” Cancer Letters 363 (1): 17–27.
https://doi.org/10.1016/J.CANLET.2015.03.026.
Tesar, Paul J., Josh G. Chenoweth, Frances A. Brook, Timothy J. Davies, Edward P.
Evans, David L. Mack, Richard L. Gardner, and Ronald D.G. McKay. 2007. “New
Cell Lines from Mouse Epiblast Share Defining Features with Human Embryonic
Stem Cells.” Nature 448 (7150): 196–99. https://doi.org/10.1038/nature05972.
Wang, H.-J., Y.-J. Hsieh, W.-C. Cheng, C.-P. Lin, Y.-S. Lin, S.-F. Yang, C.-C. Chen, et
al. 2014. “JMJD5 Regulates PKM2 Nuclear Translocation and Reprograms HIF-1 Mediated Glucose Metabolism.” Proceedings of the National Academy of Sciences
111 (1): 279–84. https://doi.org/10.1073/pnas.1311249111.
Wei, Libin, Yuanyuan Dai, Yuxin Zhou, Zihao He, Jingyue Yao, Li Zhao, Qinglong
Qiqiang Guo, et al. 2018. “Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator
for Hypoxia-Inducible Factor 1.” Development 8 (1): 1–16.
https://doi.org/10.1016/j.cell.2011.03.054.
Wei, Libin, Yuanyuan Dai, Yuxin Zhou, Zihao He, Jingyue Yao, Li Zhao, Qinglong Guo,
and Lin Yang. 2017. “Oroxylin A Activates PKM1/HNF4 Alpha to Induce
Hepatoma Differentiation and Block Cancer Progression.” Cell Death & Disease 8
(7): e2944. https://doi.org/10.1038/cddis.2017.335.
Weinhouse, SIDNEY, OTTO Warburg, DEAN Burk, and ARTHUR L Schade. 1956.
“On Respiratory Impairment in Cancer Cells.” Science 124 (3215): 267 LP – 272.
https://doi.org/10.1126/science.124.3215.267.
Wolff, Barbara, Jean-Jacques Sanglier, and Ying Wang. 1997. “Leptomycin B Is an
Inhibitor of Nuclear Export: Inhibition of Nucleo-Cytoplasmic Translocation of the
Human Immunodeficiency Virus Type 1 (HIV-1) Rev Protein and Rev-Dependent
MRNA.” Chemistry & Biology 4 (2): 139–47.
https://doi.org/https://doi.org/10.1016/S1074-5521(97)90257-X.
Wong, Carmen Chak Lui, Sandy Leung Kuen Au, Aki Pui Wah Tse, Iris Ming Jing Xu,
Robin Kit Ho Lai, David Kung Chun Chiu, Larry Lai Wei, et al. 2014. “Switching of
Pyruvate Kinase Isoform l to M2 Promotes Metabolic Reprogramming in
Hepatocarcinogenesis.” PLoS ONE 9 (12).
https://doi.org/10.1371/journal.pone.0115036.
Wong, Nicholas, Jason De Melo, and Damu Tang. 2013. “PKM2, a Central Point of
Regulation in Cancer Metabolism.” International Journal of Cell Biology 2013.
https://doi.org/10.1155/2013/242513.
Wu, Yong, Vadim Zinchuk, Olga Grossenbacher-Zinchuk, and Enrico Stefani. 2012.
“Critical Evaluation of Quantitative Colocalization Analysis in Confocal
Fluorescence Microscopy.” Interdisciplinary Sciences: Computational Life Sciences
4 (1): 27–37. https://doi.org/10.1007/s12539-012-0117-x.
Yamada, K, and T Noguchi. 1999. “Regulation of Pyruvate Kinase Gene Expression.”
Biochem. J 337: 1–11. https://doi.org/PMC1219928.
Yang, W., and Z. Lu. 2015. “Pyruvate Kinase M2 at a Glance.” Journal of Cell Science
128 (9): 1655–60. https://doi.org/10.1242/jcs.166629.
Yang, Weiwei, and Zhimin Lu. 2013. “Nuclear PKM2 Regulates the Warburg Effect.”

136
Cell Cycle 12 (19): 3154–58. https://doi.org/10.4161/cc.26182.
Yang, Weiwei, Yan Xia, Haitao Ji, Yanhua Zheng, Ji Liang, Wenhua Huang, Xiang Gao,
Kenneth Aldape, and Zhimin Lu. 2011. “Nuclear PKM2 Regulates β-Catenin
Transactivation upon EGFR Activation.” Nature 480 (7375): 118–22.
https://doi.org/10.1038/nature10598.
Yang, Weiwei, Yanhua Zheng, Yan Xia, Haitao Ji, Xiaomin Chen, Fang Guo, Costas A.
Lyssiotis, Kenneth Aldape, Lewis C. Cantley, and Zhimin Lu. 2012. “ERK1/2Dependent Phosphorylation and Nuclear Translocation of PKM2 Promotes the
Warburg Effect.” Nature Cell Biology 14 (12): 1295–1304.
https://doi.org/10.1038/ncb2629.
Ying, Qi-Long, Jason Wray, Jennifer Nichols, Laura Batlle-Morera, Bradley Doble,
James Woodgett, Philip Cohen, and Austin Smith. 2008. “The Ground State of
Embryonic Stem Cell Self-Renewal.” Nature 453 (7194): 519–23.
https://doi.org/10.1038/nature06968.
Zhang, Jin, Jing Zhao, Perrine Dahan, Vivian Lu, Cheng Zhang, Hu Li, and Michael A.
Teitell. 2018. “Metabolism in Pluripotent Stem Cells and Early Mammalian
Development.” Cell Metabolism 27 (2): 332–38.
https://doi.org/10.1016/j.cmet.2018.01.008.
Zhou, Wenyu, Michael Choi, Daciana Margineantu, Lilyana Margaretha, Jennifer
Hesson, Christopher Cavanaugh, C. Anthony Blau, et al. 2012. “HIF1α Induced
Switch from Bivalent to Exclusively Glycolytic Metabolism during ESC-toEpiSC/HESC Transition.” EMBO Journal 31 (9): 2103–16.
https://doi.org/10.1038/emboj.2012.71.
Zhou, Ying, Srinjan Basu, Ernest Laue, and Ashwin A Seshia. 2016. “Single Cell Studies
of Mouse Embryonic Stem Cell (MESC) Differentiation by Electrical Impedance
Measurements in a Microfluidic Device.” Biosensors & Bioelectronics 81 (July):
249–58. https://doi.org/10.1016/j.bios.2016.02.069.
Zhu, Hui, Shijun Hu, and Julie Baker. 2014. “JMJD5 Regulates Cell Cycle and
Pluripotency in Human Embryonic Stem Cells.” Stem Cells (Dayton, Ohio), 1–17.
https://doi.org/10.1002/stem.1724.
Zinchuk, Vadim, Yong Wu, and Olga Grossenbacher-Zinchuk. 2013. “Bridging the Gap
between Qualitative and Quantitative Colocalization Results in Fluorescence
Microscopy Studies.” Scientific Reports 3 (1): 1365.
https://doi.org/10.1038/srep01365.

137
Chapter 4
4.0.0. Chapter Title: Flow cytometric characterization of pluripotent cell protein
markers in naïve, formative, and primed pluripotent stem cells

A version of this Chapter has been submitted for publication in Methods in Molecular
Biology.

4.0.1. CRediT Author Statement:

Joshua Dierolf: Conceptualization, Methodology, Validation, Formal Analysis,
Investigation, Writing – Original Draft, Writing – Review & Editing, Visualization
Kristin Chadwick: Conceptualization, Validation
Courtney Brooks: Conceptualization, Methodology, Investigation
Dean Betts: Resources, Writing – Review & Editing, Funding Acquisition
Andrew Watson: Writing – Review & Editing

138
4.0.2. Summary:
Here we describe methodologies to characterize, delineate, and quantify pluripotent cells
between naïve, formative, and primed pluripotent state mouse embryonic stem cell
(mESCs) populations using flow cytometric analysis. This methodology can validate
pluripotent states, sort individual cells of interest and determine the efficiency of
transitioning naïve mESCs to a primed-like state as mouse epiblast-like cells (mEpiLCs)
and on to fully primed mouse epiblast stem cells (mEpiSCs). Quantification of the cell
surface markers: SSEA1(CD15) and CD24, introduces an effective method of
distinguishing individual cells from a population by their respective positioning in the
pluripotent spectrum. Additionally, this protocol can be used to demarcate and sort cells
via fluorescently activated cell sorting for downstream applications. Flow cytometric
analysis within mESCs, mEpiLCs, and mEpiSCs can be efficiently completed using these
optimized protocols.
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4.1.0. Introduction:
Flow cytometry is a method of single cell analysis utilizing a microfluidic system where
individual cells are directed, single file, through a laser, or series of lasers. Cell size and
granularity can be assessed using flow cytometry through the analysis of laser light
scatter. The measurement of side-scatter shows the level of granularity, or, the amount of
light that reflects off the individual cell and intracellular interface, whereas the forwardscatter parameter is a measure of the light that passes around the cell in question. Taken
together, an understanding of the size and intracellular complexity of the cells in a
population can be quantified and organized into subpopulations (Leif 1986). Cells can be
sorted through the process of fluorescently activated cell sorting (FACS) following the
process of gating out specific traits of a population for downstream applications.

Several methods of mouse epiblast cell-like cell (mEpiLCs) generation have been devised
(Morgani, Nichols, and Hadjantonakis 2017). This protocol have utilizes ground state
mouse embryonic stem cell (mESCs) transitioned into mEpiLCs over 48, 72, and 92
hours in transitioning media containing Activin A and Fibroblast growth factor 5 (Fgf5),
replacing mESC media containing leukemia inhibitory factor (LIF) and a small molecule
cocktail of inhibitors for Glycogen synthase kinase 3 beta (GSK3b) and Mitogenactivated protein kinase, kinase (MEK) (Hayashi et al. 2011). This flow cytometric
analysis methodology includes quantification of the cell surface markers: Stage-Specific
Embryonic Antigen-1 (SSEA1/CD15) and Cluster of differentiation 24 (CD24). SSEA1
is a naïve pluripotency associated cell surface protein marker that is expressed in mESCs
(Solter and Knowles 1978). Alternatively, CD24 is an expressed primarily in primed
mEpiSCs and has decreased expression in naïve mESCs (Shakiba et al. 2015). Together,
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I propose that SSEA1 and CD24 can be used to discriminate between either end of the
pluripotent spectrum in human and mouse pluripotent stem cells (PSCs), and can also be
used to distinguish formative pluripotent state mouse epiblast-like cells (mEpiLCs) as
well (Shakiba et al. 2015). Additional methods of flow cytometric normalization,
practises, and troubleshooting are beyond the scope of this chapter, however, for these
additional details, we refer the reader to following excellent resources (Hahne et al. 2010;
Herzenberg et al. 2006).

4.2.0. Materials:
1. Washing Solution: Sterile Dulbecco’s Phosphate Buffered Saline (no magnesium,
no calcium) (DPBS(-/-))(DPBS(-/-))(GibcoTM 14190144).
2. Flow Cytometry Staining Buffer – 10 % Fetal bovine serum (Embryonic stem-cell
FBS, qualified, US origin (Gibco 16141061)) in DPBS(-/-) filter sterilized.
3. Trypan Blue Solution (ThermoFisher Scientific 15250061).
4. Fixing Agent: 4 % paraformaldehyde (Sigma Aldrich, St Louis MO) diluted in
DPBS(-/-).
5. Cell passaging agent (StemPro Accutaseâ).
6. Antibody dilutions:
•

Live/Dead: Live/Dead viability dye such as Zombie Aqua™ Fixable Viability
Kit (BioLegend 423101), diluted 1:1000/1 million cells.

•

SSEA1: Brilliant Violet 421™ anti-mouse/human CD15 (SSEA-1) Antibody
(BioLegend 125613) diluted at 5 mL/1 million cells.
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•

CD24: APC/Cyanine7 anti-mouse CD24 Antibody (BioLegend 101821)
diluted at 0.25 mg/1 million cells.

7. 20-40 µM sterile cell strainers (Falcon™ Cell Strainers 08-771-1).
8. Flow tubes and corresponding caps, specific to your flow cytometer of choice.

4.3.0. Methods:

In the following protocol, I describe how to characterize and distinguish between
pluripotent stem cell populations representing naïve, formative, and primed pluripotent
states using flow cytometry. Methods for using both live and fixed cell preparations are
detailed. Live cell staining may be used for downstream sorting of purified populations,
and additional experimentation such as omics data analysis or differentiation assays,
whereas fixed cell staining can be sorted for downstream applications limited to nonviable cells, such as protein and transcript abundance studies. This methodology is useful
in determining the transition efficiency of generating primed-like mEpiLCs from mESCs
in comparison to primed mEpiSCs by a comparison of SSEA1 and CD24 cell surface
expression levels. These markers can be compared for both human and mouse PSCs
(Shakiba et al. 2015).

During the experimental planning step, aim to grow your pluripotent stem cells into their
third, fourth, and fifth (PX+3/4/5 minimum) passage following cryopreservation thaw.
This will allow for 3 biological replicates. To analyze geometric mean, mode, or median
data, each biological replicate should be analyzed in the same flow cytometric
experimental session. If you are only looking at pluripotent marker gating, each
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biological replicate can be run on their own session only if the full set of controls are used
for each run. Additionally, grow cells to a quantity that allows for 3 technical replicates
of each biological replicate of each cell type to be analyzed. Regardless of gating
scheme, ensure colonies are morphologically healthy with little to no signs of
differentiation and with similarly spaced-out cell densities.

Individual treatment groups require having an unstained control cell population, a single
stain control of each protein marker, a full minus one (FMO) tube containing all protein
markers except for one, and lastly a full stain sample containing each protein marker,
each of these needs to be completed for each cell type examined. Additionally, a
live/dead control is necessary to avoid autofluorescence readings produced by examining
dead and ruptured cells. This can be accomplished by using a 50/50 % mixture of live
and dead cells stained using a viability dye (e.g., Zombie Aqua) that penetrates dead cells
only. Laser intensity compensation should be completed on the unstained and single
stained specimens instead of traditionally compensation beads (see Note 1). Always
consult a spectral overlap calculator prior to ordering and running a multi-stained flow
cytometry experiment to ensure individual readings can be differentiated from each other.
The Spectral Viewer by BD Biosciences (San Jose, CA) is especially useful if you are
using a BD Biosciences flow cytometer. Prior to a running a complete experiment, it is
advised that an antibody titration series be completed for each new cell type and stain,
this can be accomplished by testing the recommended controls. See Table 4.1 for
recommended starting set-up for mouse epiblast stem cells.
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Table 4.1. Recommended Set-up for a single cell type.
Tube

Treatment/Specimen Stain
(mEpiSC)

Live/Dead

SSEA1

CD24

1.

Unstained

2.

50% Live/50%Dead

Zombie Aqua

3.

Single stain

Zombie Aqua

4.

Single stain

5.

Single stain

6.

Full minus one

7.

Full minus one

Zombie Aqua

8.

Full minus one

Zombie Aqua

BV421

9.

Full – n1

Zombie Aqua

BV421

APC

10.

Full – n2

Zombie Aqua

BV421

APC

11.

Full – n3

Zombie Aqua

BV421

APC

BV421
APC
BV421

APC
APC

4.3.1. Live pluripotent stem cell preparation.
Twenty-four hours prior to the day of harvest, remove cells for live/dead cell
compensation. This can be accomplished by leaving a conical tube of cells out of the
incubator in DPBS(-/-) overnight. Combine 200,000 dead cells with 200,000 live cells.
Aim for approximately 400,000 cells overall for the live/dead treatment. Live cells
benefit from the addition of 10 mM rho kinase inhibitor (Y-27632; STEMCELL
Technologies). This should be added gently to fresh, pre-warmed (37 °C) media on cells
for 1 hour in an incubator (see Note 2). Lift cells from their dish into a single cell
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suspension for 5 minutes incubated at 37 °C using StemPro Accutase, cover the entire
growth surface area to be effective, agitation is not necessary (see Note 3). Transfer the
lifted cells to pre-warmed (37 °C) media and centrifuged (244 rcf) for 3 minutes or until
pelleted (see Note 4). Aspirate supernatant and perform a viability cell count using
trypan blue with a hemocytometer or similar cell counting method (Strober 1997). Each
treatment should have a minimum of 400,000 cells. Divide cells into sterile, labelled, and
capped flow tubes, reconstituted in 100 µL/treatment with flow cytometry staining buffer
(FCSB). Stain live/dead viability treatments by incubating for 30 minutes in a light-tight
box at room temperature (see Note 5). For treatments without live/dead staining skip this
step and proceed to adding the appropriate fluorophore. Wash treatments with 2 mL of
FCSB, centrifuge (244 rcf) for 3 minutes. Aspirate the supernatant and reconstitute with
100 µL of FCSB. Add appropriate fluorophore conjugated antibodies taking note of
product concentration/cell count, gently vortex and incubate for 30 minutes in a lighttight box at room temperature. All samples, except for the unstained controls, are now
light sensitive and should always be handled in dim lighting conditions. Wash treatments
with 2 mL of FCSB, centrifuge (244 rcf) for 3 minutes. Reconstitute with 200 µL of
FCSB and gently vortex. Pipette the cell suspension over an upside-down 20 µm cell
strainer. Wash with 100 uL of FCSB. Flip cell strainer and pipette from the inside to get
residual cells held by surface tension. Proceed immediately to running cells through a
flow cytometer or FACS sorting for optimal results.
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4.3.2. Fixed pluripotent stem cell preparation.
Twenty-Four hours prior to the day of harvest, remove cells for live/dead cell
compensation. This can be accomplished by leaving a conical tube of cells out of the
incubator in DPBS(-/-) overnight (see Note 1.). Aim for approximately 400,000 cells.
Lift cells from their plate; enzymatic lifting works well. Colonies need to be separated
into single cells, cover the growth surface with lifting agent for 5 minutes in an incubator
(see Note 5). Centrifuge (244 rcf) the single cell suspension for 3 minutes. Aspirate
supernatant and perform a viability cell count using trypan blue with a hemocytometer or
similar cell counting method(Strober 1997). Each treatment should have a minimum of
400,000 cells. Divide cells into sterile, labelled, and capped flow tubes, reconstituted in
100 µL/treatment with flow cytometry staining buffer (FCSB). Reconstitute in DPBS(-/-)
(100 mL x tubes required), divide into flow tubes. Stain live/dead viability treatments by
incubating for 30 minutes in a light-tight box at room temperature (see Note 5). For
treatments without live/dead staining skip this step and proceed to fixation. Wash
treatments with 2 mL of FCSB and centrifuge (244 rcf) for 3 minutes. Aspirate the
supernatant and reconstitute with 100 mL of FCSB. Wash treatments with 2 mL of FCSB
and centrifuge (244 rcf) for 3 minutes. Aspirate the supernatant and add appropriate 500
mL of fixative agent (freshly made and chilled 4 % paraformaldehyde in DPBS(-/-) is
recommended for cell surface marker analysis), incubate for 10 minutes in a fume hood
on ice (see Notes 1 and 6). Wash with 2 mL of DPBS(-/-) and centrifuge (244 rcf) for 3
minutes. Aspirate supernatant and reconstitute with 100 µL of PBS(-/-) per treatment.
Add appropriate fluorophore conjugated antibodies taking note of product
concentration/cell count, gently vortex and incubate for 1 hour in a light-tight box at on
ice. All samples (except for unstained controls) are now light sensitive and should be
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handled in dim lighting conditions. Wash once with 2 mL of DPBS(-/-) and centrifuge
(244 rcf) for 3 minutes. Aspirate supernatant and reconstitute with 200 µL of DPBS(-/-)
and gently vortex. Pipette the cell suspension over an upside-down 20 µm cell strainer
and wash with 100 µL of DPBS(-/-). Flip the cell strainer and pipette from the inside to
get residual cells held by surface tension. Leave tubes in the fridge in a light-tight box
until you are ready to run on a flow cytometer. Run on a flow cytometer within 24 hours
of staining for optimal results.
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Figure 4.1. Flow cytometric characterization of SSEA1 and CD24 and gating
strategy of mEpiSCs.
a) Side-scatter-area versus forward-scatter-area flow plot detailing granularity of light
refracting off subcellular structures and cell size by light passing over the same individual
cell events. This population display can show subpopulations within the data. In
mEpiSCs, examine P1, the lower population if grown on MEFs. Forward-scatter area
versus forward-scatter-height further delineates the shape of cells passing through the
cytometer as population P2. b) Gating of viability-stained samples. Cells expressing the
viability stain are not living, the live population on interest is compared to either the
Live/Dead single stain or Live/Dead FMO specimens. c) SSEA1 versus CD24 channel
expression with crosshair gating of the SSEA1 FMO specimen with the x-axis threshold
set just above the main population of cells. d) SSEA1 versus CD24 channel expression
with crosshair gating of the CD24 FMO specimen with the y-axis threshold set just to the
right of the main population of cells. The x-axis threshold of c) is maintained.
e) SSEA1 versus CD24 channel expression with crosshair gating of the fully stained
specimen with both the x-axis and y-axis thresholds maintained. Adjunct histograms can
further distinguish the event density of the plot.
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4.3.3. Flow Cytometric Analysis.
Flow cytometric analysis will depend largely on the cytometer the user has selected. For
the development of this methodology, a BD FACSCanto™ Cell Analyzer flow cytometer
was used, however, all the steps outlined will be consistent for any current flow
cytometer. Regardless of the cytometer used, these steps should be followed to ensure
consistent and qualified results. Consult with the manufacturer for setting individual laser
parameters and ensure proper cleaning and maintenance has been completed prior to any
use. Daily quality control checks need to be completed using qualified beads to optimize
results.

Compensation was completed using BD FACSDiva™ Software. Gating was completed
using BD FlowJo™ Software. While other post-flow cytometric analysis software is
available, FlowJo™ currently provides the most comprehensive and advanced methods of
flow cytometric analysis. The following gating strategy can be applied in most situations,
however, if FlowJo is not your software of choice, start at Step 3. Each cell population
refinement can be brought into the subsequent step for a final gated flow plot (see Note
7).

Import or drag individual .fsc files into FlowJo. Drag unstained, single stained treatments
of each cell type into the compensation tab. Post-flow cytometric compensation can now
be improved using FlowJo’s Compensation Wizard. Compensated samples will be
indicated with a colored 3x3 grid marker. Begin examining the unstained sample, setting
the x- and y- axes to forward-scatter-area and side-scatter-area respectively, gate out the
main population of cells. A tightly, set polygonal gate works well (Figure 4.1.a) (see
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Note 8). Now, compare the Live/Dead stain only specimen to either the Live/Dead FMO
or the unstained specimen. Examine these using forward-scatter-area versus the
appropriate Live/Dead corresponding channel. A simple box gate scheme should suffice
for both a live and dead gate (Figure 4.1. b). This step and the following steps can be
portrayed using biexponential axes. Open both the SSEA1 FMO and CD24 FMO
specimens. Set the x- and y- axes to the corresponding CD24 and SSEA1 laser channel
respectively. Choose the crosshair gating option and set the crosshair above and to the
right of each population (Figure 4.1.c, d). These options can be performed in either order.
Finally, apply the complete gating scheme to the fully stained specimen. If possible, add
adjunct histogram to show the event density (Figure 4.1.e) (see Note 9).

4.3.4. Statistical Representations
If each biological replicate was run during the same session, FlowJo can accurately
calculate the geometric mean, mode, and median for an analysis relatively synonymous to
that of densitometry in immunoblotting studies. These options can be found under
statistical options following gating.
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Figure 4.2. Flow cytometric expression of SSEA1 and CD24 during naïve to primed
transitioning in mESCs, mEpiLCs, and mEpiSCs.
mESCs, mEpiLCs (72 hours of transitioning), and mEpiSCs examined for SSEA1 and
CD24 run on a flow cytometry within a single session can be compared within a single
flow plot to demonstrate the shifting of transitioning formative state mEpiLCs towards a
primed-like pluripotent fate. Overlay of flow cytometric plots is best represented with
adjunct histograms as pseudo-coloring of the individual events in an overlay is not
distinguishable between groups.
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Typical percentages of each population you may encounter can be found in Table 4.2.

Table 4.2. Quadrant event frequencies of SSEA1/CD24 cell surface marker
expression in mESCs, mEpiLCs, and mEpiSCs.
Cell Type

Naïve

SSEA1H/CD24

SSEA1H/CD24

SSEA1L/CD24

SSEA1L/CD24

L

H

H

L

(%Event±SD)

(%Event±SD)

(%Event±SD)

(%Event±SD)

29.8±1.9

3.2±1.4

6.1±2.9

61.0±3.2

31.1±18.5

1.8±1.2

1.9±0.3

65.2±19.4

38.6±5.2

14.9±10.9

5.9±2.5

40.3±14.1

0.7±0.2

21.1±7.6

74.4±9.4

3.6±4.6

mESCs

Formative
, 48- hour
mEpiLCs
Primedlike 96hour
mEpiLCs
Primed
mEpiSCs
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4.4.0. Notes:
1. Growing mEpiSCs is optimal on a layer of MEF feeders. mEpiSCs are much
smaller than MEFs and examining side-scatter and forward-scatter attributes can
be used as a form of size exclusion. This method of gating is limited, and it is
preferential to run samples both fixed and feeder-free when possible. Otherwise
include a pluripotent marker not expressed on MEFs, especially in the case of a
FACS study.

2. In the case of metabolism related scientific studies, consider avoiding feeding
cells prior to or during the flow cytometry or immunofluorescent imaging process
to maintain consistency and avoid spiking of metabolites and corresponding
enzymatic processes/pathways.

3. Live/Dead cell compensation requires that you have a mix of live and dead cells.
Some protocols use heated water (typically 65 °C) however mESCs can withstand
65 °C for 30 minutes, maintaining >98 % viability. Traditional compensation
beads will not work with Live/Dead stains.

4. Spectral overlap of fluorophores can confound flow cytometry results depending
on the stain and the flow cytometer used. Several spectral overlap calculators are
available, and it is highly recommended that all stains be reviewed and applied
appropriately to the correct flow cytometry laser configurations.
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5. It is often recommended that compensation beads are used with single stains for
flow cytometry. However, pluripotent stem cell marker expression will
fluorescence brighter in PSCs than current commercially available compensation
beads.

6. Fluorochromes such as phycoerythrin (PE) or allophycocyanin (APC) are large
protein molecules and will be affected the same way as other proteins by the
fixation so try to avoid alcohols. However, small fluorochromes such as
AlexaFluor488 or FITC are generally unaffected by whichever fixative is used.

7. Doing this instead of importing the .wsp file containing the experiment will result
in the x- and y- axes being flipped. This is a longstanding issue with FlowJo but
may be corrected in the future.

8. This population can be refined by setting the x- and y- axes to forward-scatterarea and forward-scatter-height respectively, further gate out the main population
of cells. A tightly, set polygonal gate works well (Fig. 4.2.a)).

9. This can be especially useful if combining and comparing several cell types or
treatments and the pseudo-color display option can’t be selected. See Figure 4.2.
for a comparison of mESCs, mEpiLCs, and mEpiSCs overlayed.
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4.5.0. Discussion:
This protocol is specifically designed to sort naïve, formative, and primed pluripotent
stem cell states. Studies examining newly derived or altered mPSCs could find such
methods useful in validating pluripotent state, calculating transitioning efficiency of
generating various pluripotent states, or following genetic manipulation (Kinoshita et al.
2020; Hayashi et al. 2011; Shakiba et al. 2015; Vidal, Stadtfeld, and Apostolou 2015). As
pluripotency is described as a continuum, this method is invaluable for studying
differences between cell types found in the developing epiblast. Originally, these
methods have focused on sorting differences between naïve mESCs and primed mEpiSCs
(Shakiba et al. 2015).

Here we uniquely describe how this procedure can be extended to also sort cells
designated as the formative stage of pluripotency (Shakiba et al. 2015). As formative
state cells are the only known pluripotent cell type capable of primordial germ cell
differentiation, this method is applicable and necessary for the investigation of
mechanisms controlling the differentiation of naïve, mESCs transitioning to a formative
pluripotent state and onward to specialized germ cell-like cells following bone
morphogenetic protein (BMP) treatment (Hayashi et al. 2011). During the development
of this methodology, a non-transient formative state was described in mouse and human
embryonic stem cells (Kinoshita et al. 2020). With the addition of Fgf/nodal signalling,
Dr. Austin Smith’s group, which originally hypothesized the formative pluripotent state,
utilized tankyrase inhibitor to inhibit Wnt signalling in cells explanted from the inner cell
mass of embryonic day 5.5 mouse embryos (Kinoshita et al. 2020). Previously, the
formative state could only be captured for 24-48 hours as a transient population, with this
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new methodology, cells can be passaged for >20 passages maintaining characteristics of
the formative state. The protocols outlined in this methodology paper could be applied to
this landmark study in generating stable formative pluripotent lines (Hayashi et al. 2011).
Given proper bone morphogenetic protein stimuli, formative state cells can efficiently
differentiate into primordial germ-like cells unlike any other pluripotent stem cell stage.
Using this flow cytometric method, one can quantify the transitioning efficiency of
formative state cells from mESCs compared to explanted formative state cells to
determine differences in chemically transitioned and native states in vitro.

Traditionally, reprogramming somatic human cells and explanting embryonic stem cells
from human embryos results in pluripotent stem cells representing the primed pluripotent
state. Recently, naïve and formative state human pluripotent stem cells have been derived
from both embryonic and adult origins (Ware et al. 2014; Giulitti et al. 2019; Kinoshita et
al. 2020). The described methodology is applicable in the study of naïve pluripotent
reversion from the primed pluripotent state and from somatic fates via reprogramming.
From the human naïve pluripotent state, it is possible to transition to formative state and
capture the transitioning efficiency as well as compare transitioned cells (i.e., naïve-like
cells) to the traditional primed state as previous studies have compared naïve and primed
mouse pluripotent states (Shakiba et al. 2015). The addition of CD40, a cell surface
pluripotency marker associated with the primed pluripotent state, could additionally be
utilized (Shakiba et al. 2015). Through previous attempts in the mouse system, we
observed that CD24 differences were more apparent than CD40.
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Currently, naïve, formative, and primed pluripotency discrimination can be completed
through transcript abundance studies, epigenetic landscape differences, differentiation
assays, and chimeric contributions (Kinoshita et al. 2020; Morgani, Nichols, and
Hadjantonakis 2017). This novel method has the added benefit of potential downstream
applications through the option of fluorescently activated cell sorting (FACS) of distinct,
purified cell populations. Following FACS, sorted fixed cells can be examined for
protein or transcript abundance studies and perhaps single cell analysis or proteomics and
live cells can be re-plated into more homogenous populations for expansion and
differentiation assays. With the advent of stable formative pluripotent states, the
described methodology with the addition of FACS could allow for the study of
subpopulations for improved studies into the development of germ cell differentiation.
Future improvements to this protocol are likely to be optimized using stable and pure
formative state PSC lines. A comparative study examining the transition of mESCs to
formative mEpiLCs compared to actual explanted formative state cells and primed
mEpiSCs examining the transition throughout the pluripotent spectrum within a smaller
time interval would be telling of the developmental changes that take place.
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5.1.0. Abstract:
Metabolism is implicated in playing both an active and passive role in embryonic
development, cell pluripotency, and cell-fate, however, little is known regarding the role
of metabolic state in the recently described formative pluripotent state. This
developmental pluripotent continuum is accompanied by a metabolic switch from a
bivalent metabolism (both glycolysis and oxidative phosphorylation) in naïve cells, to
predominantly glycolysis in primed cells. Metabolic preferences promote the
maintenance and generation of various pluripotent states. I have investigated the role of
pyruvate kinase muscle isoforms (PKM1/2) in naïve, formative, and primed mouse
embryonic stem cells through modulation of PKM1/2 mRNA transcripts using stericblocking morpholinos that downregulate PKM2 and upregulate PKM1. I have examined
these effects in naïve, formative, and primed cell states by quantifying the effects of
PKM1/2 modulation on pluripotent and metabolic transcripts and by measuring shifts in
the populations of cells expressing naïve and primed markers by flow cytometry. I found
that modulating PKM1 and PKM2 levels alters the transition from the naïve state into a
formative and primed-like pluripotent states. Therefore, I conclude that PKM1/2 actively
contributes to mechanisms that oversee early stem pluripotency and their progression
towards a primed pluripotent state.

5.2.0. Introduction:
Pluripotent stem cells (PSCs) are characterized by their unlimited self-renewal and
potential to specialize into cell types of the adult organism. Approximately 3.5 days
following fertilization (E3.5), the mouse embryo contains a niche of cells within the
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blastocyst and encircled by the trophectoderm called the inner cell mass (ICM) of the preimplantation embryo (Evans and Kaufman 1981; Martin 1981). This niche of 10-20 cells
represents the earliest pluripotent stem cell (PSC) population of the developing embryo
and these cells are the origin of the primary germ layers that result in the formation of the
fetus. These cells also represent the origins of mouse embryonic stem cells (ESCs) that
are important research models for unraveling early developmental cell fate control
mechanisms and are also key resources for the development of cell-based therapeutics.
PSCs of the developing mouse can be explanted from the embryo until E8.0, however,
several key differences underlying changes in their pluripotency arise between the E3.5
and E8.0 (Morgani, Nichols, and Hadjantonakis 2017). Some of these differences include
developmentally programmed changes in gene expression, epigenetic landscape,
metabolic preferences, and ability to contribute to all germ cell layers and chimeric
development (Nichols and Smith 2009; Zhou et al. 2012). Explanted mouse ESCs
(mESCs) between E3.5 and E4.5 and mouse epiblast stem cells (mEpiSCs) from between
E7.25 and E8.0 both express core pluripotency genes including sex determining region Y
– box 2 (Sox2), octamer-binding transcription factor 4 (Oct4), and Nanog (lower in
mouse epiblast stem cells; mEpiSCs), however, mESCs express pluripotency associated
genes such as reduced expression 1 (Rex1), platelet endothelial cell adhesion molecule 1
(Pecam-1), and orphan nuclear receptor Esrrb at greater levels than mEpiSCs (Wray et al.
2011). Conversely, mEpiSCs express pluripotency genes such as Zinc finger protein 2
(Zic2), T(Brachyury), and Cerberus (Cer1) more so than mESCs (Morgani, Nichols, and
Hadjantonakis 2017). Metabolically, mESCs are bivalent in their preference for
metabolic pathways utilizing both glycolysis and oxidative phosphorylation (OXPHOS).
However, mEpiSCs are preferentially univalent, using aerobic glycolysis, similar to the

163
preferences of most cancer cells, where regardless of oxygen availability glycolysis takes
on precedence despite OXPHOS being capable of generating more adenosine
triphosphate (ATP) (Zhou et al. 2012). Primed cells, adult stem cells, and typical cancer
cells with high rates of proliferation opt for glycolysis in this manner to generate
metabolic precursors for other anabolic processes (Vander Heiden, Cantley, and
Thompson 2009; Mathieu and Ruohola-Baker 2017). Recent studies have indicated there
is an intermediate state of pluripotency existing between the naïve and primed ends of the
pluripotent spectrum referred to as ‘formative pluripotency’, representative of the E5.5E6.0 post-implantation epiblast (Smith 2017). Therefore, E3.5-E4.5, E5.5-6.0, and
E7.25-E8.0 represent distinct states of the pluripotent continuum, and are referred to as
naïve, formative, and primed pluripotent states respectively, and represent the ICM cells
of the pre- and post-implantation epiblast (Nichols and Smith 2009; Morgani, Nichols,
and Hadjantonakis 2017; Osorno et al. 2012; Kinoshita et al. 2020).

This newly defined formative pluripotent state is consistent within the phased progression
model suggesting that all differentiating naïve cells must phase through the formative,
then primed state before exiting pluripotency. The exception to this rule is germ cell
lineages, however, it is this exception that supports the phased progression model as
formative state cells have the potential to become primordial germ cells. The formative
pluripotent state and the phased progression model rely on the concept of germ line
competence. When mESCs and are incorporated into chimeras and allowed to develop,
germ cells arise, however, when mESCs are cultured in vitro they do not produce
primordial germ cell-like cells (mPGCLCs) (Hayashi et al. 2011). In contrast, ICM cells
of the E5.5-E6.0 mouse embryo (formative interval) can readily differentiate into
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mPGCLCs through addition of bone morphogenic protein 4 (Bmp4) (Ohinata et al. 2009).
Developmentally, germ line competency occurs during the interval between naïve and
primed pluripotent states and the phased progression model hypothesis adds that somatic
cell differentiation competency is also gained at this time. The switch from metabolic
bivalency to aerobic glycolysis also begins during this transition (Kalkan et al. 2017).
Ground state mESCs that are chemically transitioned towards a primed pluripotent state
through the replacement of LIF/2i with activin and fibroblast growth factor (Fgf)
supplementation (FA), hereafter referred to as mouse epiblast-like cells (mEpiLCs), do
not fully commit to primed pluripotency and exhibit an intermediate potency with the
potential to differentiate into mPGCLCs (Guo et al. 2009; Hayashi et al. 2011).
Formative state mEpiLCs show increased expression of genes including de novo DNA
methyltransferase 3a/b (Dnmt3a/b), fibroblast growth factor 5 (Fgf5), Sal-like protein 2
(Sall2), Sox3, and POU domain class 3 transcription factor 1 (Oct6; Pou3f1), following a
decrease in Nanog expression (Smith 2017; Buecker et al. 2014).

There is a growing body of evidence showing that not only are the metabolic preferences
of naïve and primed pluripotent states are distinct, but metabolic preferences also act to
promote developmental processes, maintain pluripotency state, and enable cell fate
decisions (Dahan et al. 2019; Tsogtbaatar et al. 2020; P. Wei et al. 2018). The concept of
metabolic remodelling and reprogramming has been demonstrated in a variety of stem
cells including T cell fate control, direct reprogramming of glial cells to neurons,
neuronal metabolic preferences during differentiation, and improving stemness through
mitochondrial function by nicotinamide adenine dinucleotide (NAD) repletion (Buck et
al. 2016; Gascón et al. 2016; H. Zhang et al. 2016; Zheng et al. 2016). Regarding
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metabolic preferences, glycolysis and OXPHOS play a primary role in pluripotent state
differences (Zhou et al. 2012). On either end of the pluripotent continuum, naïve and
primed states observe unique preferential metabolic phenotypes. Naïve cells are
metabolically bivalent, in vitro colonies use both glycolytic and oxidative
phosphorylation processes, whereas primed cell colonies are preferentially glycolytic
representing a trend referred to as the ‘Warburg Effect’ (WE). These in vitro metabolic
preferences may exist as a by-product of their in vivo correlate’s metabolism due to
restricted physiological oxygen access of the pre- and post- implantation cell niches. The
recently described and stabilized intermediate pluripotent state, the formative state, has
yet to be metabolically profiled, however, as this interval is representative of the recently
post-implantation blastocyst, it may indicate a bias for aerobic glycolysis (Kinoshita et al.
2020; Smith 2017).

A key metabolic enzyme that not only links glycolysis and OXPHOS but is also a
hallmark factor in the WE is pyruvate kinase muscle isoforms 1/2 (Pkm1/2 (transcript),
PKM1/2 (protein)). Pkm1/2 is an allosterically regulated and alternatively spliced gene
that produces the pyruvate kinase enzyme responsible for the catalysis of a phosphoryl
group from phosphoenolpyruvate in glycolysis to form pyruvate, and the phosphoryl
group is transferred to adenosine diphosphate to form ATP (Jurica et al. 1998; Valentini
et al. 2000). PKM2 is implicated in cancer and the WE and recently PKM1 has been
shown to have a contributing role to small cell lung cancer (W. Yang and Lu 2015;
Growth 2018; L. Wei et al. 2017). PKM2 impinges on OXPHOS when nuclear
translocated, and upregulates glycolytic activity that favors lactate production of acetyl
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Co-A over a mitochondrial OXPHOS fate – a hallmark of the WE (Wang et al. 2014;
Weiwei Yang and Lu 2013).

As PKM1/2 are implicated in aerobic glycolysis and proliferation, it is critical to
investigate their contributions to naïve and primed cell pluripotency. Previous attempts to
study the role of PKM1/2 in naïve and primed pluripotent states did not consider the
intermediate, formative phases of the pluripotent continuum (Qin et al. 2017; Konno,
Ishii, et al. 2015; Prigione et al. 2014). This study utilized steric-blocking morpholinos to
modulate PKM1 and PKM2 isoforms in naïve and primed mouse pluripotent stem cells
and during the chemical transitioning to formative, primed-like stem cells from the naïve
state. The outcomes include effects to Pkm1 and Pkm2 transcript abundance in naïve,
formative, primed-like, and primed pluripotent stem cells, and the impact of modulating
Pkm1/2 on metabolic and pluripotent state. I also determined the impact of altering
Pkm1/2 during transitioning mESCs-to-formative and formative-to-primed-like
pluripotency. This study demonstrates that downregulation of PKM2 alone through
splice modifications results in altered metabolic transcript abundance and promotes naïveto-primed transitioning in formative mEpiLCs and downregulation of PKM2 and
upregulation of PKM1 results in a new population of naïve and primed marker expressing
cells in primed-like mEpiLCs. This study promotes metabolism as a driver of
pluripotency and development, demonstrates how to delineate intermediate states from
ground and primed pluripotency and provides evidence of PKM1 having a role in the
pluripotent developmental process.
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5.3.0. Methods:
5.3.1. Stem cell culture conditions:
Mouse embryonic stem cells (mESCs, R1 strain – 129X1 x 129S1 (gifted from Dr. Janet
Rossant, The Hospital for Sick Children, Toronto, Ontario, Canada), formative and
primed-like mouse epiblast-like cells (mEpiLCs, chemically converted R1 mESCs over
48 and 96 hours) and primed mouse epiblast stem cells (mEpiSCs, strain – 129S2 ((gifted
from Dr. Janet Rossant, The Hospital for Sick Children, Toronto, Ontario, Canada); were
cultured in the following base media; a 1:1 mixture of KnockOut DMEM/F12 (Thermo
Fisher Scientific 12660012) and Neurobasal Media (Thermo Fisher Scientific 21103049)
with 0.1% 2-Mercaptoethanol (Gibco 21985-029), 0.25% GlutaMAX (Thermo Fisher
Scientific 35050061), 1.0% N2 Supplement (100x) (Thermo Fisher Scientific 17502048),
and 2.0% B27 Supplement (50x) (Thermo Fisher Scientific 17504044) (Supp. Figure 1a).
mESCs and mEpiLCs were cultured on 0.1% porcine gelatin (Sigma-Aldrich G2500) and
mEpiSCs and MEFs were cultured on 10 µg/mL/cm2 fibronectin (Roche 11051407001).
Base media for the culture of mESCs were supplemented with 1000 units/mL ESGRO
Recombinant mouse LIF protein (EMD Millipore ESG1107), and 2i small molecule
inhibitors: 1 M PD0325901 (Reagents Direct 39-C68) and 3M CHIR99021 (Reagents
Direct 27-H76). Base media for the culture of mEpiLCs and mEpiSCs were
supplemented with 20ng/mL Activin A from mouse (Sigma-Aldrich SRP6057) and 12
ng/mL Fgf-2 from mouse (Sigma-Aldrich SRP3038). mESCs were passaged using
StemProTM AccutaseTM (Thermo Fisher Scientific A1110501) and centrifuged at 300 x g
for 5 minutes. Primed mouse epiblast stem cells were cultured in the base medium and
supplements as mEpiLCs were along with a substratum of irradiated mouse embryonic
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fibroblasts (MEFs). One hour prior to passaging, growth medium was replaced.
Passaging was completed using Gentle Cell Dissociation Buffer (GCDB) (Gibco 13151014) for 5 minutes at room temperature. Lifted cells were then centrifuged at 244 x g for
3 minutes and plated at a seeding density of 1:12 onto MEFs. RNA and protein
abundance studies were completed by excluding MEFs for feeder-free conditions and
passaging mEpiSCs once with StemProTM AccutaseTM (Thermo Fisher Scientific
A1110501) followed by a GCDB passage, this resulted in a clean and healthy population
of feeder-free mEpiSCs ready for transcript and protein abundance studies. Cells were
utilized within three to five passages following cryopreservation when possible and
studies were carried out in biological triplicate.

5.3.2. siRNA Transfection:

mESCs were grown to approximately 70-80% confluency and washed with fresh, prewarmed (37 °C) LIF/2i supplemented media. Transfection was completed using the lipidbased carrier Lipofectamine3000 (ThermoFisher L3000001) and optimal siRNA and
carrier concentrations were assessed using a FITC fluorescein conjugated siRNA control
quantitatively via flow cytometry qualitatively by fluorescent imaging.
Lipofectamine3000 was diluted in 50 µL of Opti-MEM (FisherScientific 31985070) prior
to mixing with siRNA and incubated together at room temperature for 15 minutes. Cells
were washed with Opti-MEM once and the Lipofectamine3000 and siRNA solution in
Opti-MEM were incubated on the cells for 5 hours. Cells were then aspirated and given
fresh media. Pkm1/2 siRNA design constructs were made with the aid of ThermoFisher’s
Life Sciences Solutions division. Specificity assessment was then completed using qPCR
and immunoblotting.
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5.3.3. Morpholino Delivery:

Morpholinos were transfected into mESCs, formative mEpiLCs and mEpiSCs through the
scrape delivery method (Partridge et al. 1996). In brief, once cells achieved
approximately 70-80% confluency, fresh pluripotent specific media supplemented with 5,
10, or 20 M morpholino (as a series for optimization and 20 M for experimental
studies) (fluorescein-tagged control, PKM MO 1 or PKM MO 2 morpholino) that had
been 2 m filter sterilized was ejected onto a PBS(+/+) washed growth surface (either
gelatin or fibronectin). The MO supplemented media was swirled for 10 seconds both
clockwise and counterclockwise before being allowed to incubate at room temperature for
1 minute. Rubber policeman cell scrapers (Sarstedt 83.3951) were used vertically across
the plate, then perpendicularly. Cells co-endocytosed the morpholinos through now open
transient pores for 10 minutes without permitting the cells to reattach to their substratum.
Transfected cells were replated onto larger growth spaces and allowed to incubate for 24
hours before downstream applications including fluorescent imaging, immunoblotting,
transcript abundance and flow cytometry studies. Transfected cells were compared by
phase contrast to determine if morphology was influenced. Imaging of fluorescently
transfected cells and phase contrast microscopy was completed using a Leica DMI
6000B. Morpholino design, targeting sites and post-transfection changes to PKM1/2
protein can be found in Table 5.1. Experimental timelines for morpholino transfection
and cell fate transitioning are detailed in Figure 5.01.a-b.
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Figure 5.01. mESC, mEpiLC, and mEpiSC culture and timing schematic.
Ground state, naïve mESCs, formative/primed-like transitioning to mEpiLCs, and primed
mEpiSCs experimental planning schematic. a) Experimental plating set-up and media
transitioning from mESCs into formative and primed-like mEpiLCs through media
supplementation and timing. b) Morpholino scrape delivery and incubation timelines
described per cell type in each experimental study component.
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Table 5.1. Morpholino Design.
Name

Target

Design

PKM MO

Pkm-202-

CCGAGCTATCTGTAAGGTTTAGGGT

1

i8e9

PKM MO

(Pkm-201-

2

e8i9)

ACTGCCGCCTCCTACCTGCCAGA
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5.3.4. Transcript Abundance:

RNA isolation was completed using a RNeasy RNA isolation kit (Qiagen 74104) and
Trizol (Ambion 15596018) hybrid protocol followed by DNAse treatment (Invitrogen
AM1906). cDNA synthesis was completed using iScript (BioRad 170-8891) on 500 ng
of RNA. Quantitative PCR was completed using SensiFAST™ SYBR® No-ROX Kit
(FroggaBio BIO-98020). Optimal annealing temperatures for each primer were tested in
temperature gradients followed by a dilution series to determine primer efficiencies.
Relative transcript abundance was calculated using the Pfaffl method of quantification,
normalized to mESCs not treated with a morpholino and relative to 𝛼-Tubulin transcript
abundance(Pfaffl 2001). Forward and reverse primer designs and annealing temperatures
are available in Table 5.2. TaqMan PCR was completed using TaqMan™ Advanced
Master Mix (Thermo Fisher Scientific 4444557). Relative transcript abundance was
calculated using the ∆∆Ct method of quantification, normalized to mESCs not treated
with a morpholino and relative to Hprt transcript abundance (Livak and Schmittgen
2001). The fold change in transcript abundance levels for both qPCR and TaqMan
studies was calculated and expressed as log2.
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Table 5.2. PCR Primers
Gene

Potency/

Efficiency

Annealing

Sequence

Name

Role

(%)

Temperature

(F = Forward, R = Reverse; 5’ – 3’)

(℃)
𝛼-

House

Tubulin

keeping

Pecam

Naïve

Rex1
Esrrb
Lef1
Dnmt3
Pou1fc
Zic2
Cer1
T(Bra)
Hk2
Gpi
Pgam1
Ldha
Pfkl

Aldoa
Eno1
Mdh2

Naïve
Naïve
Formative
Formative
Formative
Primed
Primed
Primed
Glycolysis
Glycolysis
Glycolysis
Glycolysis
Glycolysis

Glycolysis
Glycolysis
OXPHOS

101.0

57.0-63.0

R- CACAGTGGGAGGCTGGTAGTTAAT

90.0

63.0

96.6

63.0

103.7

63.0

108.1

57.0

99.0

63.0

99.0

60.0

90.0

63.0

99.8

60.0

104.1

60.0

91.8

63.0

102.3

63.0

94.0

63.0

98.7

63.0

103.1

F- CAAGGCCAAACAGAAACCCG
R- GCCTTCCGTTCTCTTGGTGA
F- AGAAGAAAGCAGGATCGCCT
R- TATGACTCACTTCCAGGGGG
F- CAGGCAAGGATGACAGACG
R- GAGACAGCACGAAGGACTGC
F- AGAAGAAGAAGAGGAAGAGAGAGAAGC
R- AGATGTAGGCAGCTGTCATTCTGG
F- GGCAAGGACGACGTTTTGTG
R- GTTGGACACGTCCGTGTAGTGAG
F- TTTCTCAAGTGTCCCAAGCC
R- ACCACCTCCTTCTCCAGTTG
F- GGTGACCCACGTCTCTGTG
R- CGGATGTGGTTGACCAGTTT
F- ACCTATGTGTGGATGGCTGC
R- AGATCCGGCTTGTCTTCTGC
F- CGGTGGCGAGAGAAGTGAAG
R- CTTCCCTGCGCTCTCTGTG
F- CCTGCTACAGGTCCGAGCCATCTT
R- GAGGATGAAGCTTGTACAGTGTCC
F- AACCGGCCGACCAACTCAAT TGTG
R- TGCCGTCCAGCTCTGGCTCAATTT
F- TACGCAGACCTTACTGAAGACCAG
R- AGCTCCATGATGGCCTCTTCTGAG
F- GCAGACAAGGAGCAGTGGAAGGAG
R- ACACTGAGGAAGACATCCTCATTG

63.0

F- AATGTGCTGGGCCACTTGCAGCAG
R- TGACCGGACTGAAGGCCACTACCT

101.2

63.0

98.5

63.0

104.7

F- AACCAGATGGTGAAATGTGACCCT

F- ATGAGGAGATTGCCATGGCAACGG
R- TTTAGAGCAGAGGCCTGCAGGGCT
F- ACCAACCCTAAGCGGATTGCCAAG
R- AGTCTTGATCTGCCCAGTGCAGAG

63.0

F- AGAAGTCGTGAAGGCCAAGG
R- AGTGATCTTGCCAATGCCCA
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Fh1
Sdha
Suclg1
Cs
Idh2

OXPHOS
OXPHOS
OXPHOS
OXPHOS
OXPHOS

98.4

63.0

90.5

63.0

108.7

63.0

104.0

63.0

97.8

63.0

F- CGGTTTCGCAGAAAAGGTGG
R- ACAGCAACGTGATTCCCCAT
F- AGAGATACGCACCTGTTGCC
R- ACTGGGATGGGCTCCTTAGT
F- GGTGAAATTGGTGGTCACGC
R- AAGGACACTACAGGCTTGGC
F- TGCCGGTTTGTCTACCCTTC
R- GGCAGGATGAGTTCTTGGCT
F- TCTTCACCCCAAAGGATGGC
R- TCTGGTGTTCTCGGTAATGGC
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5.3.5. Protein Abundance:
Cells were washed with chilled (PBS(+/+)) (Gibco 14040-133) and lysed with PierceTM
RIPA Buffer (Thermo Fisher Scientific 89900) supplemented with 1X Phosphatase
Inhibitor Cocktail Set 2 (Calbiochem 5246251) and 1X Protease Inhibitor Cocktail Set 1
(Calbiochem 539131). Protein quantification was completed using a PierceTM BCA
Protein Assay kit (Thermo Fisher Scientific 23225). Loading mixes were prepared at 20
µg in MilliQ H2O, LDS (NuPAGE™ LDS Sample Buffer (4X) Invitrogen NP0007) and
Reducing Agent (NuPAGE™ Sample Reducing Agent (10X) Invitrogen NP0004) at
70°C for 10 minutes before loading in NuPAGETM 4-12% Bis-Tris Gels (Invitrogen
NuPAGE NP0336). 1x MOPS (BOLT Invitrogen B000102) and 500 µL of antioxidant
containing dithiothreitol (Thermo Fisher Scientific NP0009) was added and
electrophoresis was completed at 200V for 50 minutes. Proteins were transferred to a
PVDF membrane at 100V over 2 hours. The protein transferred PVDF membrane (EMD
Immobilon IPVH00010) was blocked in 5% bovine serum albumin (BSA) (ALB001) for
pPKM2 and 5% skimmed milk (Carnation) for PKM1 and PKM2 in 1x Tris-Buffered
Saline with 0.1% Tween 20 for 1 hour at room temperature with end-to-end agitation.
Primary antibodies were incubated overnight at 4 °C with end-to-end rotation. HRPconjugated secondary antibodies were incubated for 1 hour at room temperature with endto-end rotation. Membranes were imaged with Luminata Classico Western HRP
Substrate (EMD WBLUC0500) and stripped using Restore Western Blot Stripping Buffer
(Thermo Fisher Scientific 21059). Bands of interest were compared to 𝛽-ACTIN.
Primary and secondary antibodies and their concentrations are listed in Table 5.3.
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Table 5.3. Western blot antibody/marker list
Primary

Concentration

Antibody/Marker
𝛽-ACTIN

Secondary

Concentration

Antibody
1:50000

A3854

N/A: HRP-

N/A: HRP-

linked

linked

PKM1

1:5000,

Anti-rabbit IgG,

1:2000-10,000,

15821-1-AP

5% TBST

HRP-linked

5% Milk in

Antibody #7074

TBST

Cell Signaling
Technology
pPKM2

1:5000,

Anti-rabbit IgG,

1:2000-10,000,

(Tyr105)

5% BSA in

HRP-linked

5% BSA in

3827S

TBST

Antibody #7074

TBST

Cell Signaling
Technology
PKM2

1:5000,

Anti-rabbit IgG,

1:2000

15822-1-AP

5% Skim milk

HRP-linked

5% Milk in

in TBST

Antibody #7074

TBST

Cell Signaling
Technology

177
5.3.6. Flow Cytometry:
mPSCs were lifted with StemProTM AccutaseTM (Thermo Fisher Scientific A1110501)
incubated at 37 °C for 5 minutes. Centrifugation steps were completed at 244 x g for 3
minutes. Dead cell compensation and gating was completed using a 50% mixture of live
and dead mESCs stained with Zombie Aqua™ Fixable Viability Kit (BioLegend 423101)
and incubated in the light-tight container at room temperature for 30 minutes. Cells were
washed with 2 mL of flow cytometry staining buffer (FCSB) containing: 90% PBS (-/-),
10% FBS (qualified, ESC grade), and fixed with 4% paraformaldyde (PFA) in PBS (-/-).
Fixed cells were washed with PBS(-/-), centrifuged and divided into unstained, single,
full-minus-one and full stained combinations of each cell type. Fixed cells were stained
with conjugated antibodies for 1 hour in a light-tight box at room temperature prior to
washing, centrifugation and resuspension in PBS(-/-) and ejected through a 40 µm cell
strainer (Fisherbrand™ Sterile Cell Strainers 22-363-547) with a final wash of 100 µL of
PBS (-/-). Flow cytometry was completed on a FACSCanto flow cytometer. Antibodies
and their concentrations are listed in Table 5.4.
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Table 5.4. Flow cytometry antibody/marker list
Primary

Concentration

Antibody/Marker

Secondary

Concentration

Antibody

CD24

0.25 µg/1

N/A:

N/A:

138505

million cells

Conjugated

Conjugated

SSEA1

5 µL/1 million

N/A:

N/A:

125614

cells

Conjugated

Conjugated
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5.3.7. Statistical Analyses:

Statistics were completed using a one- and two-way ANOVAs where applicable.
Characterization by flow cytometry of SSEA1/CD24 in mPSCs was completed using a
one-way ANOVA with Tukey’s multiple comparisons test. Flow cytometric analysis of
transfection efficiency compared random control morpholino groups using a one-way
ANOVA with Tukey’s multiple comparisons test. Immunoblotting for protein abundance
in the influence of PKM1/2 morpholinos utilized a one-way ANOVA with a Dunnett’s
multiple comparisons test. Determining the influence of PKM1/2 morpholinos on
transitioning formative and primed-like mEpiLCs as quantified by flow cytometry of
SSEA1/CD24 in mPSCs was completed using a one-way ANOVA with Dunnett’s
multiple comparisons test. Transcript abundance studies examining the influence of
PKM1/2 morpholinos on mPSCs was accomplished using a two-way ANOVA with
Dunnett’s multiple comparisons test.

5.4.0. Results:

5.4.1. Formative and primed-like mEpiLCs can be distinguished from primed
mEpiSCs through SSEA1 and CD24 cell surface expression.

mEpiLCs can be distinguished from naïve mESCs and primed mEpiSCs based on Stage Specific Embryonic Antigen-1 (SSEA1) and Cluster of differentiation 24 (CD24)
expression (Figure 5.02.a-e). Representative flow cytometry plots demonstrate cell
population quantification (%) of pluripotent cells with high and low expression of SSEA1
and CD24 (Figure 5.02.b-e). There was a significant difference between group mean
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values of pluripotent cell types expressing high levels of SSEA1 and low levels of CD24
(F(3,8)=8.993, p=0.0061) (Figure 5.02.a). Tukey’s multiple comparisons post hoc test
determined that the percentage of mEpiSCs expressing high levels of SSEA1 and low
levels of CD24 was significantly greater than mESCs, mEpiLCs (formative), or mEpiLCs
(primed-like) (p=0.0253, p=0200, p=0.0058 respectively) (Figure 5.02.a). Moreover,
there was a significant difference between group mean values of pluripotent cell types
expressing high levels of SSEA1 and CD24 (F(3,8)=5.777, p=0.0212) (Figure 5.01.a).
Tukey’s multiple comparisons post hoc test determined that the percentage of mEpiSCs
expressing high levels of SSEA1 and CD24 was significantly greater than mESCs or
mEpiLCs (formative) (p=0.0458, p=0.0319 respectively) (Figure 5.02.a). There was also
a significant difference between group mean values of pluripotent cell types expressing
low levels of SSEA1 and high levels of CD24 (F(3,8)=142.9, p<0.0001) (Figure 5.02.a).
Tukey’s multiple comparisons test determined that the percentage of mEpiSCs expressing
low levels of SSEA1 and high levels of CD24 was significantly greater than mESCs,
mEpiLCs (formative), or mEpiLCs (primed-like) (p=<0.0001 in all instances) (Figure
5.02.a). Lastly, there was a significant difference between group mean values of
pluripotent cell types expressing low levels of SSEA1 and CD24 (F(3,8)=15.54,
p<0.0011) (Figure 5.02.a). Tukey’s multiple comparisons test determined that the
percentage of mEpiSCs expressing low levels of SSEA1 and CD24 was significantly
greater than mESCs, mEpiLCs (formative), or mEpiLCs (primed-like) (p=0.0021,
p=0013, p=0.0276 respectively) (Figure 5.02.a).
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Figure 5.02. mESC, mEpiLC (Formative), mEpiLC (Primed-like), and mEpiSC
SSEA1 and CD24 cell surface marker characterization.
Delineation of naïve mESCs, formative and primed-like mEpiLCs, and mEpiSCs by a)
flow cytometric analysis of SSEA1 and CD24 cell surface marker expression.
Biexponential scale flow plots represent portrayals of SSEA1-compensated Brilliant
Violet 421 on a 450 nm laser versus CD24-compensated APC on a 670 nm laser of b)
mESCs, c) formative mEpiLC, d) primed-like mEpiLC, and e) mEpiSC. Data shown as
mean±SEM of treatments compared in biological triplicate as a one-way ANOVA with a
Tukey’s multiple comparisons relative to the control of each corresponding cell type; *
p<0.05, n=3 biological replicates.
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5.4.2. Efficient transfection of siRNAs and morpholino oligonucleotide delivery into
mESCs.

Transfection efficiency was determined using a FITC Fluorescein tagged control siRNA
at 10, 30, 50 pmol concentrations delivered into mESCs using the lipid-based carrier
Lipofectamine3000 at 1.5 and 3.0 µL volumes, further diluted in 50 µL of Opti-MEM.
Optimal siRNA concentration and carrier volume were determined to be 30 pmol in 3µL
respectively using flow cytometry relative to no siRNA and carrier controls (Figure
5.03.). mESCs transfected with the optimized parameters of Pkm1/2 siRNA constructs
(Table 5.5.) were assessed at 24-, 48-, and 72-hours post-transfection by a transcript
abundance study (Figure 5.04.a-c). Initial results show an upregulation of Pkm1/2
transcript abundance following siRNA transcript, with a slow leveling off towards 72
hours post-transfection. Importantly, a scrambled siRNA control influenced Pkm1/2
transcript (Figure 5.04.a,b) and protein abundance (Figure 5.05.) drawing skepticism as to
the true specificity of the siRNA constructs. Originally, this project sought to determine
the role of PKM1/2 in mESCs exiting the naïve state during a chemically driven
conversion to mEpiLCs. Our first knockdown strategy was centered around using small
interfering ribonucleic acids (siRNAs) specific to either PKM isoform, and PKM total
(both isoforms 1 and 2). Our initial troubles came from difficulties efficiently
transfecting and validating siRNAs in mESCs, and after several approaches I was able to
transfect a control siRNA tagged with a fluoresceine conjugate A as determined by flow
cytometry (Figure 5.03.). I used flow cytometry to assess an optimal concentration of
siRNA and lipid-based carrier, determining optimal transfection parameters of 30.0 pmol
siRNA with 3.0 L of Lipofectamine3000.
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These results led us to re-examining our knockdown strategy using an targeted
morpholino approach.
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Figure 5.03. mESCs can be efficiently transfected using Lipofectamine3000.
Cells were transfected using Lipofectamine3000 and FITC Fluorescein Conjugate-A.
gating comparison between the greatest transfection efficiency of a) no siRNA and no
transfection agent, and b) 30 pmol of siRNA and 3µL of Lipofectaine3000. c)
Transfection efficiencies comparing combinations of transfection agent and siRNA
quantities using a C6 Accuri flow cytometer, n=1.
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Following validation of the transfection process, I assessed our PKM1/2 siRNA designs.
These siRNAs were designed with the help of ThermoFisher bioinformatics team and 3
different sets of siRNAs targeting each isoform were made (Table 5.5.). These siRNA
constructs were transfected into mESCs, and RNA was extracted after 24, 48, and 72
hours of incubation at 10.0, 30.0, and 50.0 pmol concentrations (Figure 5.04.).
Examining the transcript abundance of these constructs following transfection
demonstrated that increases and decreases in Pkm1/2 that were not compatible with our
current question regarding downregulating Pkm1/2. Optimal siRNA constructs were
tested in mESCs for PKM1/2 protein abundance (Figure 5.05.). Unfortunately, there was
a significant influence of the scramble control siRNA on protein abundance and a lack of
either PKM1 or PKM2 isoform specificity.
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Table 5.5. siRNA construct designs
Construct

Sense

Anti-Sense

Pkm1-A

CAGCAGCUUUGAUAGUUCUTT

AGAACUAUCAAAGCUGCUGCT

Pkm1-B

GGAGGCCUCUUAUAAGUGUTT

ACACUUAUAAGAGGCCUCCAC

Pkm1-C

UGAUAGCUCGGGAGGCUGATT

UCAGCCUCCCGAGCUAUCAGG

Pkm2-A

CCAUUAUCGUGCUCACCAATT

UUGGUGAGCACGAUAAUGGCC

Pkm2-B

AUCUACCACUUGCAGCUAUTT

AUAGCUGCAAGUGGUAGAUGG

Pkm2-C

GCUAUUCGAGGAACUCCGCTT

GCGGAGUUCCUCGAAUAGCTG

Pkm-Total

-Targets exon 4

Custom Silencer Select siRNA constructs designed to target Pkm1, Pkm2, and Pkm total
specifically.
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Figure 5.04. PKM1/2 siRNA transfected mESCs altered Pkm1/2 transcript
abundance.
Cell culture conditions included N2B27 media supplemented with LIF and 2i in 20%
oxygen conditions over 3 days. Cells were transfected using custom designed Silencer
Select siRNAs, Lipofectamine3000 and Opti-MEM. mRNA abundance relative to Tbp
and calculated using △△Ct algorithm., A) Pkm1, B) Pkm2 C) Pkm Total transcript
abundance studies for 24-, 48-, and 72-hour time points. Treatments were measured using
technical triplicates, n = 1.
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Figure 5.05. Most optimal siRNA constructs for PKM1 and PKM2 influence protein
abundance in mESCs.
Naïve mESCs treated with a scramble control siRNA, PKM1, and PKM2 designed
custom silencer siRNAs transfected with Lipofectamine 3000 show a downregulation of
PKM2 protein abundance. PKM1 and PKM2 siRNAs alone downregulated PKM1
protein abundance. Protein densitometry was compared relative to -ACTIN and samples
were run in biological triplicate, error bars represent mean±SEM, *p<0.05.
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Random control Morpholinos tagged with a fluorescein label were scrape delivered into
mESCs as a concentration series of 5, 10, or 20 M (Figure 5.03.a-c). At 10 M, tagged
control morpholinos were detectable by fluorescent microscopy (Figure 5.06.a). Scrape
delivered cells were measured via flow cytometry for transfection efficiency as assessed
by FITC+ events relative to the total live cell population and mean fluorescence intensity
as measured by geometric mean of fluorescent events (Figure 5.06.b, c). There was a
significant concentration-dependent difference between FITC+ cell events using random
control morpholino treatments as determined by a one-way ANOVA (F (2,6)=45.77,
p=0.0002) (Figure 5.06.b). The concentration series for FITC+ events demonstrated: 5
M (mean=73.9%, SEM=2.1), 10 M (mean=94.7%, SEM=2.3), and 20 M (mean=98.0,
SEM=1.3) (Figure 5.06.b).

193

194
Figure 5.06. mESCs can be efficiently and effectively transfected with morpholinos
by scrape delivery at 20 M.
Scrape delivered morpholinos tagged with a fluorescein label were visible in a) mESCs as
demonstrated by fluorescent phase contrast microscopy at concentration of 10 M. Scale
bars represent 75 m. Transfection of morpholinos was optimized by comparing 5, 10,
and b) 20M fluorescein-tagged control morpholinos as determined through c) FITC+
frequency relative to total population and d) geometric mean by flow cytometric analysis
of FITC wavelength laser channel. Data shown as mean±SEM of treatments compared in
biological triplicate; * p<0.05, n=3 biological replicates.
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5.4.4. Steric-blocking Morpholinos affects PKM1 and PKM2 protein levels.
Forty-eight hours-post 20 M morpholino scrape delivery produced significant changes
to PKM1 and PKM2 protein levels in mESCs (Figure 5.07.a, Figure 5.01.b). The
transfection of a random control morpholino did not affect PKM1 or PKM2 protein
abundance compared to mESCs scraped without a morpholino (Figure 5.04.a-f). There
was a significant difference between group mean values of PKM1 protein abundance
following Morpholino treatments as determined by a one-way ANOVA (F(3,8)=52.21,
p<0001) (Figure 5.07.b). There was a significant difference between group mean values
of PKM2 protein abundance following morpholino treatments as determined by a oneway ANOVA (F (3,8)=4.619, p=0.0371) (Figure 5.07.c). A Dunnett’s multiple
comparison test determined that the addition of the PKM1 designed Morpholino, now
referred to as ‘PKM MO 1’ significantly decreased PKM2 protein abundance (p=0.0212)
(Figure 5.07.b, c). The PKM2 designed morpholino, now referred to as ‘PKM MO 2’
significantly decreased PKM2 protein abundance (p=0.0480) and significantly increased
PKM1 protein abundance (P<0.0001) (Figure 5.07.b, c). There was a significant increase
in the ratio of PKM1:PKM2 protein abundance with the addition of the PKM MO 2
(p<0.0001) (Figure 5.07.e). There was a significant increase in the ratio of PKM1:PKM2
protein abundance with the addition of the PKM MO 1 and the PKM MO 2 (p=0.0082
and p<0.0001) (Figure 5.07.e). There was a significant increase in the ratio of
pPKM2:PKM2 protein abundance with the addition of the PKM MO 1 and the PKM MO
2 (p=0.0082 and p<0.0001) (Figure 5.07.f).
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Figure 5.07. Splice-modifying morpholinos modulate PKM1 and PKM2 protein
abundance in mESCs.
a) Representative PKM1/2 immunoblotting of morpholino transfected mESCs
demonstrates b) upregulation of PKM1 and c) downregulation of PKM2 by transfecting
the PKM MO2, whereas PKM MO1 significantly downregulates PKM2. The PKM MO
2 additionally e) upregulates protein abundance of PKM1/PKM2 ratio. There was d) no
significant change in pPKM2 with the inclusion of a PKM morpholino. Data shown as
mean±SEM of treatments compared in biological triplicate as a one-way ANOVA with a
Tukey’s multiple comparisons test; * p<0.05, n=3 biological replicates.
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5.4.5. Pkm1/2 transcript abundance is altered in mESCs, formative mEpiLCs,
primed-like mEpiLCs, and mEpiSCs following PKM1/2 spliceosome modification.

A two-way ANOVA was conducted to examine the influence of treating each pluripotent
state with the PKM MO 1 or PKM MO 2 morpholinos at 20 M on Pkm1/2 transcript
abundance levels (Figure 5.08.a-c). There was a statistically significant interaction,
meaning the effects of different pluripotent cell types depends on each morpholino
treatment, for Pkm1 (Figure 5.08.a) and Pkm2 (Figure 5.08.b) transcript abundance, but
not the Pkm1/Pkm2 (Figure 5.08.c) transcript abundance ratio, (F(6,24)=11.92, p<0.001),
(F(6,24)=2.695, p=0.0382), and (F(6,24)=1.904, p=0.1214) respectively between
pluripotent cell type and morpholino treatment. Simple main effect analysis
demonstrated that within pluripotent cell types, the addition of PKM MO 1 or PKM MO 2
morpholinos significantly influenced Pkm1 transcript abundance (F(3,24)=6.253,
p=0.0027, and F(2,24)=25.86, p<0.001 respectively). Simple main effect analysis also
demonstrated that pluripotent cell type and the addition of PKM MO 1 or PKM MO 2
morpholinos significantly influenced Pkm1/Pkm2 transcript abundance ratio
(F(3,24)=14.26, p<0.0001, and F(2,24)=21.79, p<0.0001 respectively). Based on
Dunnett’s multiple comparisons tests relative to the control treatment of each pluripotent
cell type, adding a PKM MO 2 morpholino significantly enhanced Pkm1 transcript
abundance in mESCs (p<0.0001), mEpiLC (formative) (p=0.0006), and mEpiSCs
(p=0.0080), and Pkm1/Pkm2 transcript abundance ratio in mESCs (p=0.0023) and
mEpiLCs (formative) (p=0.0025). Based on Dunnett’s multiple comparisons tests
relative to the control treatment of each pluripotent cell type, treatment with the PKM
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MO 2 morpholino significantly reduced Pkm1 and Pkm2 transcript abundance in mEpiLC
(primed-like) (p=0.0025 and p=0.0497, respectively).
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Figure 5.08. PKM morpholinos influence Pkm1/2 transcript abundance in naïve
mESCs, formative mEpiLCs, primed-like mEpiLC, and primed mEpiSCs.
Delivery of the PKM MO 2 significantly influences a) Pkm1 transcript abundance in
mESCs, formative mEpiLCs, primed-like mEpiLCs, and mEpiSCs relative to control
cells of each pluripotent state. b) Pkm2 transcript abundance was significantly
downregulated in mEpiLCs with PKM2 morpholino delivery. mESCs and formative
mEpiLCs c) Pkm1 to Pkm2 transcript abundance ratio was upregulated following PKM2
morpholino transfection. Data shown as mean±SEM of treatments compared in
biological triplicate as a two-way ANOVA with a Dunnett’s multiple comparisons
relative to the control of each corresponding cell type; * p<0.05, n=3 biological replicates
run in technical triplicate. Data represents Log2 of fold change relative to Hprt and
normalized to control mESCs.
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5.4.6. Decreased PKM2 and increased PKM2 protein abundance by morpholino
modulation decreases glycolytic genes Eno1 and Hk2 transcript abundance in
primed mEpiSCs.

A two-way ANOVA was conducted that examined the influence of treatment with PKM
MO 1 or PKM MO 2 morpholinos (20 M) on glycolytic and oxidative phosphorylation
(OXPHOS) metabolic transcript abundance following transfection in mESCs,
transitioning mEpiLCs to the formative and primed-like pluripotent states and mEpiSCs
over 48 hours. There was no significant interaction for the glycolysis genes Hexokinase 2
(Hk2), Lactate dehydrogenase A (Ldha), Phosphofructokinase 1 (Pfk1), and Alphaenolase (Eno1) transcript abundance (Figure 5.09.a), however, there was a statistically
significant difference in transcript abundance between pluripotent cell types
(F3,24)=38.12,p<0.0001), (F(3,24)=13.80, p<0.0001), (F(3,24)=5.361, p=0.0057), and
(F(3,24)=4.815, p<0.0092) respectively. Based on Dunnett’s multiple comparisons tests
relative to the control treatment of each pluripotent cell type, treatment with the PKM
MO 2 morpholino significantly reduced Eno1 and Hk2 transcript abundance in mEpiSCs
(p=0.0268 and p=0.0128 respectively). There was no significant interaction for the
OXPHOS genes Isocitrate dehydrogenase 2 (Idh2), malate dehydrogenase 2 (Mdh2), and
Succinate-CoA ligase (Suclg1) transcript abundance (Figure 5.06.b), however, there was
a statistically significant difference in transcript abundance was observed between
pluripotent cell types (F(3,24)=10.35, p=0.0001),(F(3,24)=6.679, p=0.0019), and
(F(3,24)=3.299, p=0.0375).
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Figure 5.09. PKM morpholinos influence key glycolytic transcript abundance
markers in naïve mESCs, formative mEpiLCs, primed-like mEpiLC, and primed
mEpiSCs.
Quantification of transcript abundance following scrape delivery of 20 M PKM MO 1
and PKM MO 2 morpholinos into mPSCs over 48 hours. Transcript markers include a)
glycolysis genes Hk2, Gpi, Pfkl, Aldoa, Pgam1, Eno1, and Ldha, and b) oxidative
phosphorylation genes Cs, Idh2, Suclg2, Sdh-a, Fh, and Mdh2. Transcript abundance was
compared using the Pfaffl method and data is shown as mean±SEM of treatments
compared in biological triplicate as a two-way ANOVA with a Dunnett’s multiple
comparisons relative to the control of each corresponding cell type; * p<0.05, n=3
biological replicates run in technical triplicate. Data represents Log2 of fold change
relative to -Tubulin and normalized to control mESCs.
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5.4.7. PKM1/2 modulation does not alter naïve, formative, or primed pluripotency
associated transcripts in mESCs, formative mEpiLCs, primed-like mEpiLCs, and
mEpiSCs.

A two-way ANOVA was conducted that examined the influence of treating with the
PKM MO 1 or PKM MO 2 morpholinos on transcript abundance of naïve, formative, and
primed pluripotent associated transcripts. There was no significant interaction for the
naïve pluripotency genes Rex1, Pecam, or Esrrb transcript abundance (Figure 5.09.a),
however, there was observed a statistically significant difference in transcript abundance
between pluripotent cell types (F(3,24)=54.98, p<0.0001), (F(3,24)=15.93, p<0.0001),
and (F(3,24)=25.06, p<0.0001) respectively. There was no significant interaction for the
formative pluripotency genes Lef1 (Lymphoid Enhancer Binding Factor 1), Dnmt3b, or
Pou1fc transcript abundance (Figure 5.09.b), however, there was a statistically significant
differences in transcript abundance between pluripotent cell types (F(3,24)=7.380,
p=0.0011), (F(3,24)=60.28, p<0.0001), and (F(3,24)=85.18, p<0.0001) respectively.
There was no significant interaction for the primed pluripotency genes Zic2, Cer1, or
T(Brachyury) transcript abundance (Figure 5.09.c), however, there was an observed
statistically significant difference in transcript abundance between pluripotent cell types
(F(3,24)=4.071, p=0.0180), (F(3,24)=27.79, p<0.0001), and (F(3,24)=70.40, p<0.0001)
respectively.
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Figure 5.010. PKM morpholinos do not influence key naïve, formative, and primed
pluripotency transcript abundance markers in naïve mESCs, formative mEpiLCs,
primed-like mEpiLC, and primed mEpiSCs.
Quantification of transcript abundance following scrape delivery of 20 M PKM MO 1
and PKM MO 2 morpholinos into mPSCs over 48 hours. Transcript markers include a)
naïve pluripotency associated genes Pecam, Esrrb, and Rex1, b) formative pluripotency
associated genes Dnmt3b, Pou1fc, and Lef1, and c) primed pluripotency associated genes
Zic2, Cer1, and T(Brachury). Transcript abundance was compared using the Pfaffl
method and data is shown as mean±SEM of treatments compared in biological triplicate
as a two-way ANOVA with a Dunnett’s multiple comparisons relative to the control of
each corresponding cell type; * p<0.05, n=3 biological replicates run in technical
triplicate. Data represents Log2 of fold change relative to -Tubulin and normalized to
control mESCs.
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5.4.8. PKM1/2 modification alters SSEA1 and CD24 ratios in transitioning mESCs
into formative state and formative mEpiLCs into primed-like state mEpiLCs.

There was an observed a significant difference between group mean values of morpholino
treatments expressing low levels of SSEA and high levels of CD24 in formative mEpiLCs
as determined by a one-way ANOVA (F (2,6)=8.167, p=0.0194) (Figure 5.11.a). A
Dunnett’s multiple comparison test detected that the percentage of mEpiLCs (formative)
transfected with the PKM MO 1 morpholino (Figure 5.11.c) was significantly enhanced
compared to control mEpiLCs (p=0.0128). There was an observed significant difference
between group mean values of morpholino treatments expressing high levels of SSEA
and CD24 in primed-like mEpiLCs as determined by a one-way ANOVA (F(2,6)=8.486,
p=0.0178) (Figure 5.11.a). A Dunnett’s multiple comparison test determined that the
percentage of mEpiLCs (primed-like) transfected with the PKM MO 1 (Figure 5.12c.)
and PKM MO 2 morpholinos (Figure 5.12.d) was significantly greater than control
mEpiLCs for SSEA1 high and CD24 high events (p=0.0264 and p=0.0172 respectively).
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Figure 5.11. Influence of downregulating PKM on SSEA1 and CD24 expression in
transitioning formative mEpiLCs.
Scrape delivery of 20 M PKM MO 1 and PKM MO 2 morpholinos into mESCs
transitioned over 48 hours into formative mEpiLCs compared by a) SSEA1 and CD24
cell surface markers by flow cytometry. Transitioning into formative b) mEpiLCs with
the addition of c) PKM MO 1 morpholinos and significantly increased the population of
SSEA1H and CD24H cells and both PKM MO 1 and d) PKM MO 2 delivery resulted in
decreased SSEA1L and CD24L cell populations. Biexponential scale flow plots represent
portrayals of SSEA1-compensated Brilliant Violet 421 on a 450 nm laser versus CD24compensated APC on a 670 nm laser. Data shown as mean±SEM of treatments compared
in biological triplicate as a one-way ANOVA with a Dunnett’s multiple comparisons
relative to the control of each corresponding cell type; * p<0.05, n=3 biological
replicates.
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Figure 5.12. Influence of downregulating PKM on SSEA1 and CD24 expression in
transitioning primed-like mEpiLCs.
Scrape delivery of 20 M PKM MO 1 and PKM MO 2 morpholinos into formative
mEpiLCs transitioned over 48 hours into primed-like, mEpiLCs compared by a) SSEA1
and CD24 cell surface markers by flow cytometry. Transitioning into primed-like b)
mEpiLCs with the addition of c) PKM MO 1 morpholinos and d) PKM MO 2 morpholino
delivery significantly increased the population of SSEA1H and CD24H cells and
decreased SSEA1L and CD24L cell populations. Biexponential scale flow plots represent
portrayals of SSEA1-compensated Brilliant Violet 421 on a 450 nm laser versus CD24compensated APC on a 670 nm laser. Data shown as mean±SEM of treatments compared
in biological triplicate as a one-way ANOVA with a Dunnett’s multiple comparisons
relative to the control of each corresponding cell type; * p<0.05, n=3 biological
replicates.
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5.5.0. Discussion:
There is a growing body of evidence promoting metabolism as having an active role in
cell pluripotency, differentiation, and development (Tsogtbaatar et al. 2020; Dahan et al.
2018; J. Zhang et al. 2018). Within the cells of the early embryo and the pluripotent
spectrum, pyruvate kinase muscle isoforms 1 and 2 are suggested to play a variety of
roles (Konno, Koseki, et al. 2015; Konno, Ishii, et al. 2015; Jacks et al. 2016). Isoform
specific lentiviral overexpression of either Pkm1 or Pkm2 in mESCs significantly
increased the pluripotency associated genes Nanog, Eras, and Rex1 transcript abundance,
but did not influence specialization when subjected with differentiation media (Qin et al.
2017). This same study found that when Pkm1/2 were downregulated via shRNA, the
same pluripotency transcripts were significantly downregulated. Additionally, Pkm1/2
are implicated in the reprogramming of somatic cells to naïve mESCs as downregulating
total Pkm1/2 via shRNA significantly hindered induced pluripotent stem cell (iPSC)
generation as quantified by measuring alkaline phosphatase staining (Qin et al. 2017).
Alternatively, overexpression of Pkm2, but not Pkm1 significantly increased alkaline
phosphatase staining during reprogramming, suggesting that Pkm2 is the PKM isoform
that facilitates iPSC generation. The metabolic switch from OXPHOS to glycolysis is
linked to activation of hypoxia inducible factor 1 (HIF-1), where PKM2 interacts with
the HIF1 subunit promoting transactivation domain function as well as p300 recruitment
to the HIF1’s response element during somatic cell reprogramming (Luo et al. 2011).
This interaction promotes the WE and thus the switch from OXPHOS to aerobic
glycolysis (Palsson-McDermott et al. 2015). The reprogramming of human OXPHOS
reliant somatic cells to iPSCs results in primed pluripotent stem cells (hESCs) which
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exhibit an aerobic glycolytic metabolic preference, a metabolic transition not far from the
naïve-to-primed bivalency to glycolytic transition of mESCs-to-mEpiSCs (Zhou et al.
2012). In the presence of differentiation media, naïve mESCs with a Pkm2 allele knockin resist differentiation compared to the Pkm1 knock-in as measured by a microarray
analysis (Konno, Ishii, et al. 2015). Additionally, the Pkm2 allele knock-in enhances
methionine metabolism during differentiation suggesting a pro-oxidative role (Konno,
Ishii, et al. 2015). In Chapter 3, I demonstrate that PKM1 and PKM2 protein abundance
significantly increases in formative mEpiLCs, therefore, knocking down Pkm2 during this
transition could destabilize the pro-oxidative controls necessary for the developmental
transition through the formative state during differentiation.

Despite employing an isoform targeted approach of the exclusive splice sites between
PKM1 and PKM2, the results of the protein abundance study demonstrate that one of
constructs downregulated PKM2 with an upregulation to PKM1. This is not a typical
expectation when using morpholinos but is potentially related to the morpholino in
question binding across splice regulatory proteins. In this case, the alternative splicing
mechanism of PKM1/2 could be impacted by altering splice suppressor and enhancer
proteins binding to pre-mRNAs. This would cause a feedback mechanism leading to
unintended splicing edits. This alteration has been demonstrated previously in a study
examining PKM2 and myotonic dystrophy (Gao and Cooper 2013).

Between either end of the pluripotent spectrum exists a recently described and poorly
understood executive, formative stage, of which, metabolic trends and PKM expression
have yet to be fully delineated (Smith 2017). Our results demonstrate that altering PKM
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through spliceosome modification, influences metabolic and pluripotent cell surface
marker expression. Contrary to the hypothesized direction that transitioning formative
and primed-like mEpiLCs would take, knocking down PKM1/2 promoted primed
pluripotency associated cell surface marker expression and promoted an enhanced
population of cells expressing high levels of the naïve cell surface marker SSEA1 and the
primed cell surface marker CD24. Notably, there was no significant differences in
pluripotency associated transcripts following the addition of morpholinos from their nontransfected control states. While previous research has found Pkm2 to play an important
role in naïve pluripotency maintenance and reprogramming from somatic cells to either
naïve or primed states, these results demonstrate that Pkm1/2 splice modifications do alter
the pluripotent phenotype in transitioning formative and primed-like pluripotent states
towards a primed state. It has been demonstrated that naïve mESCs express high levels
SSEA1 and primed mEpiSCs express high levels of CD24, potentially the downregulation
of PKM2 and upregulation of PKM1 promotes formative state cell expression, however,
at this time little is known regarding formative state metabolic preferences (Shakiba et al.
2015). Profiling true, stable formative state cells would confirm this potential cell surface
marker trend and the role of PKM1/2 during transitioning. This investigation sheds light
on the metabolic preference of formative state cells through our transcript abundance
study. I demonstrate a downregulation of OXPHOS transcripts such as Idh2 and an
increase in glycolytic transcripts such as Ldha, these trends suggest the initiation of the
WE and reflect the in vivo correlate following post-implantation of the blastocyst. Of
note, the transcript abundance study found key differences between the formative
mEpiLCs and primed mEpiSCs, including an increase in OXPHOS transcripts in Mdh2
and Suclg1 for primed cells, these markers are known to regulate tumor growth and are
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players in the WE, suggesting that the formative state has not fully adhered to aerobic
glycolysis (Kitazawa et al. 2020). As metabolically bivalent cells, naïve mESCs
transitioning to the formative state rewire their transcriptional and epigenetic landscape,
gaining the competency to differentiate into other cell types (Smith 2017; Kinoshita and
Smith 2018). Previous studies demonstrate that reactive oxygen species (ROS)-mediated
interactions with mitochondria and nuclear functions are clearly implicated in stem cell
fate and potency (Bigarella, Liang, and Ghaffari 2014). As PKM1 plays a critical role in
the metabolic shunting of pyruvate towards an OXPHOS fate as acetyl-CoA in the
mitochondria, the ROS generated by increased PKM1 may further impinge upon the
developmental progression of the pluripotent continuum and lineage competency. This
upregulation could promote metabolic reprogramming by inducing a shift to OXPHOS or
an OXPHOS-burst to increase ROS and stabilize hypoxia inducible factor 1 (HIF-1),
such an event could be verified by examining extracellular acidification rate and oxygen
consumption rate. The master metabolic regulator HIF-1 is activated during instances
of hypoxia, decreased ROS and the glycolytic shift towards primed pluripotency. PKM2
can interact with HIF1 to further promote the WE (Prigione et al. 2014). Through
PKM2 reduction and PKM1 upregulation, these findings suggest that PKM2 reduction
promoted the primed CD24 high cell surface marker population when generating
formative state mEpiLCs and may conversely indicate a role for PKM1 in promoting
naïve pluripotency. Upregulation of PKM1 appears to have stunted the influence of
PKM2 reduction, potentially as a compensatory mechanism. This study demonstrates
that formative and primed-like pluripotent states can be effectively distinguished from the
naïve, ground, and primed pluripotent states using flow cytometry for the cell surface
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markers SSEA1 and CD24. This finding can be utilized to determine transitioning and
differentiation efficiencies within the pluripotent continuum and exit during cell lineage
specification. Previously, only naïve and primed states have been examined using these
markers and here I demonstrate that unique expression dynamics could additionally be
utilized for fluorescently activated cell sorting for downstream studies and population
purifications (Shakiba et al. 2015). This method should be used in the study of primordial
germ cell-like cell generation along with somatic lineage competency during pluripotent
development.

The results of the transcript abundance demonstrate that the glycolysis genes Pgam1 and
Gpi significantly decreased in primed mEpiSCs following PKM2 downregulation. This is
not surprising as Pkm2, Pgam1, and Gpi are heavily implicated in WE and biosynthesis;
downregulating a key protein such as PKM2 appears to have downstream effects on other
WE associated genes and may disrupt aerobic glycolysis in cells that have achieved true
primed pluripotency (Hitosugi et al. 2012; de Padua et al. 2017). Importantly, the genes
Hk2 and Eno1 significantly increased in primed mEpiSCs, and Hk2 also significantly
increased in primed-like mEpiLCs following PKM2 downregulation and PKM1
upregulation. This follows the currently described preferences for primed pluripotency,
and exit of the naïve state, by promoting a glycolytic preference over OXPHOS, and
elevated WE transcription of these two critical genes (Capello et al. 2016). The transcript
abundance results also demonstrate that the OXPHOS genes Mdh2, Fh1, and Suclg1 all
significantly increased when PKM2 was downregulated and PKM1 was upregulated in
primed-like mEpiLCs. This further promotes the primed pluripotent state as Mdh2 is
implicated in feeding the WE through nicotinamide adenine dinucleotide regeneration
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(NAD), thus supporting the glycolytic shift (Hanse et al. 2017). Fumarate hydratase
(Fh1) works to process the accumulated fumarate, which in turn works to activate
hypoxia response (Isaacs et al. 2005; Frezza et al. 2011). The increased PKM1 may
contribute towards compensating towards fumarate accumulation, however, increased
Fh1 relative to the control primed-like cells and even the naïve mESCs is unexpected and
may play a new role in generating the unique naïve SSEA1 high coupled with primed
CD24 high population. Suclg1 works to generate ADP and succinyl-CoA in the
tricarboxylic acid cycle and can work to promote substrate level phosphorylation even in
the absence of oxygen, and thus can work within the shift towards aerobic glycolysis
model in primed-like mEpiLCs (Chinopoulos and Seyfried 2018). Metabolic profiling on
the protein level through immunoblots and non-denaturing gels paired with live cell acute
measure of extracellular acidification rate and oxygen consumption rate will help to
elucidate metabolic trends in the formative state and PSCs treated with PKM
morpholinos. As both the downregulated PKM2 and the combination of downregulation
of PKM2 and upregulation of PKM1 yielded similar levels (mean of 36.4% and 38.7%
respectively) of unique population of SSEA1 high and CD24 high primed-like mEpiLCs,
the effects of PKM1 upregulation are either not strong enough to compensate or do not
have a role in the transition out of the formative state to primed state pluripotency. This
trend could additionally be in response to, or in addition to the significant increase in the
ratio of PKM1/PKM2 with the PKM MO 2 treatment. In summary, the metabolic
transcript abundance results demonstrate modulating PKM1 and PKM2 expression
appears to impact the primed-like mEpiSCs and primed mEpiSCs (Figure 5.13). This may
promote the unique population of naïve and primed cell surface marker expressing cells
in the primed-like mEpiSCs, and likely disrupts primed pluripotency in mEpiSCs by
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displacing the WE (Figure 5.12.). My strategy of targeting PKM1/2 splice events resulted
in an elevated ratio of phosphorylated-PKM2 (pPKM2), the conformation associated with
the WE, to total-PKM2, lysates showing the cumulative expression of both homotetrameric and dimeric (pPKM2) conformations. This result implicates pPKM2 as
playing a role in generating this novel expression pattern of SSEA1 high and CD24 high
expressing cells following the transition from the formative state to a primed-like
pluripotency. Previously, in Chapter 3, I demonstrated maintenance of the ratio of
PKM1/PKM2 protein abundance throughout the pluripotent continuum in murine cells,
by modulating the ratio of pPKM2/PKM2 with morpholinos, a further promotion of the
WE and enhanced metabolic shifting from bivalency to aerobic glycolysis is possible.
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Figure 5.13. Summary of Chapter 5 research findings.
The influence of PKM1/2 morpholinos on protein and transcript abundance, and cell
surface marker expression in mESCs, mEpiLCs (formative and primed-like), and
mEpiSCs. mPSCs representing the states of the pluripotent continuum treated with PKM
morpholinos result in altered metabolic transcripts related to the WE in primed-like
mEpiLCs and primed mEpiSCs. There was no difference found in pluripotency
associated transcripts across the spectrum with the addition of PKM morpholinos,
however, the cell surface markers for the pluripotency proteins SSEA1 and CD24 were
altered in mESCs transitioning to the formative state and from formative mEpiLCs
transitioning to primed-like mEpiLCs.
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Here, I demonstrate that downregulating PKM2 alone promotes primed pluripotent stem
cell populations (CD24 High) when generating formative state mEpiLCs. Importantly,
downregulating PKM2 with PKM1 upregulation does result in a significant increase in
CD24 High expressing cells. In this instance, the pro-OXPHOS nature of Pkm1 may
promote the bivalent nature of mESCs to counter the pro-transitioning influence of
downregulating PKM2. Through germline deletion of PKM2 in mice, it was found that
PKM1 becomes the predominant isoform in all cells of the developing PKM2-null mouse
compensating for the loss of PKM2, the traditional predominant form during development
(Jacks et al. 2016). These results suggest that downregulating PKM2 appears to yield a
population expressing both naïve and primed cell surface markers. Interestingly, another
intermediate pluripotent cell state referred to as ‘f-class’ cells have been shown to contain
a similar population of SSEA1+/CD24+ cells (Vidal, Stadtfeld, and Apostolou 2015;
Urbanska et al. 2017). These f-class cells are generated in rare populations following
extended transgene expression of reprogramming factors Oct4, Klf4. Sox2 and c-Myc
(Vidal, Stadtfeld, and Apostolou 2015). When the formative pluripotent state was
hypothesized, the notion that formative cells could occupy the transcriptional profile of
both naïve and primed states was suggested, potentially disrupting the fine-tuning prooxidative controls associated with the Pkm2 isoform during a transition that promotes the
formative state in vitro (Smith 2017). The lack of PKM1 specificity introduced us to an
unexpected beneficial strategy that being that our Pkm1/2 morpholinos can induce both
downregulation of PKM2 alone and downregulation of PKM2 while simultaneously
upregulating PKM1. This occurrence has been demonstrated previously using
morpholinos on the alternative spliced gene Proteolipid protein 1 (Plp1/DM20), where
Plp1 shift to DM20 alternative splicing (Tantzer et al. 2018). The cause for the lack of
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specificity in the targeted morpholino approach could be due to a duplication mutation as
the exclusive exons share a very similar sequence, downstream mutations could further
change the exonic structure. A PKM1 specific morpholino is necessary to delineate the
role of the M1 isoform in maintaining individual pluripotent states and pluripotent
transitioning. A CRISPR or TALEN strategy is possible for an alternatively spliced
isoform such as PKM1/2, however, PKM1/2 specificity has been shown using shRNAs,
germline loss of function and lentiviral allele-knock in (Qin et al. 2017; Konno, Ishii, et
al. 2015; Jacks et al. 2016). When taken together, this study promotes PKM1 and PKM2
having a role in the WE as upregulation in formative and primed-like mEpiLCs and
mEpiSCs promotes WE genes and primed pluripotency associated CD24 expression.
This is surprising as PKM2 is associated with the WE, and PKM1 has only recently been
implicated in specific cancers, this finding promotes both isoforms as having a potential
role in development and the pluripotent continuum (L. Wei et al. 2017; Morita et al.
2018). These findings promote Pkm1 and Pkm2 having distinct roles in metabolism and
pluripotency along with contributing to the growing body of evidence that metabolism is
a driver of pluripotency state.
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Chapter 6
6.0.0. General Discussion.
Pluripotent stem cells (PSCs) are hallmarked by two key traits: i) they can divide in the
undifferentiated state indefinitely and ii) they have the potential to specialize into any cell
type of the adult organism including the germ cells. These traits are referred to as selfrenewal, trilineage differentiation, and germ cell specialization. Pluripotency is described
as a developmental continuum reflecting in vivo embryological origins as individual
states (Nichols and Smith 2009; Morgani, Nichols, and Hadjantonakis 2017). The cells of
the developing inner cell mass (ICM) of the pre-implantation embryo can be explanted
and grown in vitro, with cells of this developmental stage are referred to as having naïve
pluripotency (Evans and Kaufman 1981; Martin 1981). Recently an executive,
intermediate pluripotent state has been described, also known as formative pluripotency
(Smith 2017). Immediately following implantation cells enter the formative interval and
towards the end of pluripotency, cells exhibit primed pluripotency. These three phases
represent sequential developmental intervals of the phased progression model of
pluripotency, whereby a developing cell of the embryo needs to progress throughout each
phase before specializing through the progress of differentiation (Smith 2017). Naïve,
formative, and primed pluripotency represent distinct intervals of pluripotent
development and have only recently been stably produced into cell lines instead of
transiently existing states (Kinoshita et al. 2020). Aside from their developmental
timeline, one distinguishing feature of these pluripotent states is their metabolic
preference (Zhou et al. 2012). Naïve PSCs utilize both glycolysis and oxidative
phosphorylation (OXPHOS), whereas primed PSCs use aerobic glycolysis, a trait also
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preferential in most cancer cells commonly referred to as the ‘Warburg Effect’ (Zhou et
al. 2012). The formative pluripotent state has yet to have its metabolic preferences
delineated and requires further investigation. Based on our transcript abundance study in
Chapter 5, the formative pluripotent state appears to show the onboarding of an increase
in aerobic glycolytic transcripts and a decrease in oxidative phosphorylation transcripts.

My project investigated the rate limiting and last step of glycolysis, metabolic enzymes
pyruvate kinase muscle isoforms 1 and 2 (PKM1/2). PKM2 has been found to regulate
endothelial-to-mesenchymal transition in cancer cells and is known to enhance the
reprogramming of adult cells into pluripotent cells (Hamabe et al. 2014; Qin et al. 2017).
When a PKM1 allele is knocked into naïve mouse ESCs (mESCs) grown in
differentiation media, the result is increased endoderm transcripts, whereas with a PKM2
allele knock-in there is a resistance to differentiation (Konno et al. 2015). Currently, we
have a limited understanding of PKM1/2’s role in embryonic development, formative
pluripotency, and transitioning between pluripotent states.

While there has been extensive research into characterizing naïve and primed pluripotent
states, current understanding of how ESCs transition between states and formative state
pluripotency is not well known (Zhou et al. 2012). In particular, what is known regarding
how ESCs exit from naïve state through differentiation stimulus is poorly understood
(Kalkan and Smith 2014). Several models have been published regarding the transition of
naïve cells to a primed-like pluripotent state in vitro, and artificially transitioned cells
retain the transcriptional circuitry and traits of their in vivo correlates to serve as an
effective method of study (Guo et al. 2009). This work aims to delineate the
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investigation’s main question by verifying if modulating PKM1 or PKM2 will influence
the maintenance of the naïve or primed states, and to alter the generation of the formative
or primed-like pluripotency when transitioning from a naïve pluripotent state.

One aspect of my investigation regarding metabolic preferences and cell culture
conditions that appeared to show an influence in pluripotency was altering oxygen
tension. Oxygen tension was promising as primed pluripotency is associated with aerobic
glycolysis, potentially, this trend is intrinsically programmed due to the developmental
origins of in vivo post-implantation epiblast (Shyh-Chang and Ng 2017). This trend holds
true during the reprogramming process of somatic cells to primed PSCs (Mathieu and
Ruohola-Baker 2017). Oxygen tension works to influence metabolic enzymes important
in pluripotent conversion such as HIF-1 (Zhou et al. 2012). It is well documented that
human PSCs prefer low oxygen cell culture conditions, this works to promote primed
pluripotency (Lees et al. 2019). Naïve mESCs, transitioning formative mEpiLCs, and
primed mEpiSCs can be cultured at normoxic (~21% oxygen tension) and low oxygen
(hypoxic ~2-5% and 5% oxygen tension in this study). Morphologically, mEpiSCs grew
more proficiently showing their characteristic flattened morphology (Figure 6.1.).
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Figure 6.1. Phase contrast imaging of naïve mESCs, chemically transitioned of
formative, and primed-like mEpiLCs.
Naïve mESCs can be chemically transitioned from glistening, domed colonies
characteristic of the naïve pluripotent state, into flattened colonies like the primed
pluripotent cells of the post-implantation epiblast. This conversion can be accomplished
through the swapping of required growth factors from LIF/2i conditions to FA media.
Cells were cultured in both 21% oxygen representative of normoxic conditions and 5%
oxygen conditions, referred to as hypoxic. Phased contract microscopy was completed on
10x objective. Scale bars represent 200 m.
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To study the influence of oxygen tension on each pluripotent state we additionally
examined protein lysates for metabolic and pluripotency and early lineage markers
(Figure 6.2.). Naïve mESCs, mEpiLCs transitioning over 5 days (each day harvested),
primed mEpiSCs, and as a somatic cell control, mouse embryonic fibroblasts (MEFs)
were grown in both 21% oxygen to simulate normoxic conditions and 5% oxygen to
simulate hypoxic conditions.
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Figure 6.2. Immunoblotting and Ponceau staining of mESCs, transitioning
mEpiLCs, mEpiSCs, and MEFs in normoxic and hypoxic cell culture conditions.
Naïve mESCs, transitioning mEpiLCs, mEpiSCs, and MEFs immunoblotted for
pluripotency and metabolic protein markers. Cells were grown in 21% oxygen
(atmospheric/normoxic) and 5% oxygen (hypoxic) conditions. Each lane represents an
individual biological replicate, and each cell type was run in biological triplicate.
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Examining the protein abundance of 21% and 5% oxygen tensions revealed differential
metabolic and pluripotent expression patterns throughout the pluripotent continuum
(Figure 6.3.A-G). My findings suggest that primed mEpiSCs show a beneficial influence
of culture in 5% oxygen over 21% as demonstrated with a statistically significant increase
in T(BRACHYURY) protein abundance for low oxygen conditions (Figure 6.3.C). A
significant decrease in NANOG confers an exit of the naïve state in transitioning
mEpiLCs (Figure 6.3.D) (Kinoshita and Smith 2018). While a decrease in NANOG is
expected, a drop in OCT4 is not, potentially the finding of a significant decrease in OCT4
protein abundance between 21% and 5% conditions in 4 to 5 days of transitioning
mEpiLCs may suggest that the formative pluripotent state has an elevate degree of
preference for OXPHOS (Figure 6.3.E). Early in the transitioning process (days 1 and 2)
indicate that hypoxic conditions promote the primed pluripotency associated protein
SOX17 (Figure 6.3.F) (Kinoshita and Smith 2018). It is hypothesized that the early postimplantation epiblast cell of the murine embryo should reflect the decreased oxygen
availability (Mathieu and Ruohola-Baker 2017). This may explain why the greatest
metabolic protein abundance changes in PKM1, pPKM2, and PKM2 reflect the early
formative transitioning mEpiLCs and the metabolically bivalent mESCs. There was a
significant increase in PKM1 for hypoxic conditions relative to normoxic conditions in
naïve mESCs and 1 day of transitioning mEpiLCs (Figure 6.3.A) and a significant
increase in pPKM2/PKM2 in mESCs and mEpiLCs transitioning on days 1-3 (Figure
6.3.B).
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Figure 6.3. Metabolic and pluripotent state associated protein abundance in naïve
mESCs, transitioning mEpiLCs, primed mEpiSCs, and somatic MEFs.
Naïve mESCs, transitioning mEpiLCs (over 5 days of chemical transitioning), primed
mEpiSCs, and somatic MEFs were compared relative to a loading control consisting of a
combination of each lysate. Metabolic and pluripotency associated markers were
compared by densitometry and normalized to the loading control. Data consists of mean
densitometry±SEM, run in biological triplicate, *p>0.05.

238
6.1.0. Summary of Findings:
My research contributes to evidence that metabolism has an active and passive role in
development and pluripotency. I have found differences in PKM1/2 expression and
subcellular localization between naïve, formative, and primed mouse embryonic stem
cells. Metabolism has been thought of as a by-product of cell fate, but this idea has been
challenged as metabolism has now been found to be as a necessary driver of development
(Zhang et al. 2018; Dahan et al. 2019; Tsogtbaatar et al. 2020). By better understanding
the role of metabolism during the transition between naïve and primed PSCs, in vitro
research can more closely recapitulate the in vivo mammalian development of pregastrulation embryos.

In Chapter 2, I detail a novel, comprehensive methodology in colocalization. This
methodology is beneficial in the study of nuclear and cytoplasmic protein localization of
pluripotent stem cells (PSCs). Due to the increased nuclear to cytoplasmic size ratio of
PSCs, my method utilizes the addition of 3D imaging, background negation, and an
additional nuclear reference relative to the nuclear pluripotency marker of comparison to
the protein of interest for validation. This methodology was used to demonstrate nuclear
and cytoplasmic colocalization of PKM1/2 in naïve mESCs, formative mEpiLCs, and
primed mEpiSCs relative to OCT4 and GAPDH localization, validated with Hoechst
nuclear staining. These findings show that it is critical to run positive and negative
references relative to dual fluorophore colocalization and that in the case of mouse
embryonic stem cells (mESCs), the spatial overlap data may not be sufficient to reach
quality colocalization assessment compared to correlation data when considering the
qualifying standards (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013). I observed that
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the MOC metrics in PSCs were insufficient to delineate nuclear and cytoplasmic
distinctions by colocalization and that the PCC metric was a highly effective and viable
tool for such distinction and analysis. To increase the power of traditional colocalization
studies, I did not simply analyze single images, but I also employed orthogonal
projections of stacks examining the data of individual slices to characterize the
localization patterns of a true three-dimensional structure. Additionally, I accounted for
the inherent flaws of the MOC calculation by examining only the individual colonies and
individual cells in the orthogonal and airyscanned images respectively to prevent
autofluorescence or background pixel offset. Using this methodology, my research
demonstrates that PKM1 and PKM2 have a moderate correlation and a strong spatial
overlap to the nuclear localized OCT4 and the cytoplasmic localized GAPDH in naïve
mESCs. In formative state mEpiLCs, there is a significant decrease in spatial overlap of
PKM1 and PKM2 localization relative to GAPDH. Additionally, there was a strong
correlation of PKM1 to OCT4 and a moderate correlation of PKM1 to GAPDH, whereas
PKM2 had a weak correlation to both OCT4 and GAPDH in mEpiLCs. Finally, primed
mEpiSCs had a strong overlap of PKM1 and PKM2 to the localization of OCT4 and
GAPDH, but only a weak correlation of PKM1 and PKM2 relative to OCT4 and a
moderate correlation to GAPDH. These results provide evidence of differential
subcellular localization patterns of PKM1/2, which are traditionally localized to the
cytoplasm. Nuclear translocation of each isoform may indicate non-canonical roles for
this metabolic gene similar to documented roles within cells exhibiting the Warburg
Effect (Wei et al. 2017; Weiwei Yang and Lu 2013).
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In Chapter 5, I utilized a novel method of naïve, formative, primed-like, and primed
pluripotent state delineation by flow cytometry, quantifying the pluripotent state
associated cell surface markers SSEA1 and CD24. This methodology allowed for the
distinguishing of unique SSEA1/CD24 expression for each state and allowed for the
transitioning efficiency to be determined following the addition of pre-mRNA splice
morpholinos designed to target PKM1 and PKM2. This study demonstrated that altering
PKM1/2 expression by morpholinos modulated SSEA1/CD24 expression in transitioning
pluripotent states within the pluripotent continuum and works to promote the notion that
metabolism is a driver of development. As such, blocking pre-mRNA splicing of PKM1
and PKM2 during a naïve-to-primed transition of mESCs to mEpiLCs modulates the exit
from naivety and initiation of primed pluripotency. Specifically, downregulation of
PKM2 promotes the frequency of cell events expressing the primed pluripotency cell
surface marker CD24 in naïve mESCs transitioning to the formative pluripotent state.
Additionally, downregulation of PKM2 alone or coupled with upregulation of PKM1
increases the frequency of cells expressing high levels of both the naïve cell surface
marker SSEA1 and the primed marker CD24 when transitioning from the formative state
to a primed-like pluripotency. Modulation of PKM1/2 with either targeted approach
increased the ratio of pPKM2 (homodimeric conformation attributed to the Warburg
Effect) to total PKM2 (homo-tetrameric and dimeric conformations), giving rise to the
likely possibility that pPKM2 plays a role in generating this novel expression pattern.
This enhanced ratio has been postulated to indicate a shift towards biosynthesis over
energetic processes (W. Yang and Lu 2015; Zahra et al. 2020). In Chapter 3, I
demonstrate the stable ratio of PKM1/PKM2 is demonstrated throughout the pluripotent
continuum, thus a perturbation of this ratio likely would further promote the Warburg
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Effect and enhance the metabolic shift from bivalency to aerobic glycolysis.
Colocalization data by confocal microscopy, and flow cytometric results and analysis
using the comprehensive techniques are detailed in Chapters 2 and 4, and are respectively
summarized in Figure 6.4.

Collectively, I demonstrate differential nuclear localization of PKM1 and PKM2 in
mPSCs across the pluripotent continuum. My initial observations of the presence of
nuclear PKM1 appeared to be the first of its kind, and only recently has been shown in
hepatoma cells (Wei et al. 2017). Coupled with nuclear fractionation data, my
comprehensive methodology to colocalization, detailed in Chapter 2, works to clearly
demonstrate nuclear PKM1/2 in mPSCs across the spectrum, detailed in Chapter 3.
These findings indicate a potential non-canonical role outside of metabolic processing for
PKM1/2 within the developmental process. My study proceeded to delineate the
influence of modulating PKM1/2 through spliceosome modifying morpholinos to alter
PKM1/2 expression in each pluripotent and during a transition throughout the continuum.
In chapter 5, I found that altering PKM1/2 expression had little impact on metabolic
transcripts associated with glycolysis and OXPHOS or pluripotency transcripts, however,
there was an impact on key pluripotency cell surface marker expression during
transitioning. Modulation of PKM1 and PKM2 in cells chemically transitioning from
naïve mESCs into formative mEpiLCs and subsequently into primed-like mEpiLCs
indicate that PKM1/2 are drivers of the development of the pluripotent continuum.
Decreasing PKM2 protein abundance during the in the transition to the formative state
increases expression of the primed pluripotency cell surface marker CD24. By either
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downregulating PKM2 or downregulating PKM2 while upregulating PKM1 formative
state mEpiLCs developing into primed-like mEpiLCs exhibit a novel subset of cells
expressing both the naïve pluripotency cell surface marker SSEA1 and CD24. Using the
methodology of I describe in Chapter 4, I delineated between these mPSCs with a model
of PKM1/2 modulation, and demonstrate a means of discrimination for the formative
state. Together, these results demonstrate a novel differential nuclear expression pattern
of PKM1/2 across the pluripotent continuum and by modulating expression of PKM1/2
key pluripotency cell surface markers are influenced indicating a role in pluripotent state
transitioning.
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Figure 6.4. Thesis summary of colocalization and flow cytometric results.
During the developmental transition of naïve-to-primed pluripotent states in mouse
embryonic stem cells, there is a switch in metabolic preference from bivalent oxidative
phosphorylation and glycolysis in the naïve state, to aerobic glycolysis in primed stem
cells. Using my improved colocalization technique, I examined orthogonal projections
with references to known nuclear and cytoplasmic markers, I determined that PKM1 and
PKM2 proteins are differentially expressed in nuclear and cytoplasmic regions of PSCs
throughout the pluripotent continuum, importantly, overlap of proteins indicates potential
biomolecular interaction of the protein of interest PKM1/2 and either OCT4 or GAPDH,
the nuclear and cytoplasmic reference respectively. To elucidate the potential role that
PKM1/2 has within the development of the pluripotent continuum, I utilized a
morpholino strategy targeting PKM1/2 splice modifications during chemical transitioning
between naïve-to-formative and formative-to-primed-like pluripotent states.
Alteration of PKM1/2 (downregulation of PKM2 or downregulation of PKM2 coupled
with upregulation of PKM1) through the addition of splice modifying morpholinos
resulted in an increased frequency of cells expressing high levels of the cell surface
marker SSEA1 and CD24 during a formative-to-primed-like pluripotent state transition.
Taken together, these results promote non-canonical roles for PKM1 and PKM2 in
mPSCs across the pluripotent continuum.
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6.2.0. Research Limitations:
This thesis was limited by PKM MO targeting specificity, limited metabolic profiling of
live cells and protein abundance analyses of metabolic and pluripotent sates. After
several designs, attempts, and redesigns, my PKM1 and PKM2 knockdown strategy failed
to be specific exclusively for one or the other isoform. However, I made the most of this
lack of specificity to further promote the individual role of decreasing PKM2 alone and
upregulating PKM1 concomitantly with a reduction in PKM2. To truly show the role of
PKM1/2 during this period of development, an inducible overexpression model of each
isoform should be employed. Originally, I attempted to employ a strategy of small
interfering RNAs (siRNA), however, this method did was not truly convincing. The
details of my siRNA study attempts are described in Chapter 5 (Figures 5.11.-13.). The
main issue with the siRNA investigation was a lack of PKM1 or PKM2 specificity by
protein abundance (Chapter 5., Figure 5.13.) and an apparent upregulation of Pkm1 and
Pkm2 transcript abundance (Chapter 5., Figure 5.12.). Additionally, the scrambled
control siRNA resulted in an influence of the siRNA transcript and protein abundance.
These conflicting results may be a result of the heterogenous transcriptional landscape in
naïve cells and epigenetic rewiring during development and transitioning. Naïve and
primed cells can be distinguished in terms of their DNA methylation including changes to
promotor-interactions and chromatin state maps (Chovanec et al. 2021; Messmer et al.
2019). Future studies could include an inducible overexpression model that would allow
for the study of increasing either isoform during developmental transitioning from
transient states such as the formative and primed-like states. With the recent advent of a
stably cultured formative pluripotent stem cell line, an inducible overexpression model is
not necessary to study the transition towards a primed-like state. The addition of studying
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acute live cell extracellular acidification rate and oxygen consumption rate, measure of
glycolysis and oxidative phosphorylation in each pluripotent state treated with PKM1/2
modulation would demonstrate the metabolic reprogramming effect of PKM1/2. Running
this acute study in live cells and the newly derived stable formative state cells would
remove the limitation of knowing metabolic preferences within these cells and their
modulated states following morpholino incorporation. Finally, using my comprehensive
colocalization methodology described in Chapter 2, I demonstrate nuclear PKM1 in
Chapter 3, however, this strategy was limited in proving nuclear translocation without the
addition of ChIP-sequencing coupled with single cell RNA-sequencing. The addition of
these powerful molecular techniques would greatly benefit this study to transcriptional
regulation of PKM1 during pluripotency transitioning.

6.3.0. Future Experiments:
A final and definitive method of characterizing the metabolic profiles of naïve, formative,
and primed cells will include examining extracellular acidification (ECAR) and oxygen
consumption rates (OCR) which correspond to glycolysis and OXPHOS respectively.
The Betts laboratory owns and operates a Seahorse XFe Extracellular Flux Analyzer,
which is used to measure ECAR and OCR in live cells. This technology has been shown
to be effective in comparing naïve and primed cells based on metabolic demands and can
show the influence of altering PKM splicing in live cells (Zhou et al. 2012). Agilent, the
company who created the Seahorse has expressed interest in us to profile the formative
pluripotent state. This could be a valuable part in better understanding the role of
metabolism in cell fate decisions and developmental processes. Metabolic readouts
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following adjustments PKM1/2 expression in naïve, formative and primed PSCs will
provide valuable insight into PKM1/2’s role in glycolytic shifting during developmental
progression. Future experiments should consider culturing mPSCs in low oxygen
conditions (5% oxygen) as we demonstrate an upregulation of metabolic and pluripotency
associated proteins (Figure 6.1.-3.).

Future studies should also include a stable line of formative state murine pluripotent stem
cells. These cells can be generated with the inclusion of tankyrase inhibitor with FA
media (Kinoshita et al. 2020). True formative state stem cells extracted from murine ICM
from E5.5-E6.0 would be ideal in a comparison of explanted naïve mESCs and primed
mEpiSCs. It would be especially interesting to see if the unique SSEA1 high/CD24 high
population corresponds with an increased expression of CD61 as expected of primordial
germ cell differentiation (Kinoshita et al. 2020). This may allude to PKM1/2 being
implicated in direct conversion of germ cell specialization.

Precise targeted disruption of PKM1/2 demonstrated by isoform specificity should be
further explored. This study utilized a PKM2 downregulation and PKM2 downregulation
with PKM1 upregulation strategy using the tools we had at our disposal. Future studies
should utilize either a knockdown or knockout approach and overexpression specific to
each isoform. Additionally, the combination of such tactics to produce a knockdown or
knockout of one isoform and an overexpression of the other would further promote the
roles of each isoform and perhaps further validate our morpholino results in primed-like
mEpiSCs and cell expressing both CD24 and SSEA1. The incorporation of inducible
overexpression of PKM1 or PKM2 would also work to further promote if PKM1/2 is
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necessary or sufficient to maintain or hinder pluripotency and developmental
transitioning.

Finally, the colocalization study would greatly benefit from a mass spectroscopy study of
nuclear PKM1/2 and co-immunoprecipitation study with OCT4. Previous studies have
used mass spectroscopy to study nuclear PKM2 interactions with JMJD5 (Wang et al.
2014). This study should begin with a non-denaturing gel of each pluripotent state
examining dimeric and tetrameric PKM2 levels, this has been completed in other cell
types and is possible to complete (Verma and Patel 2019). The work of this thesis
demonstrates differences in each conformation; however, this experiment would further
solidify differences and allow for downstream analysis by mass spectroscopy. These
aspects work to promote nuclear translocation during development. Future studies into
the role of nuclear PKM1 during this time interval is necessary to promote non-canonical
roles of this metabolic enzyme that traditionally is not known to translocate into nuclear
compartments (Wei et al. 2017). To delineate novel targets of PKM1 and PKM2 within
the nucleus, ChIP-sequencing and single cell RNA sequencing could be employed to
identify potential regulatory targets of metabolism and pluripotency.

Additionally, evidence of the role of PKM1/2 during a naïve-to-primed transition could
be provided by a pharmacological approach. There are a variety of commercially
available chemical PKM1/2 inhibitors and activators. Inhibitors such as shikonin, a
Chinese herb derivative, have been reported to knockdown greater than 50% of PKM2
activity with no apparent influence on PKM1 (Chen et al. 2011). While chemical
inhibitors are readily available, there is a tendency to focus on PKM2 or PKM total,
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leaving PKM1 partially or fully functioning. Chemical inhibitors such as DASA-58 and
TEPP-46 work as a PKM2 activator, specifically enabling the homotetramer
conformation and destabilizing the homodimer by preventing phosphorylation
(Anastasiou et al. 2012). Alternatively, promyelocytic leukemia protein works in the
opposite fashion by maintaining the nuclear localizing PKM2 homodimer and
destabilizing the homotetramer thus promoting aerobic glycolysis and the Warburg Effect
(Shimada, Shinagawa, and Ishii 2008).

6.4.0. Significance of Findings:
This area of research promotes metabolism as having an active role in pluripotent
development, rather than a passive role as a by-product of differentiation. Knowing
whether PKM1/2 has a role in early development has yet to be determined and this
project has further clarified that role. Efficient transitioning of naïve and primed
pluripotent states has regenerative medicine implications as well in terms of disease
modelling or the scaling up of cells. Human ESCs (hESCs) isolated from blastocysts are
traditionally representative of the primed state and while hESCs are pluripotent, induction
towards a naïve state is for desirable for improved scalability and the enhanced ability to
be feeder-free (Vallier 2005). Reprogramming somatic cells or inducing primed cells to a
more naïve-like state is becoming an increasing important area of research that will yield
benefits regenerative medicine.

From a therapeutic standpoint, this aim works to transition mESCs to formative mEpiLCs
(48 hours of transitioning in FA media), and primed-like mEpiLCs (72≤ hours of
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transitioning in FA media) in a more homogenous and stable population. Currently,
induced pluripotent stem cells (iPSCs) are favored over ESCs for disease modelling,
despite both being equally capable (Halevy and Urbach 2014). Despite reduced
reprogramming efficiency and epigenetic memory, the preference for iPSCs is largely due
to challenges associated with ESCs legalities and genome editing. However, several
diseases are better portrayed using ESCs largely due to epigenetic memory and landscape.
In a comparison of X-linked autosomal diseases, it was found that disorders such as
Turner’s Syndrome, epigenetic silencing in Fragile X Syndrome and Huntington’s
Disease are better modelled using ESCs than iPSCs (Halevy and Urbach 2014).

In summary, my investigation of differential pyruvate kinase muscle isoform expression
in naïve-to-primed mESC development promotes PKM1 and PKM2 having an important
role in in vitro pluripotency throughout the pluripotent continuum and may suggest a
developmental link as these cells have appear to demonstrate a metabolic preference bias
like their in vivo counterparts of the pre- and post- implantation blastocyst. Differential
localization patterns of PKM1/2 through the pluripotent continuum demonstrate
subcellular changes to nuclear and cytoplasmic localization and potential interaction of
both isoforms to the pluripotency protein OCT4 may indicate a role in governing
pluripotency. The presence of nuclear PKM1 was a first of its kind observation and
indicates a potential non-metabolic role. Modulation of PKM1/2 does not drastic alter
metabolic or pluripotency transcript abundance, however, when transitioning between the
naïve and formative state, downregulation of PKM2 enhances CD24 expression, a key
protein associated with primed pluripotency. Additionally, when transitioning from a
formative state to a primed-like pluripotency, the downregulation of PKM2 and
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downregulation of PKM2 with upregulation of PKM1 increases the frequency of cells
expression both SSEA1 and CD24, characteristics of both naïve and primed cells. Using
the methodology findings of Chapter 4, I demonstrate that the formative pluripotency
state can be distinguished from both the naïve and primed states. My refined
colocalization and flow cytometric methodology further the field of molecular techniques
and fill benefit downstream analysis and applications such as improved cell sorting. The
results of this thesis support my governing hypothesis that PKM1/2 is differentially
localized during the development of PSCs in the pluripotent continuum and altering
PKM1/2 expression appears to modulate developmental progression during transition
from the naïve pluripotent state and formative state. My thesis sheds light on the role of
metabolism and pyruvate shuttling during early development and has the potential to
enhance our knowledge of mechanisms controlling pluripotent cell conversion, ultimately
benefiting disease modelling and cell replacement therapies. The findings of my works
promote PKM1/2 as having a non-canonical role outside of metabolic processing during
developing stem cells of the pluripotency continuum and further promotes metabolism as
a driver of pluripotency and development.
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